᪂つヨ㦂ἲᥦ᱌᭩             ᖹᡂ  ᖺ  ᭶  ᪥                                  1R 
⓶⭵ឤసᛶヨ㦂௦᭰ἲ Direct Peptide Reactivity Assay (DPRA)㸸
࣌ࣉࢳࢻ⤖ྜᛶヨ㦂࡟㛵ࡍࡿᥦ᱌ ᖹᡂ 26 ᖺ 12 ᭶ 17 ᪥࡟ᮾிࠊᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ࡟࡚㛤ദࡉࢀࡓ᪂つヨ㦂ἲホ౯఍㆟㸦㏻⛠㸸JaCVAM ホ౯఍㆟㸧࡟࠾࠸࡚௨ୗࡢᥦ᱌ࡀ࡞ࡉࢀࡓࠋ   ᥦ᱌ෆᐜ㸸 ࣌ࣉࢳࢻ⤖ྜᛶヨ㦂࡛㝧ᛶࡢ⤖ᯝࡀᚓࡽࢀࡓሙྜࠊࡑࡢ໬Ꮫ≀㉁ࢆᙉ࠸ឤసᛶ
≀㉁࡟ศ㢮ࡍࡿࡇ࡜ࡣ⾜ᨻୖྍ⬟࡛࠶ࡿࠋࡋ࠿ࡋ࡞ࡀࡽࠊࡲࢀ࡟ഇ㝧ᛶࡢ⤖ᯝࡀ⏕ࡌࡿࡇ࡜࡟␃ពࡋ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ୍᪉ࠊ࣌ࣉࢳࢻ⤖ྜᛶヨ㦂ࡢ㝜ᛶ⤖ᯝࡀᚓࡽࢀࡓሙྜࠊࡑࡢ໬Ꮫ≀㉁ࡢ⓶⭵ឤసᛶࡣഇ㝜ᛶࡢྍ⬟ᛶࡀ࠶ࡾࠊDPRA ༢⊂࡛ࡑࡢ⓶⭵ឤసᛶࢆุᐃࡍࡿࡇ࡜ࡣ㞴ࡋ࠸ࠋࡑࡢ௚ࡢ᝟ሗ※࡜⤌ࡳྜࢃࡏ࡚ホ౯ࡍࡿࡇ࡜࡟ࡼࡾࠊ࣌ࣉࢳࢻ⤖ྜᛶヨ㦂ࡣ⾜ᨻⓗ࡟฼⏝ྍ⬟࡛࠶ࡿ࡜⪃࠼ࡿࠋࡇࡢᥦ᱌᭩ࡣࠊOECD TG 442C; In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay(DPRA)࠾ࡼࡧ JRC Scientific and Policy report, EURL ECVAM Recommendation on the
Direct Peptide Reactivity Assay (DPRA) for Skin Sensitisation Testingࢆࡶ࡜࡟ࠊ⓶⭵ឤసᛶヨ㦂㈨ᩱ⦅⧩ጤဨ఍࡟ࡼࡾࡲ࡜ࡵࡽࢀࡓᩥ᭩ࢆ⏝࠸࡚ࠊJaCVAMホ౯఍㆟ࡀホ౯࠾ࡼࡧ᳨ウࡋࡓ⤖ᯝࠊࡑࡢ᭷⏝ᛶࡀ☜ㄆࡉࢀࡓࡇ࡜࠿ࡽసᡂࡉࢀࡓࠋ ௨ୖࡢ⌮⏤࡟ࡼࡾࠊ⾜ᨻᙜᒁࡢᏳ඲ᛶホ౯᪉ἲ࡜ࡋ࡚⓶⭵ឤసᛶヨ㦂௦᭰ἲ ࣌ࣉࢳࢻ⤖ྜᛶヨ㦂ࡢ౑⏝ࢆᥦ᱌ࡍࡿࡶࡢ࡛࠶ࡿࠋ
 

኱㔝Ὀ㞝
Ὀ㞝                      すᕝ⛅ె
JaCVAM ホ౯఍㆟ ㆟㛗               JaCVAM 㐠Ⴀጤဨ఍ ጤဨ㛗

i

-D&9$0 ホ౯఍㆟኱㔝Ὀ㞝㸦㐠Ⴀጤဨ఍᥎⸀㸧㸸ᗙ㛗஬༑ᔒⰋ᫂㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ ⏕ά⾨⏕໬Ꮫ㒊㸧୍㨣 ຮ㸦᪥ᮏ໬Ꮫᕤᴗ༠఍㸧⠛⏣࿴ಇ㸦⊂❧⾜ᨻἲே ་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓ㸧ᮡᒣ┿⌮Ꮚ㸦᪥ᮏ໬⢝ရᕤᴗ㐃ྜ఍㸧㇂ᕝᾈᏊ㸦᪥ᮏື≀ᐇ㦂௦᭰ἲᏛ఍㸧すᕝ⛅ె㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮㸧ᖹ㈡⚽᫂㸦⊂❧⾜ᨻἲே ་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓ㸧∾ ᰤ஧㸦᪥ᮏච␿ẘᛶᏛ఍㸧ቑ⏣ග㍤㸦ᗙ㛗᥎⸀㸧᳃⏣ ೺㸦᪥ᮏ⎔ቃኚ␗ཎᏛ఍㸧ᒣ⏣㝯ᚿ㸦⊂❧⾜ᨻἲே 〇ရホ౯ᢏ⾡ᇶ┙ᶵᵓ㸧ᶓ㛵༤㞝㸦᪥ᮏ⓶⭵࢔ࣞࣝࢠ࣮࣭᥋ゐ⓶⭵⅖Ꮫ఍㸧ྜྷ⏣Ṋ⨾㸦᪥ᮏẘᛶᏛ఍㸧ྜྷ⏣ ⥳

㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ⑓⌮㒊㸧ྜྷᮧ ຌ㸦ᗙ㛗᥎⸀㸧Ώ㒊୍ே㸦᪥ᮏ〇⸆ᕤᴗ༠఍㸧                  ௵ᮇ㸸ᖹᡂ 26 ᖺ 4 ᭶ 1 ᪥㹼ᖹᡂ 28 ᖺ 3 ᭶ 31 ᪥ii

-D&9$0 㐠Ⴀጤဨ఍すᕝ⛅ె㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮㸧㸸ጤဨ㛗ᕝす ᚭ  㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ㸧᳜ᮧᒎ⏕㸦ཌ⏕ປാ┬ ་⸆㣗ရᒁ ᑂᰝ⟶⌮ㄢ㸧ᑠᕝஂ⨾Ꮚ 㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ⑓⌮㒊㸧Ⳣ㔝 ⣧

㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ẘᛶ㒊㸧಴ᣢ᠇㊰㸦ཌ⏕ປാ┬ ་⸆㣗ရᒁ ໬Ꮫ≀㉁Ᏻ඲ᑐ⟇ᐊ㸧㛵㔝♸Ꮚ㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ⸆⌮㒊㸧㧗ᮌ⠜ஓ㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ẘᛶ㒊 ື≀⟶⌮ᐊ㸧᮰㔝ṇ᫂㸦ཌ⏕ປാ┬ ་⸆㣗ရᒁ ໬Ꮫ≀㉁Ᏻ඲ᑐ⟇ᐊ㸧୰ᮧ㧗ᩄ㸦⊂❧⾜ᨻἲே ་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓ㸧᪥⏣ ඘

㸦ཌ⏕ປാ┬ ་⸆㣗ရᒁ ໬Ꮫ≀㉁Ᏻ඲ᑐ⟇ᐊ㸧ᗈ℩᫂ᙪ  㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ⥲ྜホ౯◊
✲ᐊ㸧
ᮏ㛫ṇ඘

㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ኚ␗㑇ఏ㒊㸧ᑠᓥ ⫕㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ⸆⌮㒊᪂つヨ㦂⾲ホ౯ᐊ㸧㸸஦ົᒁ

iii

iv

JaCVAM statement on
Direct Peptide Reactivity Assay for Skin Sensitisation Testing
At a meeting held on 17 December 2014 at the National Institute of Health Sciences (NIHS)
in Tokyo, Japan, the Japanese Center for the Validation of Alternative Methods (JaCVAM)
Regulatory Acceptance Board unanimously endorsed the following statement:
Proposal: When using the Direct Peptide Reactivity Assay (DPRA) in a regulatory context,
it is reasonable for substances that give positive results to be classified as a strong
sensitiser, i.e., a Category 1 substance under the Globally Harmonized System ofClassification and Labelling of Chemicals (GHS). It is, however, necessary to bearin mind that this assay occasionally yields false positive results for certain
substances. Conversely, it is quite possible that the DPRA will yield false negative
results for some chemicals, which means that it would be unreasonable to use thisassay as a standalone test for assessing skin sensitisation potency. We therefore
conclude that the use of the DRPA in a regulatory context requires that theassessment also take into account information from other sources.
This statement was prepared following a review of OECD TG No. 442C “In Chemico Skin
Sensitisation: Direct Peptide Reactivity Assay (DPRA)” as well as a JRC Scientific and Policy
Report “EURL ECVAM Recommendation on the Direct Peptide Reactivity Assay (DPRA) for
Skin Sensitisation Testing”. The JaCVAM Regulatory Acceptance Board acknowledges thatthe results of this review as well as of a study of materials prepared by the JaCVAM Editorial
Committee indicate that this assay is useful in a regulatory context.
Based on the above, we propose that regulatory agencies performing safety assessment of skinsensitisation potency consider using the DPRA Assay as an alternative to testing withlaboratory animals.

Yasuo Ohno
Chairperson
JaCVAM Regulatory Acceptance Board

Akiyoshi Nishikawa
Chairperson
JaCVAM Steering Committee

20 March 2015v

The JaCVAM Regulatory Acceptance Board was established by the JaCVAM Steering
Committee, and is composed of nominees from the industry and academia.
This statement was endorsed by the following members of the JaCVAM Regulatory
Acceptance Board:

Mr. Yasuo Ohno (nominee by JaCVAM Steering Committee): Chairperson
Mr. Hideaki Hiraga (Pharmaceuticals and Medical Devices Agency)
Mr. Tsutomu Ichiki (Japan Chemical Industry Association)
Mr. Yoshiaki Ikarashi (National Institute of Health Sciences: NIHS)
Mr. Eiji Maki (Japanese Society of Immunotoxicology)
Mr. Mitsuteru Masuda (nominee by Chairperson)
Mr. Takeshi Morita (Japanese Environmental Mutagen Society)
Mr. Akiyoshi Nishikawa (NIHS)
Mr. Kazutoshi Shinoda (Pharmaceuticals and Medical Devices Agency)
Ms. Mariko Sugiyama (Japan Cosmetic Industry Association)
Ms. Koko Tanigawa (Japanese Society for Alternatives to Animal Experiments)
Mr. Takashi Yamada (National Institute of Technology and Evaluation)
Mr. Hiroo Yokozeki (Japanese Society for Dermatoallergology and Contact Dermatitis)
Ms. Midori Yoshida (NIHS)
Mr. Takemi Yoshida (Japanese Society of Toxicology)
Mr. Isao Yoshimura (nominee by Chairperson)
Mr. Kazuto Watanabe (Japan Pharmaceutical Manufacturers Association)
Term: From 1st April 2014 to 31st March 2016vi

This statement was endorsed by the following members of the JaCVAM steering Committee
after receiving the report from JaCVAM Regulatory Acceptance Board:

Mr. Akiyoshi Nishikawa (BSRC, NIHS): Chairperson
Mr. Toru Kawanishi (NIHS)
Mr. Mitsuru Hida (Ministry of Health, Labour and Welfare)
Mr. Akihiko Hirose (Division of Risk Assessment, BSRC, NIHS)
Mr. Masamitsu Honma (Division of Genetics and Mutagenesis, BSRC, NIHS)
Mr. Jun Kanno (Division of Cellular and Molecular Toxicology, BSRC, NIHS)
Mr. Kenji Kuramochi (Ministry of Health, Labour and Welfare)
Mr. Takatoshi Nakamura (Pharmaceutical & Medical Devices Agency)
Ms. Kumiko Ogawa (Division of Pathology, BSRC, NIHS)
Ms. Yuko Sekino (Division of Pharmacology, BSRC, NIHS)
Mr. Atsuya Takagi (Animal Management Section of the Division of Cellular andMolecular Toxicology, BSRC, NIHS)
Mr. Masaaki Tsukano (Ministry of Health, Labour and Welfare)
Mr. Nobuo Uemura (Ministry of Health, Labour and Welfare)Mr. Hajime Kojima (Section for the Evaluation of Novel Methods, Division of
Pharmacology, BSRC, NIHS): Secretary

vii

viii

࣌ࣉࢳࢻ⤖ྜᛶヨ㦂㸸Direct Peptide Reactivity Assay㸦DPRA㸧┠  ḟ
ホ౯఍㆟ሗ࿌᭩ ------------------------------------------------------------------------------ 1
ホ౯ሗ࿌᭩ ------------------------------------------------------------------------------------ 7
OECD GUIDELINE FOR THE TESTING OF CHEMICALS,In Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA)---------------------------------------------------------------------------------------------------------23

JRC SCIENTIFIC AND POLICY REPORTS,
EURL ECVAM Recommendation on the Direct Peptide Reactivity Assay(DPRA) for Skin Sensitisation Testing -------------------------------------------------43ix

x࣌ࣉࢳࢻ⤖ྜᛶヨ㦂㸦Direct Peptide Reactivity Assay㸸DPRA㸧ࡢホ౯఍㆟ሗ࿌᭩

JaCVAM ホ౯఍㆟

ᖹᡂ 27 ᖺ㸦2015 ᖺ㸧2 ᭶ 6 ᪥

11

JaCVAM ホ౯఍㆟኱㔝Ὀ㞝㸦㐠Ⴀጤဨ఍᥎⸀㸧㸸ᗙ㛗஬༑ᔒⰋ᫂ 㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ ⏕ά⾨⏕໬Ꮫ㒊㸧୍㨣 ຮ㸦᪥ᮏ໬Ꮫᕤᴗ༠఍㸧⠛⏣࿴ಇ㸦⊂❧⾜ᨻἲே ་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓ㸧ᮡᒣ┿⌮Ꮚ 㸦᪥ᮏ໬⢝ရᕤᴗ㐃ྜ఍㸧㇂ᕝᾈᏊ㸦᪥ᮏື≀ᐇ㦂௦᭰ἲᏛ఍㸧すᕝ⛅ె㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮㸧ᖹ㈡⚽᫂㸦⊂❧⾜ᨻἲே ་⸆ရ་⒪ᶵჾ⥲ྜᶵᵓ㸧∾ ᰤ஧㸦᪥ᮏච␿ẘᛶᏛ఍㸧ቑ⏣ග㍤㸦ᗙ㛗᥎⸀㸧᳃⏣ ೺㸦᪥ᮏ⎔ቃኚ␗ཎᏛ఍㸧ᒣ⏣㝯ᚿ㸦⊂❧⾜ᨻἲே 〇ရホ౯ᢏ⾡ᇶ┙ᶵᵓ㸧ᶓ㛵༤㞝㸦᪥ᮏ⓶⭵࢔ࣞࣝࢠ࣮࣭᥋ゐ⓶⭵⅖Ꮫ఍㸧ྜྷ⏣Ṋ⨾㸦᪥ᮏẘᛶᏛ఍㸧ྜྷ⏣ ⥳ 㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ Ᏻ඲ᛶ⏕≀ヨ㦂◊✲ࢭࣥࢱ࣮ ⑓⌮㒊㸧ྜྷᮧ ຌ㸦ᗙ㛗᥎⸀㸧Ώ㒊୍ே㸦᪥ᮏ〇⸆ᕤᴗ༠఍㸧                  ௵ᮇ㸸ᖹᡂ 26 ᖺ 4 ᭶ 1 ᪥㹼ᖹᡂ 28 ᖺ 3 ᭶ 31 ᪥

22࣌ࣉࢳࢻ⤖ྜᛶヨ㦂㸦Direct Peptide Reactivity Assay 㸸DPRA) ࡣࠊ໬Ꮫ≀㉁ࡢ⓶⭵ឤసᛶࢆண
ࡍࡿヨ㦂ἲ࡛࠶ࡾࠊᚑ᮶ࡢࣔࣝࣔࢵࢺࡢ⓶⭵ឤసᛶヨ㦂㸦OECD TG406㸧ࠊ࣐࢘ࢫࡢᒁᡤࣜࣥࣃ⠇ヨ㦂㸦Local Lymph Node Assay: LLNAࠊOECD TG429㸧࠾ࡼࡧ LLNA ࡢኚἲ࡛࠶ࡿ LLNA:DA (OECDTG442A)࡞ࡽࡧ࡟ LLNA:BrdU-ELISA (OECD TG442B)࡜ẚ࡭ࠊື≀ࢆ⏝࠸࡞࠸࡜࠸࠺≉ᚩࢆ᭷ࡍࡿࠋDPRA ࡣࠊ⓶⭵ឤసᛶᡂ❧ࡢึᮇẁ㝵ࡢ཯ᛂ࡛࠶ࡿࣁࣉࢸࣥ࡜ࢱࣥࣃࢡ㉁ࡢ⤖ྜᛶࢆㄪ࡭ࡿࡇ࡜࡟
ࡼࡾࠊ⓶⭵ឤసᛶࡢ᭷↓ࢆணࡍࡿヨ㦂ἲ࡛࠶ࡿࠋEuropean Union Reference Laboratory for

Alternatives to Animal Testing (EURL ECVAM)࡟ࡼࡿࣂࣜࢹ࣮ࢩࣙࣥ◊✲ࢆᇶ࡟ࡋࡓ ESAC㸦ECVAM
Scientific Advisory Committee㸧 ࡟ࡼࡿ➨୕⪅ホ౯ࡀ⤊஢ࡋ OECD ࡟ࡼࡿᑓ㛛ᐙ఍㆟ࢆ⤒࡚ࠊOECD
TG442C ࡜ࡋ࡚ 2015 ᖺ 2 ᭶ 5 ᪥࡟᥇ᢥࡉࢀࡓ 1)ࠋJaCVAM ホ౯఍㆟ࡣࠊ⓶⭵ឤసᛶヨ㦂㈨ᩱ⦅⧩ጤ
ဨ఍ࡣࠊୖグ㈨ᩱࢆࡶ࡜࡟సᡂࡋࡓ⓶⭵ឤసᛶヨ㦂ホ౯ሗ࿌᭩ࢆ⏝࠸࡚ࠊDPRA ࡢጇᙜᛶ࡟ࡘ࠸᳨࡚ウࡋࡓࠋ㸯㸬ヨ㦂ἲࡢᐃ⩏ྡ⛠㸸 ࣌ࣉࢳࢻ⤖ྜᛶヨ㦂㸦Direct Peptide Reactivity Assay 㸸DPRA)
௦᭰ࡍࡿᑐ㇟ẘᛶヨ㦂㸸 ࣔࣝࣔࢵࢺࡢ⓶⭵ឤసᛶヨ㦂㸦OECD TG406㸧࠾ࡼࡧ࣐࢘ࢫࡢᒁᡤࣜࣥ
ࣃ⠇ヨ㦂 [Local Lymph Node Assay: LLNA (OECD TG429)ࠊLLNA:DA (OECD TG442A)ࠊ
LLNA:BrdU-ELISA (OECD TG442B)]
ヨ㦂ἲࡢᴫ␎㸸 DPRA ࡣࠊ⏕య࡟࠾ࡅࡿ⓶⭵ឤసᛶⓎ⌧ࡲ࡛ࡢ㐣⛬ࡢ໬Ꮫ≀㉁࡜ࢱࣥࣃࢡ㉁࡜ࡢ
Ᏻᐃ࡞⤖ྜ≀ࡢᙧᡂᛶࢆホ౯ࡍࡿ͆ື≀ࢆ⏝࠸࡞࠸ in chemico ヨ㦂͇࡛࠶ࡿࠋDPRA ࡛ࡣࠊ⓶⭵ෆࡢࢱࣥࣃࢡ㉁ࡢ௦ࢃࡾ࡟ 7 ಶࡢ࢔࣑ࣀ㓟࠿ࡽᡂࡿྜᡂ࣌ࣉࢳࢻࡢࢩࢫࢸ࢖ࣥྵ᭷࣌ࣉࢳࢻ࡜
ࣜࢪࣥྵ᭷࣌ࣉࢳࢻࡢ 2 ✀㢮㸦࠸ࡎࢀࡶᕷ㈍ရ㸧ࢆ౑⏝ࡍࡿࠋ໬Ꮫ≀㉁࡜ࡑࢀࡒࢀࡢ࣌ࣉࢳࢻࢆ
ΰྜࡍࡿࡇ࡜࡟ࡼࡾ཯ᛂࡉࡏࠊΰྜ 24 ᫬㛫ᚋ࡟࠾ࡅࡿᮍ཯ᛂࡢ࣌ࣉࢳࢻ㔞ࢆ HPLC ࡛ศ㞳ᐃ㔞ࡍࡿࠋヨ㦂ᡂ❧᮲௳ࢆ‶ࡓࡋࡓ໬Ꮫ≀㉁ࡢ཯ᛂᛶࡣࠊ ᐃࡈ࡜ࡢ࣌ࣉࢳࢻῶᑡ⋡࠿ࡽᖹᆒ್ࢆ⟬ฟࡋࠊணࣔࢹࣝ࡟ᚑࡗ࡚ HighࠊModerateࠊLow ࠾ࡼࡧ Minimal ࡢ 4 ẁ㝵࡟ศ㢮ࡉࢀࡿࠋࡑࡢ

⤖ᯝࠊ཯ᛂᛶࡀ LowࠊModerate ࠾ࡼࡧ High ࡟ศ㢮ࡉࢀࡿ໬Ꮫ≀㉁ࡣ⓶⭵ឤసᛶ࠶ࡾࠊMinimal࡟ศ㢮ࡉࢀࡿ໬Ꮫ≀㉁ࡣ⓶⭵ឤసᛶ࡞ࡋ࡜ண

ࡉࢀࡿࠋ㸰㸬ホ౯࡟⏝࠸ࡓ㈨ᩱ࠾ࡼࡧホ౯ෆᐜࡢ⛉Ꮫⓗጇᙜᛶ
DPRA ࡣࠊEURL ECVAM ୺ᑟࡢࣂࣜࢹ࣮ࢩࣙࣥヨ㦂࡜ࡑࢀ࡟⥆ࡃ ESAC ࡟ࡼࡿ⊂❧ࡋࡓ➨୕⪅ホ౯࡟࠾࠸࡚ホ౯ࡉࢀࠊ௦᭰ヨ㦂ἲ࡜ࡋ࡚⛉Ꮫⓗ࡟ጇᙜ࡛࠶ࡿ࡜ሗ࿌ࡉࢀ࡚࠸ࡿ 2)ࠋᮏ㑥࡟࠾࠸࡚ࡣࠊJaCVAM ⓶⭵ឤసᛶヨ㦂㈨ᩱ⦅⧩ጤဨ఍ࡀࠊDPRA ࡢ⓶⭵ឤసᛶヨ㦂௦᭰ἲ࡜ࡋ࡚ࡢ⛉Ꮫⓗጇᙜᛶ࡟ࡘ࠸࡚ࠊOECD TG442C㸯㸧ࠊEURL ECVAM ࡢࣂࣜࢹ࣮ࢩࣙࣥሗ࿌᭩ 3)ࡢࡳ࡞ࡽࡎ⌧ᅾࡲ࡛33බ㛤ࡉࢀ࡚࠸ࡿ᝟ሗ 4)ࢆᇶ࡟᳨ドࡋࡓࠋ᳨ドࡢ⤖ᯝ 5)ࠊDPRA ࡟ࡣឤసᛶⓎ⌧ᶵᗎ࡟࠾ࡅࡿึᮇࡢ㔜せ࡞࢖࣋ࣥࢺ࡛࠶ࡿࢱࣥࣃࢡ㉁࡜໬Ꮫ≀㉁ࡢ⤖ྜ཯ᛂࢆ᳨ฟࡍࡿ࡜࠸࠺⛉Ꮫᛶࡀ࠶ࡾࠊinchemico ࡢ⓶⭵ឤసᛶヨ㦂௦᭰ἲ࡜ࡋ࡚ጇᙜ࡛࠶ࡿ࡜⪃࠼ࡽࢀࡓࠋ

㸱㸬ᮏヨ㦂ἲࡢ᭷⏝ᛶ࡜㐺⏝㝈⏺
DPRA ࡣࠊື≀ࢆ⏝࠸࡞࠸ in chemico ࡢヨ㦂ἲ࡛ࠊ3Rs ࡢ⢭⚄࡟ྜ⮴ࡋ࡚࠸ࡿࠋࡲࡓࠊ㸯࢔ࢵࢭ࢖ᙜࡓࡾࡢ⤒㈝ࡶࠊLLNA ࡜ẚ㍑ࡋ࡚ 1/10 ⛬ᗘ࡛ᐇ᪋ྍ⬟࡛࠶ࡾࠊヨ㦂ᮇ㛫ࡶ LLNA ࡼࡾ▷ᮇ㛫࡛࠶ࡿࡇ࡜࠿ࡽࠊᮏヨ㦂ἲࡣ⡆౽ᛶ࠾ࡼࡧ⤒῭ᛶࡢ㠃࠿ࡽ᭷⏝࡜࠸࠼ࡿࠋ᭦࡟ࠊDPRA ࡣࠊឤసᛶ
Ⓨ⌧ᶵᗎ࡟࠾ࡅࡿึᮇࡢ㔜せ࡞࢖࣋ࣥࢺ࡛࠶ࡿࢱࣥࣃࢡ㉁࡜໬Ꮫ≀㉁ࡢ⤖ྜ཯ᛂࢆ᳨ฟࡍࡿࡶࡢ
࡛࠶ࡾࠊ໬Ꮫ≀㉁ࡢឤసᛶࢆุ᩿ࡍࡿୖ࡛㔜せ࡞᝟ሗࢆ୚࠼ࡿࠋ
ࡋ࠿ࡋ࡞ࡀࡽࠊDPRA ࡢ᪋タෆ෌⌧ᛶ࡟࠾࠸࡚ࠊUnited Nations (UN) Globally Harmonized System ofClassification and Labelling of Chemicals (GHS) ༊ศ 1B ࡢ≀㉁㸦ᙅ࠸ឤసᛶ≀㉁㸧࡛ࡣ෌⌧ᛶࡀᚓࡽࢀ

࡞࠿ࡗࡓࡓࡵ㐩ᡂᇶ‽㸦85㸣㸧ࢆ‶ࡓࡏࡎࠊDPRA ࡛ࡣᙅ࠸ឤసᛶ≀㉁࡟ᑐࡋ࡚ࡣุᐃࢆㄗࡿᠱᛕ
ࡀ࠶ࡿࠋࡲࡓࠊ᪋タ㛫෌⌧ᛶ࡟࠾࠸࡚ࡣࠊ࣌ࣉࢳࢻ࡜ඹ᭷⤖ྜࢆ⏕ࡌ࠺ࡿᐁ⬟ᇶࢆᣢࡓ࡞࠸㔠ᒓሷࢆ㝖ࡃࡇ࡜࡟ࡼࡾ෌⌧ᛶࡣ 82%࡜࡞ࡾࠊ㐩ᡂᇶ‽ (80%) ࢆୖᅇࡿࠋᚑࡗ࡚ࠊDPRA ࡟࠾࠸࡚㔠ᒓሷࡣ㐺⏝⠊ᅖእ࡜ࡍ࡭ࡁ࡛࠶ࡿࠋDPRA ࡣᾮ┦୰࡛཯ᛂࢆ⾜࠺ࡓࡵࠊ໬Ꮫ≀㉁ࡣᣦᐃࡉࢀࡓᩘ✀㢮ࡢ⁐፹࡟⁐ゎࡍࡿᚲせࡀ࠶ࡾࠊ␯Ỉᛶࡢ㧗࠸໬Ꮫ≀㉁ࡣṇࡋࡃุᐃࡉࢀ࡞࠸ྍ⬟ᛶࡀ࠶ࡿࠋࡲࡓࠊDPRA ࡢ᳨ドヨ㦂࡟࠾ࡅࡿឤᗘࡣࠊヨ㦂㐺⏝እ࡜⪃࠼ࡽࢀࡿ㔠ᒓሷࢆ㝖࠸ࡓሙྜ࡛ࡶ 75%࡛࠶ࡾࠊ
DPRA ࡛㝜ᛶࡢ⤖ᯝࡀᚓࡽࢀࡓሙྜࡣࠊഇ㝜ᛶࡢྍ⬟ᛶࢆ⪃៖ࡋࠊ⿵᏶ࡋᚓࡿ௚ࡢヨ㦂ἲ࡜ࡢ⤌ࡳྜࢃࡏ࡛☜ㄆࡍࡿᚲせࡀ࠶ࡿࠋࡇࢀࡲ࡛ࡢ⤖ᯝ࠿ࡽࠊ⓶⭵ឤసᛶࡀ Moderate ࡲࡓࡣ Weak ࡢ໬Ꮫ≀㉁ࠊឤసᛶࡢ⋓ᚓ࡟௦ㅰⓗ࠶ࡿ࠸ࡣ㠀௦ㅰⓗάᛶ໬ࢆᚲせ࡜ࡍࡿࣉࣟࣁࣉࢸࣥ࠶ࡿ࠸ࡣࣉࣞࣁࣉࢸ
ࣥࠊ࠾ࡼࡧ␯Ỉᛶࡢ㧗࠸໬Ꮫ≀㉁ࡣഇ㝜ᛶࢆ♧ࡍྍ⬟ᛶࡀ㧗࠸ࡓࡵࠊヨ㦂⤖ᯝࡢゎ㔘࡟ࡣὀពࡀᚲ
せ࡛࠶ࡿ㸲㸬┠ⓗ࡜ࡍࡿ≀㉁ཪࡣ〇ရࡢẘᛶࢆホ౯ࡍࡿヨ㦂ἲ࡜ࡋ࡚ࡢࠊ⾜ᨻୖࡢ฼⏝࠾ࡼࡧ♫఍ⓗཷࡅධࢀࡢྍ⬟ᛶ ♫఍ⓗཷࡅධࢀᛶ㸸
DPRA ࡣࠊHPLC ศᯒࡀྍ⬟࡞᪋タ࡛࠶ࢀࡤᐜ᫆࡟ᐇ᪋࡛ࡁࡿヨ㦂ἲ࡛࠶ࡾࠊࡲࡓ໬Ꮫ≀㉁࡜
ࡢ཯ᛂ࡟⏝࠸ࡿ 2 ✀㢮ࡢྜᡂ࣌ࣉࢳࢻࡶᕷ㈍ࡉࢀ࡚࠾ࡾࠊධᡭ࡟ไ㝈ࡣ࡞࠸ࠋDPRA ࡢᐇ᪋࡟ᙜ
ࡓࡗ࡚ࡣࠊ໬Ꮫ≀㉁ࡢᛶ㉁ࢆぢᴟࡵࠊᚓࡽࢀࡓ⤖ᯝࡢゎ㔘࡟ὀពࢆᡶ࠺ᚲせࡀ࠶ࡿࠋࡋ࠿ࡋࠊDPRA ࡣ⓶⭵ឤసᛶᡂ❧ࡢึᮇẁ㝵ࡢ໬Ꮫ≀㉁࡜ࢱࣥࣃࢡ㉁ࡢ⤖ྜ཯ᛂࢆ᳨ฟࡋ࡚࠾ࡾࠊ໬Ꮫ≀㉁ࡢឤసᛶࢆ⪃࠼ࡿୖ࡛㔜せ࡞᝟ሗࢆ୚࠼࡚࠸ࡿࡇ࡜ࠊࡲࡓࠊ⡆౽࠿ࡘᏳ౯࡞ヨ㦂ἲ࡛࠶ࡿࡇ࡜࠿ࡽࠊDPRA ࡢ♫఍ⓗཷࡅධࢀᛶࡣ㧗࠸ࡶࡢ࡜⪃࠼ࡿࠋ44 ⾜ᨻୖࡢ฼⏝ᛶ㸸
DPRA ࡛㝧ᛶࡢ⤖ᯝࡀᚓࡽࢀࡓሙྜࠊࡑࡢ໬Ꮫ≀㉁ࢆ UN GHS ༊ศ㸯࡟ศ㢮㸦ᙉ࠸ឤసᛶ≀㉁㸧
ࡍࡿࡇ࡜ࡣ⾜ᨻୖྍ⬟࡛࠶ࡿࠋࡋ࠿ࡋ࡞ࡀࡽࠊࡲࢀ࡟ഇ㝧ᛶࡢ⤖ᯝࡀ⏕ࡌࡿࡇ࡜࡟␃ពࡋ࡞ࡅࢀࡤ
࡞ࡽ࡞࠸ࠋ୍᪉ࠊDPRA ࡢ㝜ᛶ⤖ᯝࡀᚓࡽࢀࡓሙྜࠊࡑࡢ໬Ꮫ≀㉁ࡢ⓶⭵ឤసᛶࡣഇ㝜ᛶࡢྍ⬟ᛶ
ࡀ࠶ࡾࠊDPRA ༢⊂࡛ࡑࡢ⓶⭵ឤసᛶࢆุᐃࡍࡿࡇ࡜ࡣ㞴ࡋ࠸ࠋIntegrated Approaches to Testing andAssessment: IATA)* ࢆᵓᡂࡍࡿࡑࡢ௚ࡢ᝟ሗ※࡜⤌ࡳྜࢃࡏ࡚ホ౯ࡍࡿࡇ࡜࡟ࡼࡾࠊDPRA ࡣ⾜ᨻⓗ࡟฼⏝ྍ⬟࡛࠶ࡿ࡜⪃࠼ࡿࠋ
*:OECD ࡟࡚࢞࢖ࢲࣥࢫ᱌ࡀ᳨ウ୰ཧ⪃ᩥ⊩1) OECD Test Guideline 442C, In Chemico Skin Sensitisation, Direct Peptide Reactivity Assay (DPRA)(2015)
http://www.oecd-ilibrary.org/environment/test-no-442c-in-chemico-skin-sensitisation_97892642297
09-en;jsessionid=2d30155etbl8v.x-oecd-live-022) EC EURL-ECVAM (2013). Recommendation on the Direct Peptide Reactivity Assay (DPRA) for skinsensitization testing.
3) EUROPEAN COMMISSION (2012) Direct Peptide Reactivity Assay (DPRA) , ECVAM Validation
Study Report
http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eurl-ecvam-recommendations/files-dpra/DPRA%20V
alidation%20Study%20Report.pdf
4) Gerberick GF, Vassallo JD, Foertsch LM, Price BB, Chaney, JG, Lepoittevin JP. (2007).
Quantification of chemical peptide reactivity for screening contact allergens: A classification treemodel approach. Toxicol. Sci. 97(2), 417-427
5) JaCVAM ⓶⭵ឤసᛶヨ㦂㈨ᩱ⦅⧩ጤဨ఍㸸⓶⭵ឤసᛶヨ㦂ホ౯ሗ࿌᭩ Direct Peptide
Reactivity Assay (DPRA)㸦ᖹᡂ 27 ᖺ 2 ᭶ 6 ᪥㸧

5

5

6

⓶⭵ឤసᛶヨ㦂ホ౯ሗ࿌᭩Direct Peptide Reactivity Assay (DPRA)㸸
࣌ࣉࢳࢻ⤖ྜᛶヨ㦂ᖹᡂ 27 ᖺ 2 ᭶ 6 ᪥

JaCVAM ⓶⭵ឤసᛶヨ㦂㈨ᩱ⦅⧩ጤဨ఍

1

7

JaCVAM ⓶⭵ឤసᛶヨ㦂㈨ᩱ⦅⧩ጤဨ఍
ጤဨ㛗 ⟄஭ᑦஂ㸦⏣㎶୕⳻〇⸆ᰴᘧ఍♫㸧ጤ ဨ Ᏻ㐩⋹Ꮚ㸦ᅜ❧་⸆ရ㣗ရ⾨⏕◊✲ᡤ㸧  㔠⃝⏤ᇶᏊ㸦୍⯡㈈ᅋἲே 㣗ရ⸆ရᏳ඲ࢭࣥࢱ࣮㸧  ᑠᓥᖾ୍㸦୍⯡㈈ᅋἲே 㣗ရ⸆ရᏳ඲ࢭࣥࢱ࣮㸧  బ⸨୍༤㸦ᅜ❧኱Ꮫἲே ⚟஭኱Ꮫ㸧  Ṋྜྷṇ༤㸦୍⯡㈈ᅋἲே ໬Ꮫ≀㉁ホ౯◊✲ᶵᵓ㸧  ᳃ᮏ㝯ྐ㸦ఫ཭໬Ꮫᰴᘧ఍♫㸧

2

8

せ᪨
⓶⭵ឤసᛶࡣ໬Ꮫ≀㉁ࡢᏳ඲ᛶホ౯࡟࠾࠸࡚㔜せ࡞ホ౯㡯┠࡛࠶ࡾࠊᚑ᮶ࠊࣔࣝࣔࢵࢺ
ࡸ࣐࢘ࢫࢆ⏝࠸ࡿື≀ᐇ㦂࡟ࡼࡗ࡚ホ౯ࡉࢀ࡚ࡁࡓࠋ㏆ᖺ EU ࡟࠾ࡅࡿḢᕞ໬Ꮫရつไ࡛ࡣࠊᏳ඲ᛶホ౯ࡣࢥࣥࣆ࣮ࣗࢱ࣮ࢆ⏝࠸ࡓᐃ㔞ⓗᵓ㐀άᛶ┦㛵㸦 Quantitative Structure-Activity
Relationship: QSAR㸧ࣔࢹࣝࡸ in vitro ヨ㦂ࡢ௦᭰ἲࡀ᥎ዡࡉࢀ࡚࠾ࡾࠊື≀ᐇ㦂࡟ࡼࡾᏳ඲ᛶホ౯ࡉࢀࡓᡂศࢆྵࡴ໬⢝ရࡢ㍺ධ㈍኎ࡀ⚗Ṇࡉࢀࡓࡇ࡜࠿ࡽ㸦2013 ᖺ 3 ᭶඲㠃᪋⾜㸧ࠊື≀ࢆ⏝࠸࡞࠸ in vitro ヨ㦂ἲࡢ㛤Ⓨࡀᙉࡃᮃࡲࢀ࡚࠸ࡿࠋDirect Peptide Reactivity Assay㸦DPRA㸸࣌ࣉࢳࢻ⤖ྜᛶヨ㦂㸧ࡣឤసᛶᡂ❧ึᮇẁ㝵ࡢ཯ᛂ࡛࠶ࡿࢱࣥࣃࢡ㉁࡜໬Ꮫ≀㉁ࡢ⤖ྜ཯ᛂࢆᶵჾศᯒ࡟ࡼࡗ࡚ホ౯ࡍࡿᡭἲ࡛࠶ࡿࠋᮏሗ࿌᭩ࡣࠊࡇࡢ DPRA ࡟ࡘ࠸࡚ࠊ
ࡑࡢᡭ㡰ࡸ᭷⏝ᛶ࡜㝈⏺ࢆ The European Union Reference Laboratory for Alternatives to Animal
Testing㸦 EURL ECVAM㸧࡟ࡼࡾᐇ᪋ࡉࢀࡓࣂࣜࢹ࣮ࢩࣙࣥሗ࿌᭩ཬࡧ EURL ECVAM

Scientific Advisory Committee㸦ESAC㸧➨୕⪅ホ౯㸦ࣆ࢔ࣞࣅ࣮ࣗ㸧ሗ࿌᭩࡞࡝ࢆᇶ࡟సᡂ
ࡋࡓࡶࡢ࡛࠶ࡿࠋDPRA ࡣࢩࢫࢸ࢖ࣥྵ᭷࣌ࣉࢳࢻ㸦Ac-RFAACAA-COOH㸧࡜⿕㦂≀㉁ཬࡧࣜࢪࣥྵ᭷࣌
ࣉࢳࢻ㸦Ac-RFAAKAA-COOH㸧࡜⿕㦂≀㉁ࢆࡑࢀࡒࢀΰྜ࣭཯ᛂࡉࡏࠊ24 ᫬㛫ᚋ࡟࠾ࡅࡿ
ᮍ཯ᛂࡢ࣌ࣉࢳࢻ㔞ࢆᇶ࡟⿕㦂≀㉁ࡢ཯ᛂᛶࢆศ㢮ࡍࡿᡭἲ࡛࠶ࡾࠊ㧗㏿ᾮయࢡ࣐ࣟࢺࢢ
ࣛࣇ࢕࣮㸦HPLC㸧ศᯒࡀྍ⬟࡞᪋タ࡛࠶ࢀࡤᐜ᫆࡟ᐇ᪋ࡍࡿࡇ࡜ࡀ࡛ࡁࡿࠋᮏヨ㦂ἲࡢඛ⾜ࣂࣜࢹ࣮ࢩࣙࣥヨ㦂࡟࠾ࡅࡿ᪋タෆ෌⌧ᛶࡣ 73%-100%࡛࠶ࡾࠊ3 ᪋タ୰ 1 ᪋タ࡟࠾࠸࡚ࠊ
GHS ༊ศ 1B㸦ᙅ࠸ឤసᛶ≀㉁㸧ࡢ≀㉁࡛෌⌧ᛶࡀప࠿ࡗࡓࡓࡵࠊ㐩ᡂᇶ‽㸦85㸣㸧࡟㐩ࡋ࡚࠾ࡽࡎࠊᙅ࠸ឤసᛶ≀㉁࡛ࡣุᐃࡀࡪࢀࡿᠱᛕࡀ࠶ࡗࡓࠋ୍᪉ࠊ᪋タ㛫෌⌧ᛶࡣ 75%࡛࠶ࡾࠊ㐩ᡂᇶ‽㸦80㸣㸧ࢆ‶ࡓࡉ࡞࠿ࡗࡓࡀࠊ㐺⏝⠊ᅖእࡢ㔠ᒓሷࢆ㝖࠸ࡓሙྜ࡟㐩ᡂᇶ‽ࢆୖᅇࡗࡓࠋ
᥋ゐ⓶⭵⅖ࡢࣜࢫࢡࢆື≀࡛ணࡍࡿヨ㦂ἲ࡜ࡋ࡚▱ࡽࢀ࡚࠸ࡿ࣐࢘ࢫࢆ⏝࠸ࡿᒁᡤࣜ

ࣥࣃ⠇ヨ㦂㸦Local Lymph Node Assay: LLNA㸧ࡢヨ㦂⤖ᯝࢆཧ↷ࡋࠊඛ⾜ࣂࣜࢹ࣮ࢩࣙࣥヨ㦂࡟࠾ࡅࡿṇ☜ᗘ㸦Accuracy㸧ࡣ 78㸣ࠊឤᗘ㸦Sensitivity㸧ࡣ 71㸣ࠊ≉␗ᗘ㸦Specificity㸧ࡣ
92%࡜ሗ࿌ࡉࢀ࡚࠸ࡿࠋᮏヨ㦂㐺⏝እࡢ㔠ᒓሷࢆ㝖࠸ࡓሙྜ࡟࡛ࡶឤᗘࡣ⣙ 75㸣࡛࠶ࡾࠊ㝜ᛶࡢ⤖ᯝࡀᚓࡽࢀࡓሙྜࡣࠊഇ㝜ᛶࡢྍ⬟ᛶࢆ⪃៖ࡋࠊ⿵᏶ࡋᚓࡿ௚ࡢヨ㦂ἲ࡟ࡼࡾ☜ㄆࡋ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋDPRA ࡣឤసᛶⓎ⌧ᶵᗎ࡟࠾ࡅࡿึᮇࡢ㔜せ࡞࢖࣋ࣥࢺ࡛࠶ࡿࢱࣥࣃࢡ㉁࡜໬Ꮫ≀㉁ࡢ
⤖ྜ཯ᛂࢆ᳨ฟࡋ࡚࠾ࡾࠊ໬Ꮫ≀㉁ࡢឤసᛶࢆุ᩿ࡍࡿୖ࡛㔜せ࡞᝟ሗࢆ୚࠼࡚ࡃࢀࡿࠋ
LLNA ࡢ 1/10 ⛬ᗘࡢ⤒㈝࡛ᐇ᪋ྍ⬟࡛࠶ࡾࠊື≀ࢆ⏝࠸࡞࠸ in chemico ヨ㦂ἲ࡛࠶ࡿࡇ࡜
࠿ࡽࠊ᭷⏝ᛶࡣ㧗࠸ࠋࡋ࠿ࡋ࡞ࡀࡽࠊᮏἲࡣ௦ㅰ⣔ࢆḞࡃ໬Ꮫⓗヨ㦂ἲ࡛࠶ࡾࠊάᛶ໬࡟
௦ㅰ⣔ࡸ㠀⏕≀ⓗάᛶ໬ࢆᚲせ࡜ࡍࡿឤసᛶ≀㉁ࠊᙅ࠸ឤసᛶ≀㉁ࡸ㔠ᒓሷࠊ␯Ỉᛶࡢ㧗࠸≀㉁࡞࡝ࡣṇࡋࡃࡑࡢឤసᛶࡀ᳨ฟࡉࢀ࡞࠸ྍ⬟ᛶࡀ࠶ࡿࠋ௨ୖࡢ஦ᐇࢆ㋃ࡲ࠼ࠊ㈨ᩱ
⦅⧩ጤဨ఍ࡣࠊドᣐࡢ㔜ࡳ௜ࡅࡸ௚ࡢヨ㦂ἲ㸦LLNAࠊࣔࣝࣔࢵࢺࢆ⏝࠸ࡿ⓶⭵ឤసᛶヨ㦂㸧࡜⤌ࡳྜࢃࡏ࡛ࡢホ౯ࢆ᥎ዡࡍࡿࠋ

3

9

㸯㸬⥴ゝ
 ⓶⭵ឤసᛶࢆホ౯ࡍࡿࡇ࡜ࡣ໬Ꮫ≀㉁ࡢᏳ඲ᛶホ౯࡟࠾࠸࡚㔜せ࡛࠶ࡿࠋ໬Ꮫ≀㉁ࡢ⓶⭵࡛ࡢ᥋ゐ⓶⭵⅖ࡢࣜࢫࢡࢆື≀࡛ணࡍࡿヨ㦂ἲ࡜ࡋ࡚ࣔࣝࣔࢵࢺࢆ⏝࠸ࡿ⓶⭵ឤసᛶ

ヨ㦂㸦OECD TG406㸧ࡸ࣐࢘ࢫࢆ⏝࠸ࡿᒁᡤࣜࣥࣃ⠇ヨ㦂㸦Local Lymph Node Assay: LLNA,
OECD TG429㸧ࡀ࠶ࡿࠋࡇࡢ[3H-Methyl]-thymidine ྲྀ㎸㔞ࢆ఩ඖ⣲㸦RI㸧ࢆ⏝࠸ࡎ ATP 㔞ࢆ㔞ࢆᐃࡍࡿ LLNA ௨እ࡟ᨺᑕᛶྠ

ᐃࡍࡿ LLNA:DA㸦OECD TG442A㸧ࡸ Bromodeoxyuridine

ᐃࡍࡿ LLNA:BrdU-ELISA㸦OECD TG442B㸧ࡀ࠶ࡿࠋࡇࡢࡼ࠺࡟ࠊ⌧ᅾ OECD ࠿ࡽ࢞࢖ࢻࣛ࢖ࣥ࡜ࡋ࡚බ⾲ࡉࢀ࡚࠸ࡿヨ㦂ἲࡣࠊື≀ࢆ⏝࠸ࡓ in vivo ࡢヨ㦂ἲࡢࡳ࡛࠶ࡿࠋ
 EU ࡟࠾ࡅࡿḢᕞ໬Ꮫရつ๎㸦Registration, Evaluation, Authorization and Restriction ofChemicals: REACH㸧࡛ࡣࠊᏳ඲ᛶホ౯ࡣࢥࣥࣆ࣮ࣗࢱ࣮ࢆ⏝࠸ࡓᐃ㔞ⓗᵓ㐀άᛶ┦㛵㸦Quantitative Structure-Activity Relationship: QSAR㸧ࣔࢹࣝࡸ in vitro ヨ㦂➼࡟ࡼࡿ௦᭰ἲࡀ᥎
ዡࡉࢀ࡚࠾ࡾࠊື≀ᐇ㦂࡟ࡼࡾᏳ඲ᛶࡀホ౯ࡉࢀࡓᡂศࢆྵࢇࡔ໬⢝ရࡢ㍺ධཬࡧ㈍኎ࡀ
⚗Ṇࡉࢀࡓ㸦2013 ᖺ 3 ᭶඲㠃᪋⾜㸧ࠋࡑࡢࡓࡵࠊ໬Ꮫ≀㉁ࡢ⓶⭵ឤసᛶࢆホ౯ࡍࡿ௦᭰ἲࡢ
㛤Ⓨࡀᙉࡃồࡵࡽࢀ࡚࠸ࡿࠋ ⌧ᅾࠊ࣌ࣉࢳࢻ࡜ࡢ⤖ྜ཯ᛂࢆ฼⏝ࡋࡓ Direct Peptide Reactivity Assay㸦DPRA㸸࣌ࣉࢳࢻ⤖ྜᛶヨ㦂㸧
ࠊ༢⌫⣔⣽⬊ࡢάᛶ໬ࢆ฼⏝ࡋࡓ human Cell Line Activation Test㸦h-CLAT㸧ཬࡧ Myeloid U937 Skin Sensitization Test㸦MUSST㸧ࠊࢣࣛࢳࣀࢧ࢖ࢺ⣽⬊⣔ࡢᶆⓗ㑇ఏᏊࢆ⏝࠸ࡓ ARE-Nrf2 Luciferase Test Method㸦KeratinoSensτἲ㸧࡞࡝ࡢ⓶⭵ឤసᛶヨ㦂ࡢື≀ࢆ⏝࠸ ࡞ ࠸ື ≀ᐇ 㦂 ௦᭰ ἲࡀ ᥦ ᱌ࡉ ࢀ࡚ ࠾ ࡾࠊ The European Union Reference Laboratory for
Alternatives to Animal Testing㸦EURL ECVAM㸧➼࡟࠾࠸࡚ඛ⾜ࣂࣜࢹ࣮ࢩࣙࣥ◊✲ࡀ⾜ࢃࢀ࡚࠸ࡿࠋ DPRA ࡣࠊ໬Ꮫ≀㉁ࡀ࣌ࣉࢳࢻ࡜ඹ᭷⤖ྜࡋච␿ᛂ⟅ࢆᘬࡁ㉳ࡇࡍᢠཎ࡜࡞ࡿᛶ㉁ࢆ฼⏝ࡋࠊᮍ཯ᛂࡢࢩࢫࢸ࢖ࣥᡈ࠸ࡣࣜࢪࣥࢆྵࡴ࣌ࣉࢳࢻࢆ㧗㏿ᾮయࢡ࣐ࣟࢺࢢࣛࣇ࢕࣮
㸦HPLC㸧࡛ᐃࡍࡿヨ㦂ἲ࡛࠶ࡿࠋᮏἲࡢඛ⾜ࣂࣜࢹ࣮ࢩࣙࣥ◊✲ࡢ⤖ᯝ࡟ࡘ࠸࡚ࡣࠊ

EURL ECVAM Scientific Advisory Committee㸦ESAC㸧࡟ࡼࡿ➨୕⪅ホ౯㸦ࣆ࢔ࣞࣅ࣮ࣗ㸧ࡀ᏶஢ࡋ࡚࠸ࡿࠋJaCVAM ⓶⭵ឤసᛶヨ㦂㈨ᩱ⦅⧩ጤဨ఍㸦௨ୗࠊጤဨ఍㸧ࡀ DPRA ࡢ⓶⭵ឤసᛶヨ㦂௦᭰ἲ࡜ࡋ࡚ࡢ⛉Ꮫⓗጇᙜᛶ࡟ࡘ࠸࡚ࠊ⌧ᅾࡲ࡛࡟බ㛤ࡉࢀ࡚࠸ࡿ᝟ሗࢆࡶ࡜࡟ホ౯ࡋࡓࡢ࡛ࠊࡑࡢ⤖ᯝࢆሗ࿌ࡍࡿࠋ
㸰㸬ヨ㦂ἲࡢཎ⌮⓶⭵ឤసᛶࡣࠊࣄࢺ࡛ࡣ᥋ゐ⓶⭵⅖ࠊື≀㸦㱎ṑ㢮㸧࡛ࡣ᥋ゐ㐣ᩄ⑕࡜ࡋ࡚▱ࡽࢀࡿ໬Ꮫ≀㉁ࡢẘᛶࡢ୍ࡘ࡛࠶ࡿࠋOECD ࡀࡲ࡜ࡵࡓ Adverse Outcome Pathway㸦AOP㸧࡛ࡣࠊ໬Ꮫ≀㉁࡟ࡼࡿ⓶⭵ឤసᛶࡣḟࡢ 4 ࡘࡢ Key event ࠿ࡽᡂࡿ࡜ࡉࢀ࡚࠸ࡿ 1)ࠋ
1㸧໬Ꮫ≀㉁࡜ࢱࣥࣃࢡ㉁ࡢࢩࢫࢸ࢖ࣥṧᇶ࠶ࡿ࠸ࡣࣜࢪࣥṧᇶ࡜ࡢඹ᭷⤖ྜ
2 㸧 ࢣ ࣛ ࢳ ࣀ ࢧ ࢖ ࢺ ࡟ ࠾ ࡅ ࡿ ⅖ ⑕ ᛶ ᛂ ⟅ ཬ ࡧ Antioxidant/electrophile response element(ARE)-dependent pathway ࡟ࡼࡿ㑇ఏᏊⓎ⌧
4

10

3㸧ᶞ≧⣽⬊ࡢάᛶ໬㸦≉␗ⓗ⣽⬊⾲㠃࣐࣮࣮࢝ࡢⓎ⌧ࠊࢣࣔ࢝࢖ࣥࡸࢧ࢖ࢺ࢝࢖ࣥࡢ⏘⏕㸧
4㸧ࣜࣥࣃ⠇࡟࠾ࡅࡿ T ⣽⬊ࡢቑṪ
DPRA ࡣࠊୖ㏙ࡋࡓ⓶⭵ឤసᛶࡢ AOP ࡟࠾ࡅࡿࠗ໬Ꮫ≀㉁࡜ࢱࣥࣃࢡ㉁ࡢඹ᭷⤖ྜ࠘࡟ᑐᛂࡋࡓື≀ࢆ⏝࠸࡞࠸ in chemico ヨ㦂࡛࠶ࡿࠋ௚࡟ࡶ in chemico ࡢ⓶⭵ឤసᛶヨ㦂ࡀ࠸ࡃࡘ࠿ሗ࿌ࡉࢀ࡚࠸ࡿ 2)-4)ࠋ
DPRA ࡛ࡣࠊ⓶⭵ෆࡢࢱࣥࣃࢡ㉁ࡢ௦ࢃࡾ࡟ྜᡂ࣌ࣉࢳࢻ࡛࠶ࡿࢩࢫࢸ࢖ࣥྵ᭷࣌ࣉࢳࢻ
㸦Ac-RFAACAA-COOH㸧࡜ࣜࢪࣥྵ᭷࣌ࣉࢳࢻ㸦Ac-RFAAKAA-COOH㸧ࡢ 2 ✀㢮ࢆ౑⏝ࡍࡿࠋ໬Ꮫ≀㉁࡜ࡑࢀࡒࢀࡢ࣌ࣉࢳࢻࢆΰྜࡋࠊ཯ᛂࡉࡏࠊΰྜ 24 ᫬㛫ᚋ࡟࠾ࡅࡿᮍ཯ᛂࡢ
࣌ࣉࢳࢻ㔞ࢆ㧗㏿ᾮయࢡ࣐ࣟࢺࢢࣛࣇ࢕࣮㸦HPLC㸧࡛ศ㞳ᐃ㔞ࡍࡿࠋࡑࡢ⤖ᯝࢆᇶ࡟ࠊ໬
Ꮫ≀㉁ࡢ཯ᛂᛶࢆ 4 ẁ㝵㸦High, Moderate, Low, Minimal㸧࡟ศ㢮ࡍࡿࠋ㸱㸬ヨ㦂ᡭ㡰㸭ุᐃ 5)
3-1. ౑⏝ࡍࡿ࣌ࣉࢳࢻ࠾ࡼࡧ㝧ᛶᑐ↷ࡢㄪ〇࣭ࢩࢫࢸ࢖ࣥྵ᭷࣌ࣉࢳࢻ/ࣜࣥ㓟⦆⾪⁐ᾮ㸦ࢩࢫࢸ࢖ࣥྵ᭷࣌ࣉࢳࢻ⁐ᾮ㸧ࢩࢫࢸ࢖ࣥྵ᭷࣌ࣉࢳࢻ㸦Ac-RFAACAA-COOHࠊ⣧ᗘ㸸90-95%㸧ࡣࠊࣜࣥ㓟⦆⾪ᾮ
㸦pH7.5㸧࡟ 0.667 mM ࡢ⃰ᗘ࡟࡞ࡿࡼ࠺࡟⁐ゎࡉࡏࡿࠋ࣭ࣜࢪࣥྵ᭷࣌ࣉࢳࢻ/㓑㓟࢔ࣥࣔࢽ࣒࢘⦆⾪⁐ᾮ㸦ࣜࢪࣥྵ᭷࣌ࣉࢳࢻ⁐ᾮ㸧ࣜࢪࣥྵ᭷࣌ࣉࢳࢻ㸦Ac-RFAAKAA-COOHࠊ⣧ᗘ㸸90-95%㸧ࡣࠊ㓑㓟࢔ࣥࣔࢽ࣒࢘⦆
⾪ᾮ㸦pH10.2㸧࡟ 0.667 mM ࡢ⃰ᗘ࡟࡞ࡿࡼ࠺࡟⁐ゎࡉࡏࡿࠋ࣭㝧ᛶᑐ↷㸸Cinnamic Aldehyde㸦CAS No:104-55-2ࠊ⣧ᗘӍ95%㸧
  Cinnamic Aldehyde ࢆࠊAcetonitrile ࡟ 100 mM ࡢ⃰ᗘ࡛⁐ゎࡉࡏࠊࡑࡢᚋ⿕㦂≀㉁࡜ྠ
ᵝ࡟୧࣌ࣉࢳࢻ⁐ᾮ࡜ΰྜࡍࡿࠋ
3-2. ᪉ἲ௨ୗࡢࣇ࣮ࣟࢳ࣮ࣕࢺ࡟ᚑ࠸ࠊᐇ᪋ࡍࡿࠋ

511

1. ⿕㦂≀㉁ࢆ100mMࡢ⃰ᗘ࡛௨ୗࡢ࠸ࡎࢀ࠿ࡢ፹య࡟⁐ゎࡉࡏࡿ㸦⿕㦂≀㉁⁐ᾮ㸧ࠋ࠙፹యࠚAcetonitrileࠊWaterࠊ Acetonitrile 㸸Water(1:1)ࠊIsopropanolࠊAcetoneࠊ
Acetone : Acetonitrile(1:1)ࠊDMSO: Acetonitrile(1:9)ࠊ
DMSO: Acetonitrile(1:1)
2. ⿕㦂≀㉁⁐ᾮ࡜㺫㺽㺪㺽㺟㺢㺼⁐ᾮࢆΰྜࡍࡿ
2-A. ⿕㦂≀㉁⁐ᾮ࡜㺚㺛㺡㺐㺻ྵ᭷㺫㺽㺪㺽㺟㺢㺼⁐ᾮࢆ10:1࡛ΰྜ(n=3)࣭Sample:⿕㦂≀㉁⁐ᾮ㸩㺚㺛㺡㺐㺻ྵ᭷㺫㺽㺪㺽㺟ࢻ⁐ᾮ࣭Co-elusion Control:⿕㦂≀㉁⁐ᾮ㸩㺶㺻㓟⦆⾪ᾮ࣭Reference Control: ፹య㸩㺚㺛㺡㺐㺻ྵ᭷㺫㺽㺪㺽㺟ࢻ⁐ᾮ
2-B.⿕㦂≀㉁⁐ᾮ࡜ 㺶㺚㺼㺻ྵ᭷㺫㺽㺪㺽㺟㺢㺼⁐ᾮࢆ50:1࡛ΰྜ(n=3)࣭Sample:⿕㦂≀㉁⁐ᾮ㸩㺶㺚㺼㺻ྵ᭷㺫㺽㺪㺽㺟ࢻ⁐ᾮ࣭Co-elusion Control:⿕㦂≀㉁⁐ᾮ㸩㓑㓟㺏㺻㺱㺤㺑㺯⦆⾪ᾮ࣭Reference Control: ፹య㸩㺶㺚㺼㺻ྵ᭷㺫㺽㺪㺽㺟ࢻ⁐ᾮ
3. ྛΰྜᾮࢆ24s2᫬㛫㺐㺻㺕㺋㺫㺼㺎㺢㸦ᬯᐊࠊ25s2.5Υ㸧ࡍࡿ
4. HPLC࡛ศᯒࡍࡿ*5. ᮍ཯ᛂ㺫㺽㺪㺽㺟㺢㺼ࡢPeak㠃✚࠿ࡽࠊ௨ୗࡢᘧ࡟ࡼࡾ
㺫㺽㺪㺽㺟㺢㺼ῶᑡ⋡㸦Percent Peptide Depletion㸧ࢆ⟬ฟ ࡍࡿ
Percent Peptide Depletion=

1--

Peptide Peak Area in Sample
Mean Peptide Peak Area in Reference Controls

100*ศᯒ᮲௳㸦᥎ዡ㸧᥎ዡ࣒࢝ࣛ㸸Zorbax SB-C18 㸦3.5 ȣm, 2.1mm×100mm㸧➼ᗘ㸸30Υ
UV ᳨ฟἼ㛗㸸220 nm
ὶ㏿㸸0.35 mL/min⛣ື┦㸸 㸦A㸧0.1%ࢺࣜࣇࣝ࢜ࣟ㓑㓟Ỉ
㸦B㸧0.085%ࢺࣜࣇࣝ࢜ࣟ㓑㓟࢔ࢭࢺࢽࢺࣜࣝ
᫬㛫㸦ศ㸧

A%

B%

0

90

10

10

75

25

11

10

90

13

10

90

13.5

90

10

3-3. ヨ㦂ᡂ❧ࡢ᮲௳1) ヨ㦂ᡂ❧࡟ࡣࠊ௨ୗࡢ᮲௳ࢆ‶ࡓࡉ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ
࣭ࢩࢫࢸ࢖ࣥྵ᭷࣌ࣉࢳࢻ࠾ࡼࡧࣜࢪࣥྵ᭷࣌ࣉࢳࢻࡢࡑࢀࡒࢀࢆ⏝࠸࡚ࠊ
0.0167~0.534mM ࡢ⠊ᅖࡢ 6 ⃰ᗘ࡟࡚ᶆ‽᭤⥺ࡢసᡂࢆ⾜࠸ࠊࡑࡢ┦㛵ಀᩘࡀ 0.99 ࡼࡾ኱ࡁࡃ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ
࣭㝧ᛶᑐ↷࡛࠶ࡿ Cinnamic aldehyde ࡢ⤖ᯝࡣࠊࢩࢫࢸ࢖ࣥྵ᭷࣌ࣉࢳࢻ࡛ࡣ 3 ᅇࡢ⧞ࡾ㏉ࡋ࡟ࡼࡿᖹᆒ࣌ࣉࢳࢻῶᑡ⋡ࡣ 60.8%~100%࡛ࠊᶆ‽೫ᕪࡣ 14.9%ࡼࡾᑠࡉࡃࠊࣜࢪࣥྵ
612

᭷࣌ࣉࢳࢻ࡛ࡣ 3 ᅇ⧞ࡾ㏉ࡋ࡟ࡼࡿᖹᆒ࣌ࣉࢳࢻῶᑡ⋡ࡣ 40.2%~69.0%࡛ࠊᶆ‽೫ᕪࡣ
11.6%ࡼࡾᑠࡉࡃ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ
࣭ࡑࢀࡒࢀࡢ࣌ࣉࢳࢻࡈ࡜࡟ 3 ✀㢮ࡢ Reference Control
㸦A, B, C㸧ࢆタࡅࡿࠋReference Control
A㸦n=3㸧ࡣࠊศᯒ๓ࡢ HPLC ࢩࢫࢸ࣒㐺ྜᛶࡢ☜ㄆࡢࡓࡵࡢࡶࡢࠊ Reference Control B㸦n=6㸧ࡣศᯒ᫬㛫୰ࡢ Reference Control ࡢᏳᐃᛶࢆ☜ㄆࡍࡿࡓࡵࡢࡶࡢࠊ Reference
Control C㸦n=3㸧ࡣ౑⏝ࡉࢀࡓ⁐፹ࡀ࣌ࣉࢳࢻࡢῶᑡ࡟ᙳ㡪ࡋ࡞࠸ࡇ࡜ࢆ☜ㄆࡍࡿࡓࡵࡢ
ࡶࡢ࡛࠶ࡿࠋReference Control A ࡢᖹᆒ࣌ࣉࢳࢻ⃰ᗘࡣ 0.50s0.05mM ࡜࡞ࡾࠊ9 ࡘࡢ
Reference Control B ࠾ࡼࡧ C ࡛ࡣ࣌ࣉࢳࢻࣆ࣮ࢡ㠃✚ࡢኚືಀᩘࡀ 15.0%ࡼࡾᑠࡉࡃ࡞ࡅ
ࢀࡤ࡞ࡽ࡞࠸ࠋ
2) ⿕㦂≀㉁ࢆྵࡴ Sample ࡢ⤖ᯝ࡛ࡣࠊ௨ୗࡢ᮲௳ࡀ‶ࡓࡉࢀ࡞ࡅࢀࡤ࡞ࡽ࡞࠸
࣭⧞ࡾ㏉ࡋ࡛⾜࠺ศᯒ್ࡢ᭱኱ᶆ‽೫ᕪࡣࠊࢩࢫࢸ࢖ࣥྵ᭷࣌ࣉࢳࢻῶᑡ⋡࡛ࡣ 14.9%ࡼ
ࡾᑠࡉࡃࠊࣜࢪࣥྵ᭷࣌ࣉࢳࢻῶᑡ⋡࡛ࡣ 11.6%ࡼࡾᑠࡉࡃ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ
࣭3 ࡘࡢ Reference Control C ࡢᖹᆒ⃰ᗘࡣ 0.50s0.05mM ࡛࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ
3-4. ホ౯⿕㦂≀㉁ࡢ཯ᛂᛶࡣࠊ

ᐃࡈ࡜ࡢ࣌ࣉࢳࢻῶᑡ⋡㸦Percent Peptide Depletion㸧࠿ࡽࠊᖹᆒ

್ࢆ⟬ฟࡋࠊ௨ୗࡢ DPRA ศ㢮ணࣔࢹࣝ㸦⾲ 1㸧࡟ᚑࡗ࡚཯ᛂᛶࢆศ㢮ࡍࡿ 5)ࠋ཯ᛂᛶࡢ

ศ㢮࡛ࠊLowࠊModerate ࠾ࡼࡧ High ࡟ศ㢮ࡉࢀࡿ໬Ꮫ≀㉁ࡣ㝧ᛶࠊNo or Minimal ࡟ศ㢮ࡉࢀࡿ໬Ꮫ≀㉁ࡣ㝜ᛶ࡜ணࡍࡿ 6)ࠋࡕ࡞ࡳ࡟ࠊ࣌ࣉࢳࢻ࡜⿕㦂≀㉁ࡢ⁐ฟ᫬㛫ࡀ㔜࡞ࡗࡓሙྜ㸦Co-elution㸧ࠊ࣌ࣉࢳࢻῶᑡ⋡㸦Percent Peptide Depletion㸧ࡢ⟬ฟࡀ୙ྍ⬟࡜࡞ࡿࡀࠊࡑ
ࡢ⁐ฟ᫬㛫ࡢ㔜࡞ࡾࡀࠊࣜࢪࣥྵ᭷࣌ࣉࢳࢻ࡛ࡢࡳㄆࡵࡓሙྜ࡟ࡣࠊࢩࢫࢸ࢖ࣥྵ᭷࣌ࣉ
ࢳࢻࡢ⤖ᯝ࠿ࡽࠕࢩࢫࢸ࢖ࣥ 1:10 ࡢࡳࡢண⾲1ศ㢮ணࣔࢹࣝࠖ࡟ᚑ࠸ࠊ཯ᛂᛶࢆศ㢮ࡋࠊண

ࡍࡿࠋ

ࣔࢹࣝ

ࢩࢫࢸ࢖ࣥ 1:10 ࠾ࡼࡧࣜࢪࣥ 1:50 ࡢணࣔࢹࣝࢩࢫࢸ࢖ࣥࡢῶᑡ⋡࡜ࣜࢪࣥࡢῶᑡ⋡ࡢᖹᆒ್

DPRA ண

཯ᛂᛶࡢศ㢮

0%ӌῶᑡ⋡ࡢᖹᆒ್ӌ6.38%

No or Minimal㝜ᛶ

6.38%<ῶᑡ⋡ࡢᖹᆒ್ӌ22.62%

Low

㝧ᛶ

22.62%<ῶᑡ⋡ࡢᖹᆒ್ӌ42.47%

Moderate

42.47%<ῶᑡ⋡ࡢᖹᆒ್ӌ100%

Highࢩࢫࢸ࢖ࣥ 1:10 ࡢࡳࡢணࣔࢹࣝࢩࢫࢸ࢖ࣥࡢῶᑡ⋡DPRA ண

཯ᛂᛶࡢศ㢮

0%ӌῶᑡ⋡ӌ13.89%

No or Minimal㝜ᛶ

13.89%<ῶᑡ⋡ӌ23.09%

Low

㝧ᛶ

23.09%<ῶᑡ⋡ӌ98.24%

Moderate

98.24%<ᖹᆒῶᑡ⋡ӌ100%

High

7

13

㸲㸬⢭ᗘ
ᮏἲࡣࠊEURL ECVAM ࡟࠾࠸࡚ࠊ⾲ 2 ࡟♧ࡍ 24 ≀㉁ࢆ⏝࠸࡚ඛ⾜ࣂࣜࢹ࣮ࢩࣙࣥヨ㦂ࡀᐇ᪋ࡉࢀࠊᢏ⾡⛣㌿ᛶࠊ᪋タෆ෌⌧ᛶཬࡧ᪋タ㛫෌⌧ᛶࡀホ౯ࡉࢀ࡚࠸ࡿࠋ
4-1. ᢏ⾡⛣㌿ᛶ
 16 ≀㉁ࢆ⏝࠸࡚୺ᑟ᪋タࡢ P㸤G ♫࠿ࡽ Ricerca ♫࡜ IVMU㸦EURL ECVAM ࡢ◊✲ࣘࢽࢵࢺ㸧࡬ࡢᢏ⾡⛣㌿ᛶ࡟ࡘ࠸࡚ホ౯ࡀ⾜ࢃࢀ࡚࠸ࡿࠋࡑࡢ⤖ᯝࠊタഛࡀᩚࡗ࡚࠸࡚カ⦎ࡉࢀࡓࢫࢱࢵࣇࡀᒃࢀࡤ 3 ᪥㛫ࡢࢺ࣮ࣞࢽࣥࢢ࡛ P㸤G ♫࠿ࡽ Ricerca ♫࡜ IVMU ࡬ࡢ DPRAࡢᢏ⾡⛣㌿ࡀྍ⬟࡛࠶ࡗࡓࠋࡲࡓࠊDPRA ࡣ㞴ࡋ࠸᧯సᡭ㡰ࢆᚲせ࡜ࡏࡎࠊ⿦⨨ࡸヨ⸆ࡣ㉎ධྍ⬟࡛࠶ࡾࠊᶆ‽᧯సᡭ㡰᭩㸦Standard Operating Procedure: SOP㸧ࡀヲ⣽࡟సᡂࡉࢀ࡚࠸ࡿ
ࡇ࡜࠿ࡽࠊጤဨ఍ࡣࠊᮏ㑥࡛ࡣỗ⏝ HPLC ཬࡧࡑࡢᢏ⾡ࢆಖ᭷ࡍࡿ᪋タ࡛ᐜ᫆࡟ᐇ᪋ྍ⬟࡜⪃࠼ࡿࠋ
4-2. ᪋タෆ෌⌧ᛶ㸦⾲ 3-1㸧
 15 ≀㉁ࢆ⏝࠸ࡓ 3 ᪋タࡢ᪋タෆ࡛ࡢ⓶⭵ឤసᛶ㸦S㸧࡜㠀ឤసᛶ㸦NS㸧ࡢ୍⮴ᗘࡣࠊP&G♫㸸73.3%, Ricerca ♫㸸100%, IVMU㸸86.7%࡛࠶ࡗࡓࠋ㐩ᡂᇶ‽ࡣ 85㸣࡟タᐃࡉࢀ࡚࠾ࡾࠊ
P㸤G ♫ࡣࡇࡢ್ࢆୗᅇࡗࡓࠋP&G ♫ࡣࠊGHS ༊ศ 1A ࡢ 6 ≀㉁ࡣࡍ࡭࡚෌⌧ᛶࡢ࠶ࡿ⤖ᯝ࡛࠶ࡗࡓࡀࠊ1B ࡢ 3 ≀㉁୰ 2 ≀㉁㸦Benzyl Salicylate ཬࡧ R(+)Limonene㸧࡛෌⌧ᛶࡀᚓࡽࢀ
࡞࠿ࡗࡓࡓࡵࠊ㐩ᡂᇶ‽ࢆୗᅇࡗࡓ࡜⪃࠼ࡽࢀࡓࠋࡲࡓࠊMinimal, Low, Moderate, High ࡢ 4ࢡࣛࢫࡢ୍⮴ᗘࡣ P&G ♫㸸66.7㸣ࠊRicerca ♫㸸100㸣ࠊIVMU㸸73.3%࡛࠶ࡗࡓࠋ
4-3. ᪋タ㛫෌⌧ᛶ㸦⾲ 3-2㸧
 24 ≀㉁ࡢ 3 ᪋タࡢ᪋タ㛫෌⌧ᛶࡣ⓶⭵ឤసᛶ㸦S㸧࡜㠀ឤసᛶ㸦NS㸧ࡢ୍⮴ᗘ࡛ࡣ 75%࡜࡞ࡾ㐩ᡂᇶ‽ࡢ 80%ࢆୗᅇࡗࡓࠋ24 ≀㉁ࡢ୰࡟ࡣ㔠ᒓሷ࡛࠶ࡿ Beryllium sulfate ཬࡧ
Nickel chloride ࡀྵࡲࢀ࡚࠾ࡾࠊ㔠ᒓሷࡣᑐ㇟࣌ࣉࢳࢻ࡜ࡢඹ᭷⤖ྜࢆ⏕ࡌ࠺ࡿᐁ⬟ᇶࢆᣢࡓ࡞࠸ࡇ࡜࠿ࡽࠊᮏἲࡢ㐺⏝⠊ᅖእ࡜ุ᩿ࡉࢀࡿࡓࡵ㺂ࡇࢀࡽ 2 ≀㉁ࢆ㝖࠸ࡓሙྜࡢ᪋タ㛫෌⌧ᛶࡣ 82%࡛࠶ࡗࡓࠋࡲࡓࠊ24 ≀㉁࡛ࡢ Minimal, Low, Moderate, High ࡢ 4 ࢡࣛࢫ࡛ࡣࠊ᪋タ㛫෌⌧ᛶࡣ 62.5%࡛࠶ࡗࡓࠋ
㸳㸬ṇ☜ᗘ㸦ឤᗘཬࡧ≉␗ᗘ㸧⢭ᗘ࡜ྠᵝ࡟ࠊ⾲ 2 ࡟♧ࡍ 24 ≀㉁ࢆ⏝࠸ࡓ EURL ECVAM ࡢඛ⾜ࣂࣜࢹ࣮ࢩࣙࣥヨ㦂ࡢᡂ⦼ࢆᇶ࡟᪤▱ࡢ LLNA ࡢᡂ⦼࡜ࡢ୍⮴ᗘࠊឤᗘཬࡧ≉␗ᗘࡀホ౯ࡉࢀ࡚࠸ࡿࠋ
 24 ≀㉁඲࡚ࡢᡂ⦼ࢆᇶ࡟ホ౯ࢆ⾜ࡗࡓሙྜࠊᐇ᪋ 3 ᪋タࡢᡂ⦼ࡢ✚⟬࡟ࡼࡿឤᗘ
㸦Sensitivity㸧ࡣ 70.8%ࠊ≉␗ᗘ㸦Specificity㸧ࡣ 91.7%ࠊṇ☜ᗘ㸦Accuracy㸧ࡣ 77.8%࡛࠶ࡗࡓࠋヨ㦂᪋タẖࡢᡂ⦼ࡣࠊヨ㦂᪋タ 1㸦P&G㸧࡛ࡣឤᗘࡣ 68.8%ࠊ≉␗ᗘࡣ 100%ࠊṇ☜ᗘ
ࡣ 79.2㸣ࠊヨ㦂᪋タ 2㸦Ricerca㸧࡛ࡣឤᗘࡣ 68.8%ࠊ≉␗ᗘࡣ 100%ࠊṇ☜ᗘࡣ 79.2㸣ࠊヨ㦂᪋タ 3㸦IVMU㸧࡛ࡣឤᗘࡣ 75㸣ࠊ≉␗ᗘࡣ 75%ࠊṇ☜ᗘࡣ 75㸣࡛࠶ࡗࡓࠋࡲࡓࠊᮏἲ
ࡢṇ☜ᗘ࡟㛵ࡋ࡚㛤Ⓨ᪋タ࡛࠶ࡿ P&G ࠿ࡽᥦฟࡉࢀࡓࣄࢫࢺࣜ࢝ࣝࢹ࣮ࢱ࡛ࡣ 86㸣ࠊ᪤ሗ8

14

࡛ࡣ 80㸣㹼89㸣࡜ሗ࿌ࡉࢀ࡚࠸ࡿࠋ
24 ≀㉁ࡢヨ㦂≀㉁ࡢ୰࡟ࡣ㔠ᒓሷ࡛࠶ࡿ Beryllium sulfate ཬࡧ Nickel chloride ࡀྵࡲࢀ࡚
࠾ࡾࠊ㔠ᒓሷࡣᑐ㇟࣌ࣉࢳࢻ࡜ࡢඹ᭷⤖ྜࢆ⏕ࡌ࠺ࡿᐁ⬟ᇶࢆᣢࡓ࡞࠸ࡇ࡜࠿ࡽࠊᮏἲࡢ
㐺⏝⠊ᅖእ࡜ุ᩿ࡉࢀࡿࡓࡵ㺂ࡇࢀࡽࢆ㝖ࡃ 22 ≀㉁࡟ࡼࡿホ౯ࢆ⾜ࡗࡓሙྜࠊᐇ᪋ 3 ᪋タࡢᡂ⦼ࡢ✚⟬࡟ࡼࡿឤᗘࡣ 76.2%ࠊ≉␗ᗘࡣ 91.7%ࠊṇ☜ᗘࡣ 81.8%࡜࡞ࡿࠋ㐺⏝⠊ᅖእ࡜⪃࠼ࡽࢀࡿ㔠ᒓሷࢆ㝖እࡋࡓሙྜ࡛ࡶࠊ඲࡚࠶ࡿ࠸ࡣ୍㒊ࡢ᪋タ࡛ 5 ≀㉁㸦DihydroeugenolࠊChlorpromazine HClࠊBenzylsalicylateࠊBenzylcinnamateࠊR㸦+㸧-Limonene㸧ࡀഇ㝜ᛶ࡜ホ౯ࡉࢀࡿࡀࠊࡇࢀࡽࡢ≀㉁ࡢ୰࡛ Dihydroeugenol ཬࡧ Limonene ࡣࣉࣟࣁࣉࢸ
ࣥ࠶ࡿ࠸ࡣࣉࣞࣁࣉࢸࣥ࡜ࡋ࡚▱ࡽࢀ࡚࠾ࡾࠊᮏヨ㦂⣔ࡀ௦ㅰ⣔ࢆ᭷ࡉ࡞࠸༢⣧࡞໬Ꮫ཯ᛂࢆ᳨ฟࡍࡿヨ㦂⣔࡛࠶ࡿࡇ࡜ࡀഇ㝜ᛶ࡜࡞ࡿ୍ᅉ࡜ᛮࢃࢀࡿࠋ
࡞࠾ࠊ඲࡚ᡈ࠸ࡣ୍㒊ࡢ᪋タ࡛ഇ㝜ᛶ࡜ุᐃࡉࢀࡿ Chlorpromazine HClࠊBenzylsalicylate
ཬࡧ Benzylcinnamate ࡢ 3 ≀㉁ࠊ୍㒊ࡢ᪋タ࡛ഇ㝧ᛶ࡜ุᐃࡉࢀࡿ Benzyl alcohol ཬࡧMethylsalicylate ࡢ 2 ≀㉁࡟ࡘ࠸࡚ࠊࣂࣜࢹ࣮ࢩࣙࣥሗ࿌᭩࡛ࡣࠊࡑࡢ⌮⏤࡟ࡘ࠸࡚᫂☜࡞ㄝ᫂ࡣ࡞ࡉࢀ࡚࠸࡞࠸ࠋࡋ࠿ࡋࠊࡇࢀࡽࡢ୰࡛ഇ㝜ᛶ࡜ุᐃࡉࢀࡿ 3 ≀㉁ࡢ cLogP ࡢ್ࡣ࠸ࡎࢀࡶ 3.2 ௨ୖ࡛࠶ࡾࠊࡑࡢ␯Ỉᛶࡢ㧗ࡉࡀỈ⣔࡛ࡢ཯ᛂࢆᚲせ࡜ࡍࡿᮏἲ࡛ഇ㝜ᛶ࡜࡞ࡿ୍せᅉ࡜᥎ᐹࡉࢀࡿࠋ୍᪉࡛ 2-Mercaptobenzothiazole㸦cLogP㸸3.42㸧ࡣ㧗␯Ỉᛶ࡟ࡶ࠿࠿ࢃ
ࡽࡎṇࡋࡃ㝧ᛶ࡜ุᐃࡉࢀ࡚࠸ࡿࡀࠊࡇࢀࡣᮏ≀㉁ࡢᣢࡘ SH ᇶࡀࣜࢪࣥṧᇶ࡜㧗࠸཯ᛂᛶࢆ᭷ࡍࡿࡇ࡜࡟㉳ᅉࡍࡿ࡜ᛮࢃࢀࡿࠋ

915

⾲ 2 ౪ヨ≀㉁ࣜࢫࢺ 6)
No.

Chemical NameCAS

S tatecLogP*

LLNA

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Benzoquinone
4-Phenylenediamine
Kathon CG (1.2% CM I)
Beryllium sulfate
Formaldehyde
Chloramine T
Chlorpromazine HCl
2-M ercaptobenzothiazole
Dihydroeugenol
1-Thioglycerol
Imidazolidinylurea
M ethylmethacrylate
Benzylsalicylate
Nickel chloride
Benzylcinnamate
R(+)-Limonene
Glycerol
2,4-Dichloronitrobenzene
Benzyl alcohol
M ethylsalicylate
Isopropanol
Dimethylisophthalate
4-Aminobenzoic acid
Xylene106-51-4
106-50-3
26172-55-4
7787-56-6
50-00-0
127-65-1
69-09-0
149-30-4
2785-87-7
96-27-539236-46-9
80-62-6
118-58-1
7718-54-9
103-41-3
5989-27-5
56-81-5
611-06-3
100-51-6
119-36-8
67-63-01459-93-4
150-13-0
1330-20-7

Solid
Solid
LiquidSolid
Liquid
Solid
Solid
Solid
LiquidLiquidSolid
LiquidLiquidSolid
Solid
LiquidLiquidSolid
LiquidLiquidLiquidSolid
Solid
Liquid

0.96
0.43
-0.69
4.89
3.42
2.84
-0.5
-1.28
1.14
3.2
3.89
3.01
-1.33
3.06
1.02
1.46
0.38
2.12
0.78
3.01

+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+

LLNA
potency
category**
extremestrongextremeextremestrongstrongstrongmoderate
moderate
moderateweak
weak
moderateno category
weak
weak
no categoryno categoryno categoryno categoryno categoryno categoryno category
weak

GHS
potency
category
1A
1A
1A
1A
1A
1A
1A
1A
1B
1B
1B
1B
1B
1B
1B
1B
NC
NC
NC
NC
NC
NC
NC
NC

+㸸LLNA 㝧ᛶࠊ-㸸LLNA 㝜ᛶࠊNC㸸GHS ༊ศእࠋ*㸸ChemBio Draw Ultra 11.0 (Cambridge Soft) ࢆ⏝࠸࡚⟬ฟࠋ**㸸ECETOC Technical Report #87 ࡢศ㢮࡟ࡼࡿࠋDirect Peptide Reactivity Assay (DPRA) , ECVAM Validation Study Report 㸦 EUROPEAN
COMMISSION, 2012㸧グ㍕ࡢ᝟ሗࢆᇶ࡟⦅㞟ࠋ

1016

⾲ 3-1 ᪋タෆ෌⌧ᛶᐇ㦂ᡂ⦼ 6)
ChemicalKathon CG (1.2% CM I)
Beryllium sulfate
Formaldehyde
Chloramine T
Chlorpromazine HCl
2-M ercaptobenzothiazole
Benzylsalicylate
Nickel chloride
Benzylcinnamate
R(+)-Limonene
M ethylsalicylate
Isopropanol
Dimethylisophthalate
4-Aminobenzoic acid
XyleneReference result(GHS category)
+(1A)
+(1A)
+(1A)
+(1A)
+(1A)
+(1A)
+(1B)
+(1B)
+(1B)
+(1B)
-(NC)
-(NC)
-(NC)
-(NC)
-(NC)

Ricerca
P&G
Exp 1 Exp 2 Exp 3 Exp 1 Exp 2 Exp 3
SLYS
SLYS
S
S
S
SLYS
S
S
S
NS
NS
NS
S
S
S
S
S
S
SLYS
SLYS
SLYS
SLYS
SLYS
SLYS
NS
NS
NS
NS
NS
NS
SLYS
SLYS
SLYS
S
S
S
NS
NS
NS
S
S
S
NS
NS
S
NS
NS
NS
NS
NS
NS
NS
NS
NS
S
NS
S
S
S
S
NS
NS
S
NS
NS
NS
NS
NS
NS
NS
NS
NS
NSLYS NSLYS NSLYS NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
NS
S
NS
NS
NS

IVMU
Exp 1 Exp 2 Exp 3
S
S
S
NS
NS
NS
S
S
S
S
S
S
NS
NS
NS
S
S
S
NS
NS
NS
S
NS
S
S
NS
NS
S
S
S
S
S
S
NS
NS
NS
NSLYS NSLYS NSLYS
NS
NS
NS
NS
NS
NS

+㸸LLNA 㝧ᛶࠊ-㸸LLNA 㝜ᛶࠊNC㸸GHS ༊ศእࠋSLYS ᡈ࠸ࡣ NSLYS㸸ࣜࢪࣥྵ᭷࣌ࣉࢳࢻ࡟࡚ Co-elution ࡀ⏕ࡌࡓࡓࡵࠊࢩࢫࢸ࢖ࣥྵ᭷࣌ࣉ
ࢳࢻࡢ⤖ᯝࡢࡳ࠿ࡽࠊุᐃ
S:⓶⭵ឤసᛶ࠶ࡾ࡜ุᐃࠊNS:⓶⭵ឤసᛶ࡞ࡋ࡜ุᐃ
Direct Peptide Reactivity Assay (DPRA) , ECVAM Validation Study Report 㸦 EUROPEAN
COMMISSION, 2012㸧グ㍕ࡢ᝟ሗࢆᇶ࡟⦅㞟ࠋ

1117

⾲ 3-2 ᪋タ㛫෌⌧ᛶᐇ㦂ᡂ⦼ 6)
Chemical

Reference result(GHS category)

P&G

Ricerca

IVMU

Benzoquinone

+(1A)

S

SLYS

S

4-Phenylenediamine

+(1A)

S

SCL

S

Kathon CG (1.2% CMI)

+(1A)

S

S

S

Beryllium sulfate

+(1A)

S

NS

NS

Formaldehyde

+(1A)

S

S

S

Chloramine T

+(1A)

S

S

S

Chlorpromazine HCl

+(1A)

NS*

NS

NS

2-Mercaptobenzothiazole

+(1A)

S

S

S

Dihydroeugenol

+(1B)

NS

NSLYS

S

1-Thioglycerol

+(1B)

SLYS

SCL

SCL

Imidazolidinylurea

+(1B)

S

S

S

Methylmethacrylate

+(1B)

SCL

SCL

S

Benzylsalicylate

+(1B)

NS

NS

S

Nickel chloride

+(1B)

NS

S

NS

Benzylcinnamate

+(1B)

NS

NS

NS

R(+)-Limonene

+(1B)

S

S

S

Glycerol

-(NC)

NS

NS

NS

2,4-Dichloronitrobenzene

-(NC)

NS

NS

NS

Benzyl alcohol

-(NC)

NSLYS

NS

S

Methylsalicylate

-(NC)

NS

NS

S

Isopropanol

-(NC)

NS

NS

NS

Dimethylisophthalate

-(NC)

NS

NS

NS

4-Aminobenzoic acid

-(NC)

NS

NS

NS

Xylene

-(NC)

NS

NS

NS

+㸸LLNA 㝧ᛶࠊ-㸸LLNA 㝜ᛶࠊNC㸸GHS ༊ศእࠋLYS ᡈ࠸ࡣ CL㸸Co-elution ࡀ⏕ࡌࡓࡇ࡜ࢆ♧ࡍࠋ
S:⓶⭵ឤసᛶ࠶ࡾ࡜ุᐃࠊNS:⓶⭵ឤసᛶ࡞ࡋ࡜ุᐃ
*ኴᏐࡢᡂ⦼ࡣ๓ฟࡢ᪋タෆ෌⌧ᛶࢹ࣮ࢱࡢከᩘỴุᐃ࡟ࡼࡾỴᐃࡉࢀࡓࡶࡢࠋ
Direct Peptide Reactivity Assay (DPRA) , ECVAM Validation Study Report 㸦 EUROPEAN
COMMISSION, 2012㸧グ㍕ࡢ᝟ሗࢆᇶ࡟⦅㞟ࠋ

1218

㸴㸬ホ౯ྍ⬟࡞≀㉁ࡢ⠊ᅖGerberick ࡽࡢ 82 ໬Ꮫ≀㉁ࢆ⏝࠸ࡓホ౯࡛ࡣࠊ⾲ 4 ࡟♧ࡍ㏻ࡾࠊᵝࠎ࡞໬Ꮫ≀㉁ࡢ⓶⭵ឤసᛶࡢணࡀྍ⬟࡛࠶ࡿࡇ࡜ࡀ♧ࡉࢀ࡚࠸ࡿࠋࡓࡔࡋࠊLLNA ࡛ Weak sensitizer ࡟ศ㢮ࡉࢀ

ࡿ 5 ≀ ㉁ 㸦 D-Hexylcinnamaldehyde, D-Amylcinnamaldehyde, Oxalic acid, Benzyl benzoate,
2,2,6,6-Tetramethyl-3,5-heptanedione㸧 ࡜ Modelate sensitizer ࡟ศ㢮ࡉࢀࡿ 1 ≀㉁㸦Nonanoyl
chloride㸧ࡣࠊDPRA ࡛ࡣ Minimal ࡜࡞ࡾࠊ㝜ᛶ࡟ศ㢮ࡉࢀ࡚࠸ࡿࠋࡋࡓࡀࡗ࡚ࠊឤసᛶ࣏
ࢸࣥࢩࣕࣝࡢᙅ࠸≀㉁ࡣࠊഇ㝜ᛶ࡜ุᐃࡉࢀࡿሙྜࡀ࠶ࡿࡇ࡜࡟␃ពࡍࡿᚲせࡀ࠶ࡿࠋ୍㒊ࡢࣉࣞࣁࣉࢸࣥ㸦౛ࠊ4-Phenylenediamine㸧ࡣṇࡋࡃุᐃࡉࢀࡿࡀࠊࣉࣞࣁࣉࢸࣥཬ
ࡧࣉࣟࣁࣉࢸࣥࡢࡍ࡭࡚ࢆホ౯ྍ⬟࡞≀㉁࡜ࡍࡿ᰿ᣐࡣ༑ศ࡟ࡣ࡞࠸ࠋࡲࡓࠊᮏヨ㦂ἲࡣࠊ୺࡟ࢩࢫࢸ࢖ࣥᇶࡸࣜࢪࣥᇶ࡜཯ᛂࡍࡿ໬Ꮫ≀㉁ࢆᑐ㇟࡜ࡍࡿࠋ୍᪉ࠊࢱࣥࣃࢡ㉁࡜㓄఩⤖ྜࢆᙧᡂࡍࡿ㔠ᒓ㢮ࡣࠊホ౯ྍ⬟࡞≀㉁ࡢ⠊ᅖ࠿ࡽእࢀࡿࠋ
⾲ 4 82 ໬Ꮫ≀㉁ࡢホ౯⤖ᯝ 7)
Chemical Name
Diphenylcyclopropenone
Oxazolone
Benzoyl peroxide
Kathon CG
Bandrowski's base
5-Chloro-2-methyl-4-isothiazolin-3-one
p -Benzoquinone
Tetrachlorosalicylanilide
2,4-Dinitrochlorobenzene
Glutaraldehyde
Fluorescein isothiocynate
Phthalic anhydride
Lauryl gallate
Propyl gallate
CD3
Trimellitic anhydride
Formaldehyde
M etol2-Hydroxyethyl acrylate
GlyoxalVinyl pyridine
2-M ercaptobenzothiazole
Nonanoyl chloride
2-M ethyl-2H-isothiazol-3-one
1,2-Benzisothiazolin-3-one
M ethyl-2-nonynoate
Cinnamaldehyde
Phenylacetaldehyde
Benzylideneacetone
2,4-Heptadienal
Squaric acidTrans-2-hexanal
Diethyl maleate
2-Phenylpropionaldehyde
Perillaldehyde
Palmitoyl chloride
1-(4-M ethoxyphenyl)-1-penten-3-one
a-Hexylcinnamaldehyde
a-Amylcinnamaldehyde
2,3-Butanedione
Farnesal

EC3 value
0.0003
0.003
0.004
0.008
0.008
0.009
0.0099
0.04
0.05
0.1
0.14
0.16
0.3
0.32
0.6
0.6
0.61
0.8
1.4
1.4
1.6
1.7
1.8
1.9
2.3
2.5
3
3
3.7
4
4.3
5.5
5.8
6.3
8.1
8.8
9.3
11
11
11
12

LLNA
categoly
ExtremeExtremeExtremeExtremeExtremeExtremeExtremeExtremeExtremeStrongStrongStrongStrongStrongStrongStrongStrongStrongM oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
M oderate
Weak
Weak
Weak
Weak

Reactivity based onCys(1:10) andLys(1:50) data
High
High
High
High
High
High
High
M oderate
High
High
High
M oderate
High
High
High
Low
M oderate
High
High
High
M oderateHigh
M inimal
High
High
High
High
M oderateHighHigh
M oderateHighHigh
M oderate
M oderate
M oderate
Low
M inimalM inimalHigh
Low

Chemical Name
Oxalic acid
Benzyl benzoate
4-Allylanisole
LilialCyclamen aldehyde
Imidazolidinyl urea
5-M ethyl-2,3-hexanedione
2,2,6,6-Tetramethyl-3,5-heptanedione
Ethyleneglycol dimethacrylate
Ethyl acrylate
Hydroxycitronellal
GlycerolHexaneDiethyl phthalate
Octanoic acid
2-Hydroxypropyl methacrylate
1-Butanol
4-Hydroxybenzoic acid
6-M ethyl coumarin
M ethyl salicylate
Chlorobenzene
Lactic acid
1-Bromobutane
2-Acetylcyclohexanone
4-M ethoxyacetophenone
Ethylbenzoylacetate
Ethyl vanillin
Isopropanol
Propylene glycol
Sulfanilamide
Isopropyl myristate
Benzaldehyde
M ethylparaben
Nonanoic acid
Propyl paraben
Rsorcinol
Salicylic acid
Sulphanilic acid
Vanillin
Coumarin
Vinylidene dichloride

EC3 value

LLNA
categoly

15
17
18
19
22
24
26
27
28
28
33
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
21 (False +)Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated
Not calculated

Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Weak
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer
Non sensitizer

Reactivity based onCys(1:10) andLys(1:50) data
M inimalM inimal
Low
Low
Low
M oderate
Low
M inimal
High
High
Low
M inimalM inimalM inimalM inimalLow
M inimalM inimalM inimalM inimalM inimalM inimalLow
Low
M inimalM inimalM inimalM inimalM inimalM inimalM inimalM inimalM inimalM inimalM inimalM inimalM inimalM inimalM inimalM inimal㸵㸬᭷⏝ᛶ࡜㝈⏺ᮏἲࡣỗ⏝ HPLC ཬࡧࡑࡢᢏ⾡ࢆಖ᭷ࡍࡿ᪋タ࡛ᐜ᫆࡟ᐇ᪋ྍ⬟࡛࠶ࡿࠋࡲࡓࠊᮏἲࡣ
ື≀ࢆ⏝࠸࡞࠸ in chemico ࡢᡭἲ࡛࠶ࡾࠊ⛉Ꮫⓗ࡞┠ⓗࡢࡓࡵ࡟ᐇ᪋ࡉࢀࡿື≀ᐇ㦂࡟㛵ࡋࠊࠕື≀ࡢឡㆤཬࡧ⟶⌮࡟㛵ࡍࡿἲᚊࠖཬࡧ 3Rs ࡢ⢭⚄࡜ྜ⮴ࡋ࡚࠸ࡿࠋࡉࡽ࡟ DPRA ཬࡧ
LLNA ࡟ࡘ࠸࡚౑⏝ࡍࡿᾘ⪖ရ㈝ࢆヨ⟬ࡋࡓ࡜ࡇࢁࠊ1 ࢔ࢵࢭ࢖ᙜࡓࡾࡢᾘ⪖ရ㈝ࡣ LLNA
1319࡛⣙ 10 ୓෇࡛࠶ࡿࡢ࡟ᑐࡋࠊDPRA ࡛ࡣ⣙ 1 ୓෇࡜ 1/10 ⛬ᗘࡢ⤒㈝࡛ᐇ᪋ྍ⬟࡛࠶ࡾࠊᐇ
㦂ᮇ㛫ࡶ LLNA ࡼࡾ▷ᮇ㛫࡛ᐇ᪋ྍ⬟࡛࠶ࡿࡇ࡜࠿ࡽࠊヨ㦂ἲ࡜ࡋ࡚⡆౽ᛶ࣭⤒῭ᛶࡢ㠃࠿ࡽ᭷⏝࡜ᛮࢃࢀࡿࠋ
ࡋ࠿ࡋ࡞ࡀࡽࠊᮏἲࡣᾮ┦୰࡛ࡢ཯ᛂࢆᚲせ࡜ࡍࡿࡓࡵࠊ⿕㦂≀㉁ࡣᑡ࡞ࡃ࡜ࡶ㐺ษ࡞⁐፹㸦AcetonitrileࠊWaterࠊAcetonitrile:Water (1:1)ࠊIsopropanolࠊAcetoneࠊAcetone:Acetonitrile(1:1)ࠊDMSO:Acetonitrile (1:9) ࠊDMSO:Acetonitrile (1:1)㸧࡟ 100mM ࡢ⃰ᗘ࡛⁐ゎࡍࡿᚲせࡀ࠶ࡿࠋࡲࡓࠊᮏἲࡢឤᗘࡣヨ㦂㐺⏝እ࡜⪃࠼ࡽࢀࡿ㔠ᒓሷࢆ㝖࠸ࡓሙྜ࡛ࡶ⣙ 75㸣࡛࠶ࡾࠊ1/4 ࡢ໬ྜ≀ࡀഇ㝜ᛶ࡜ホ౯ࡉࢀࡿࡓࡵࠊࡇࡢヨ㦂ἲ༢⊂࡛⓶⭵ឤసᛶࡢ௦᭰ἲ࡜ࡋ࡚
⪃࠼ࡿࡢࡣ㞴ࡋ࠸ࠋ≉࡟ୗグࡢ໬ྜ≀ࡀഇ㝜ᛶ࡜࡞ࡿྍ⬟ᛶࡀ㧗࠸ࡓࡵヨ㦂⤖ᯝࡢゎ㔘࡟ࡣὀពࡀᚲせ࡜⪃࠼ࡽࢀࡿࠋ
1㸧LLNA ࡛ moderate ࡲࡓࡣ weak ࡢ໬ྜ≀
LLNA

࡛

weak

sensitizer࡟ ศ 㢮 ࡉ ࢀ ࡿ

5≀ ㉁ 㸦 D-Hexylcinnamaldehyde,

D-Amylcinnamaldehyde, Oxalic acid, Benzyl benzoate, 2,2,6,6-Tetramethyl-3,5-heptanedione㸧 ࡜Modelate sensitizer ࡟ศ㢮ࡉࢀࡿ 1 ≀㉁㸦Nonanoyl chloride㸧ࡣࠊDPRA ࡛ࡣ Minimal ࡜࡞ࡾࠊ㝜ᛶ࡟ศ㢮ࡉࢀࡿࠋ
2㸧ࣉࣟࣁࣉࢸࣥࠊࣉࣞࣁࣉࢸࣥ
ᮏヨ㦂⣔ࡣ௦ㅰ⣔ࢆ᭷ࡉ࡞࠸༢⣧࡞໬Ꮫ཯ᛂࢆ᳨ฟࡍࡿヨ㦂⣔࡛࠶ࡿࡇ࡜࠿ࡽࠊឤసᛶ
ࡢ⋓ᚓ࡟௦ㅰⓗᡈ࠸ࡣ㠀௦ㅰⓗάᛶ໬ࢆᚲせ࡜ࡍࡿࣉࣟࣁࣉࢸࣥᡈ࠸ࡣࣉࣞࣁࣉࢸࣥ
㸦౛㸸Dihydroeugenol ཬࡧ Limonene㸧ࡣഇ㝜ᛶ࡜ホ౯ࡉࢀࡿྍ⬟ᛶࡀ࠶ࡿࠋ
3㸧␯Ỉᛶࡢ㧗࠸≀㉁➼ṇ☜ᗘ㸦ឤᗘཬࡧ≉␗ᗘ㸧࡛㏙࡭ࡓ࡜࠾ࡾࠊỈ⣔࡛ࡢ཯ᛂࢆᚲせ࡜ࡍࡿᮏἲ࡛ࡣ␯Ỉᛶࡢ㧗࠸≀㉁㸦౛㸸Chlorpromazine HCl㸧ࡣഇ㝜ᛶ࡜ุᐃࡉࢀࡿሙྜࡀ࠶ࡿࠋࡉࡽ࡟ࢩࢫࢸ࢖
ࣥࡸࣜࢪࣥ௨እࡢ࢔࣑ࣀ㓟࡜ඃඛⓗ࡟཯ᛂࡍࡿࡼ࠺࡞ồ㟁Ꮚṧᇶࢆ᭷ࡍࡿ≀㉁࡟㛵ࡋ࡚ࡶṇࡋࡃุᐃࡉࢀ࡞࠸ྍ⬟ᛶࡀ࠶ࡿࠋ
௨ୖࡢࡇ࡜࠿ࡽࠊDPRA ࡟ࡼࡾឤసᛶ㝜ᛶ࡜ุ᩿ࡉࢀࡓሙྜࡣࠊࡑࡢ≀ᛶ➼࡟ࡼࡾഇ㝜ᛶ࡜࡞ࡿྍ⬟ᛶࢆ⪃៖ࡋࠊ⿵᏶ࡋᚓࡿ௚ࡢヨ㦂ἲ࡟ࡼࡾ☜ㄆࡍࡿᚲせࡀ࠶ࡿࠋඛ⾜ࣂࣜࢹ࣮ࢩࣙࣥヨ㦂ࡢᡂ⦼࠿ࡽ DPRA ࡟ࡼࡾ㝧ᛶ࡜ุ᩿ࡉࢀࡓሙྜࡣࠊឤసᛶ㝧ᛶ࡜ุ᩿ࡍࡿࡇ࡜ࡣྍ⬟࡜⪃࠼ࡿࡀࠊᮏἲࡢ≉␗ᗘࡣ⣙ 90㸣࡛࠶ࡾࠊᕼ࡟ഇ㝧ᛶࡢ⤖ᯝࡀ⏕ࡌࡿྍ⬟ᛶࡀ࠶ࡿࡇ࡜࡟ࡶ␃ពࡍࡿᚲせࡀ࠶ࡿࠋ࡞࠾ࠊᮏἲࡣ⤖ྜᙉᗘࢆ Minimal, Low,
Moderate, High ࡢ 4 ࢡࣛࢫࡢศ㢮ࡍࡿ᪉ἲࡶᥦ᱌ࡉࢀ࡚࠸ࡿࡀࠊ᪋タ㛫෌⌧ᛶࡣ 62.5%࡜ప
ࡃࠊ⤖ྜᙉᗘࡢศ㢮࡟ࡣ㐺ࡉ࡞࠸࡜⪃࠼ࡿࠋ୍᪉ࠊDPRA ࡣឤసᛶⓎ⌧ᶵᗎ࡟࠾ࡅࡿึᮇࡢ㔜せ࡞࢖࣋ࣥࢺ࡛࠶ࡿࢱࣥࣃࢡ㉁࡜໬Ꮫ
≀㉁ࡢ⤖ྜ཯ᛂࢆ᳨ฟࡋ࡚࠾ࡾࠊ໬Ꮫ≀㉁ࡢឤసᛶࢆุ᩿ࡍࡿୖ࡛㔜せ࡞᝟ሗࢆ୚࠼ࡿࡇ࡜࠿ࡽࠊドᣐࡢ㔜ࡳ௜ࡅࡸ௚ࡢヨ㦂ἲ࡜⤌ࡳྜࢃࡏ࡛ࡢホ౯ࢆ᥎ዡࡍࡿࠋ
14

20

㸶㸬⤖ㄽ
DPRA ࡣࠊ⡆౽ᛶ࣭⤒῭ᛶࡢ㠃࠿ࡽ᭷⏝࡞ື≀ᐇ㦂௦᭰ἲ࡛࠶ࡿࠋ
ᮏヨ㦂ἲࡢඛ⾜ࣂࣜࢹ࣮ࢩࣙࣥヨ㦂࡟࠾ࡅࡿ᪋タෆ෌⌧ᛶࡣࠊ3 ᪋タ୰ 1 ᪋タ࡟࠾࠸࡚ࠊ
GHS ༊ศ 1B㸦ᙅ࠸ឤసᛶ≀㉁㸧ࡢ≀㉁࡛෌⌧ᛶࡀᚓࡽࢀ࡞࠿ࡗࡓࡓࡵ㐩ᡂᇶ‽࡟㐩ࡋ࡚࠾ࡽࡎࠊᙅ࠸ឤసᛶ≀㉁࡛ࡣุᐃࡀࡪࢀࡿᠱᛕࡀ࠶ࡿࠋ୍᪉ࠊ᪋タ㛫෌⌧ᛶࡣࠊ㐺⏝⠊ᅖእࡢ㔠ᒓሷࢆ㝖࠸ࡓሙྜ࡟㐩ᡂᇶ‽ࢆୖᅇࡗࡓࠋ
ᮏヨ㦂ἲ㐺⏝እࡢ㔠ᒓሷࢆ㝖࠸ࡓሙྜࡢඛ⾜ࣂࣜࢹ࣮ࢩࣙࣥヨ㦂࡟࠾ࡅࡿឤᗘࡣ⣙ 75㸣࡛࠶ࡿࡓࡵࠊ㝜ᛶࡢ⤖ᯝࡀᚓࡽࢀࡓሙྜࡣࠊഇ㝜ᛶࡢྍ⬟ᛶࢆ⪃៖ࡋࠊ⿵᏶ࡋᚓࡿ௚ࡢヨ㦂ἲ࡟ࡼࡾ☜ㄆࡋ࡞ࡅࢀࡤ࡞ࡽ࡞ࡃࠊDPRA ࡢࡳ࡛⓶⭵ឤసᛶࢆ㝜ᛶ࡜ุᐃࡍࡿࡇ࡜ࡣ࡛ࡁ
࡞࠸ࠋඛ⾜ࣂࣜࢹ࣮ࢩࣙࣥヨ㦂࡟࠾ࡅࡿᮏἲࡢ≉␗ᗘࡣ⣙ 90㸣࡛࠶ࡾࠊ㝧ᛶࡢ⤖ᯝࡀᚓࡽࢀࡓ
ሙྜࡣࠊឤసᛶ㝧ᛶ࡜ุ᩿ࡍࡿࡇ࡜ࡣྍ⬟ࡔࡀࠊᕼ࡟ഇ㝧ᛶࡢ⤖ᯝࡀ⏕ࡌࡿྍ⬟ᛶࡀ࠶ࡿࡇ࡜࡟␃ពࡋ࡞ࡅࢀࡤ࡞ࡽ࡞࠸ࠋ
࡞࠾ࠊᮏἲࡣ⤖ྜᙉᗘࢆ Minimal, Low, Moderate, High ࡢ 4 ࢡࣛࢫ࡟ศ㢮ࡍࡿ᪉ἲࡶᥦ᱌
ࡉࢀ࡚࠸ࡿࡀࠊ᪋タ㛫෌⌧ᛶࡣ 62.5%࡜పࡃࠊ⤖ྜᙉᗘࡢศ㢮࡟ࡣ㐺ࡉ࡞࠸ࠋ
DPRA ࡣឤసᛶⓎ⌧ᶵᗎ࡟࠾ࡅࡿึᮇࡢ㔜せ࡞࢖࣋ࣥࢺ࡛࠶ࡿࢱࣥࣃࢡ㉁࡜໬Ꮫ≀㉁ࡢ
⤖ྜ཯ᛂࢆ᳨ฟࡋ࡚࠾ࡾࠊ໬Ꮫ≀㉁ࡢឤసᛶࢆุ᩿ࡍࡿୖ࡛㔜せ࡞᝟ሗࢆ୚࠼࡚ࡃࢀࡿࠋ
LLNA ࡢ 1/10 ⛬ᗘࡢ⤒㈝࡛ᐇ᪋ྍ⬟࡛࠶ࡾࠊື≀ࢆ⏝࠸࡞࠸ in chemico ヨ㦂ἲ࡛࠶ࡿࡇ࡜
࠿ࡽࠊ᭷⏝ᛶࡣ㧗࠸ࠋࡋ࠿ࡋ࡞ࡀࡽࠊᮏἲࡣ௦ㅰ⣔ࢆḞࡃ໬Ꮫⓗヨ㦂ἲ࡛࠶ࡾࠊάᛶ໬࡟
௦ㅰ⣔ࡸ㠀⏕≀ⓗάᛶ໬ࢆᚲせ࡜ࡍࡿឤసᛶ≀㉁ࠊᙅ࠸ឤసᛶ≀㉁ࡸ㔠ᒓሷࠊ␯Ỉᛶࡢ㧗࠸≀㉁࡞࡝ࡣṇࡋࡃࡑࡢឤసᛶࡀ᳨ฟࡉࢀ࡞࠸ྍ⬟ᛶࡀ࠶ࡿࠋ௨ୖࡢ஦ᐇࢆ㋃ࡲ࠼ࠊጤဨ఍ࡣࠊドᣐࡢ㔜ࡳ௜ࡅࡸ௚ࡢヨ㦂ἲ㸦LLNAࠊࣔࣝࣔࢵࢺࢆ⏝࠸ࡿ⓶⭵ឤసᛶヨ㦂㸧࡜⤌ࡳྜࢃࡏ࡛ࡢホ౯ࢆ᥎ዡࡍࡿࠋ

15

21

ᘬ⏝ᩥ⊩
1) OECD ENV/JM/MONO (2012) /Part1, The adverse outcome pathway for skin sensitization
Initiated by covalent binding to proteins : Scientific evidence.
2) Kato H., Okamoto M., Yamashita K., Nakamura Y., Fukumori Y., Nakai K. and Kaneko H. (2003)
Peptide binding assessment using mass spectrometory as a new screening method for skinsensitization. J. Toxicol. Sci. 28(1), 19-24.
3) Natsch, A. and Gfeller H. (2008) LC-MS-based characterization of the peptide reactivity ofchemicals to improve the in vitro prediction of the skin sensitization potential. Toxicol. Sci.
106(2), 464-478
4) Chipinda I., Ajibola R. O., Marakinyo M. K., Ruwona T. B. Simoyi R. H. and Siegel P. D. (2010)
Rapid and simple kinetics screening assay for electrophillic dermal sensitizers using
nitrobenzenethiol. Chem. Res. Toxicol. 23(5) 918-925.
5) OECD (2015) In Chemico Skin Sensitization: Direct Peptide Reactivity Assay (DPRA). OECD
Guideline for the Testing of Chemicals No. 442C.
6) EUROPEAN COMMISSION (2012) Direct Peptide Reactivity Assay (DPRA) , ECVAM
Validation Study Report
http://ihcp.jrc.ec.europa.eu/our_labs/eurl-ecvam/eurl-ecvam-recommendations/files-dpra/DPRA%20Validation%20Study%20Report.pdf
7) Gerberick F., Vassallo J.D., Foertsch L.M., Price B. B., Chaney, J. G., Lepoittevin, J-P. (2007)
Quantification of chemical peptide reactivity for screening contact allergens: a classification treemodel approach. Toxicol. Sci. 97(2), 417-427

16

22

OECD/OCDETG 442C$GRSWHG)HEUXDU\
OECD GUIDELINE FOR THE TESTING OF CHEMICALSIn Chemico Skin Sensitisation: Direct Peptide Reactivity Assay (DPRA)INTRODUCTION$VNLQVHQVLWLVHUUHIHUVWRDVXEVWDQFHWKDWZLOOOHDGWRDQDOOHUJLFUHVSRQVHIROORZLQJVNLQFRQWDFW
DV GHILQHG E\ WKH 8QLWHG 1DWLRQV *OREDOO\ +DUPRQL]HG 6\VWHP RI &ODVVLILFDWLRQ DQG /DEHOOLQJ RI
&KHPLFDOV 81 *+6    7KLV 7HVW *XLGHOLQH 7*  SURYLGHV DQ in chemico SURFHGXUH 'LUHFW 3HSWLGH
5HDFWLYLW\$VVD\±'35$ WREHXVHGIRUVXSSRUWLQJWKHGLVFULPLQDWLRQEHWZHHQVNLQVHQVLWLVHUVDQGQRQVHQVLWLVHUVLQDFFRUGDQFHZLWKWKH81*+6  
7KHUHLVJHQHUDODJUHHPHQWUHJDUGLQJWKHNH\ELRORJLFDOHYHQWVXQGHUO\LQJVNLQVHQVLWLVDWLRQ7KH
H[LVWLQJNQRZOHGJHRIWKHFKHPLFDODQGELRORJLFDOPHFKDQLVPVDVVRFLDWHGZLWKVNLQVHQVLWLVDWLRQKDVEHHQ
VXPPDULVHGLQWKHIRUPRIDQ$GYHUVH2XWFRPH3DWKZD\ $23   IURPWKHPROHFXODULQLWLDWLQJHYHQWWKURXJK WKH LQWHUPHGLDWH HYHQWV WR WKH DGYHUVH HIIHFW QDPHO\ DOOHUJLF FRQWDFW GHUPDWLWLV LQ KXPDQV RU
FRQWDFWK\SHUVHQVLWLYLW\LQURGHQWV:LWKLQWKHVNLQVHQVLWLVDWLRQ$23WKHPROHFXODULQLWLDWLQJHYHQWLVWKH
FRYDOHQWELQGLQJRIHOHFWURSKLOLFVXEVWDQFHVWRQXFOHRSKLOLFFHQWUHVLQVNLQSURWHLQV
7KH DVVHVVPHQW RI VNLQ VHQVLWLVDWLRQ KDV W\SLFDOO\ LQYROYHG WKH XVH RI ODERUDWRU\ DQLPDOV 7KHFODVVLFDOPHWKRGVEDVHGRQJXLQHDSLJVWKH0DJQXVVRQ.OLJPDQ*XLQHD3LJ0D[LPLVDWLRQ7HVW *037 
DQGWKH%XHKOHU7HVW7*  VWXG\ERWKWKHLQGXFWLRQDQGHOLFLWDWLRQSKDVHVRIVNLQVHQVLWLVDWLRQ$PXULQH WHVW WKH /RFDO /\PSK 1RGH $VVD\ //1$   7*    DQG LWV WZR QRQUDGLRDFWLYHPRGLILFDWLRQV//1$'$7*$  DQG//1$%UG8(/,6$7*%  ZKLFKDOODVVHVVWKH
LQGXFWLRQ UHVSRQVH H[FOXVLYHO\ KDYH DOVR JDLQHG DFFHSWDQFH VLQFH WKH\ SURYLGH DQ DGYDQWDJH RYHU WKHJXLQHDSLJWHVWVLQWHUPV RIDQLPDOZHOIDUHDQGDQREMHFWLYHPHDVXUHPHQWRIWKHLQGXFWLRQSKDVHRIVNLQVHQVLWLVDWLRQ
0RUHUHFHQWO\PHFKDQLVWLFDOO\EDVHGin chemicoDQGin vitroWHVWPHWKRGVKDYHEHHQFRQVLGHUHG
VFLHQWLILFDOO\YDOLGIRUWKHHYDOXDWLRQRIWKHVNLQVHQVLWLVDWLRQKD]DUGRIFKHPLFDOV+RZHYHUFRPELQDWLRQVRI QRQDQLPDO PHWKRGV in silico in chemico in vitro  ZLWKLQ ,QWHJUDWHG $SSURDFKHV WR 7HVWLQJ DQG$VVHVVPHQW ,$7$ ZLOOEHQHHGHGWREHDEOHWRIXOO\VXEVWLWXWHIRUWKHDQLPDOWHVWVFXUUHQWO\LQXVHJLYHQ
WKHUHVWULFWHG$23PHFKDQLVWLFFRYHUDJHRIHDFKRIWKHFXUUHQWO\DYDLODEOHQRQDQLPDOWHVWPHWKRGV    
7KH'35$LVSURSRVHGWRDGGUHVVWKHPROHFXODULQLWLDWLQJHYHQWRIWKHVNLQVHQVLWLVDWLRQ$23
QDPHO\SURWHLQUHDFWLYLW\E\TXDQWLI\LQJWKHUHDFWLYLW\RIWHVWFKHPLFDOVWRZDUGVPRGHOV\QWKHWLFSHSWLGHVFRQWDLQLQJHLWKHUO\VLQHRUF\VWHLQH  &\VWHLQHDQGO\VLQHSHUFHQWSHSWLGHGHSOHWLRQYDOXHVDUHWKHQXVHGWRFDWHJRULVHDVXEVWDQFHLQRQHRIIRXUFODVVHVRIUHDFWLYLW\IRUVXSSRUWLQJWKHGLVFULPLQDWLRQEHWZHHQVNLQVHQVLWLVHUVDQGQRQVHQVLWLVHUV  
© OECD, (2015)<RX DUH IUHH WR XVH WKLV PDWHULDO IRU SHUVRQDO QRQFRPPHUFLDO SXUSRVHV ZLWKRXW VHHNLQJ SULRU FRQVHQW
IURPWKH2(&'SURYLGHGWKHVRXUFHLVGXO\PHQWLRQHG$Q\FRPPHUFLDOXVHRIWKLVPDWHULDOLVVXEMHFWWRZULWWHQSHUPLVVLRQIURPWKH2(&'23

TG 442C

OECD/OCDE
7KH '35$ KDV EHHQ HYDOXDWHG LQ D (XURSHDQ 8QLRQ 5HIHUHQFH /DERUDWRU\ IRU $OWHUQDWLYHV WR
$QLPDO 7HVWLQJ (85/ (&9$0 OHDG YDOLGDWLRQ VWXG\ DQG VXEVHTXHQW LQGHSHQGHQW SHHU UHYLHZ E\ WKH
(85/(&9$06FLHQWLILF$GYLVRU\&RPPLWWHH (6$& DQGZDVFRQVLGHUHGVFLHQWLILFDOO\YDOLG  WREH
XVHGDVSDUWRIDQ,$7$WRVXSSRUWWKHGLVFULPLQDWLRQEHWZHHQVNLQVHQVLWLVHUVDQGQRQVHQVLWLVHUVIRUWKH
SXUSRVH RI KD]DUG FODVVLILFDWLRQ DQG ODEHOOLQJ ([DPSOHV RQ WKH XVH RI '35$ GDWD LQ FRPELQDWLRQ ZLWKRWKHULQIRUPDWLRQDUHUHSRUWHGLQWKHOLWHUDWXUH        'HILQLWLRQVDUHSURYLGHGLQ$QQH[,INITIAL CONSIDERATIONS, APPLICABILITY AND LIMITATIONS
7KHFRUUHODWLRQRISURWHLQUHDFWLYLW\ZLWKVNLQVHQVLWLVDWLRQSRWHQWLDOLVZHOOHVWDEOLVKHG      1HYHUWKHOHVV VLQFH SURWHLQ ELQGLQJ UHSUHVHQWV RQO\ RQH NH\ HYHQW DOEHLW WKH PROHFXODU LQLWLDWLQJ
HYHQWRIWKHVNLQVHQVLWLVDWLRQ$23SURWHLQUHDFWLYLW\LQIRUPDWLRQJHQHUDWHGZLWKWHVWLQJDQGQRQWHVWLQJPHWKRGV PD\ QRW EH VXIILFLHQW RQ LWV RZQ WR FRQFOXGH RQ WKH DEVHQFH RI VNLQ VHQVLWLVDWLRQ SRWHQWLDO RI
FKHPLFDOV 7KHUHIRUH GDWD JHQHUDWHG ZLWK WKLV 7HVW *XLGHOLQH VKRXOG EH FRQVLGHUHG LQ WKH FRQWH[W RI
LQWHJUDWHGDSSURDFKHVVXFKDV,$7$FRPELQLQJWKHPZLWKRWKHUFRPSOHPHQWDU\LQIRUPDWLRQHJGHULYHG
IURP in vitro DVVD\V DGGUHVVLQJ RWKHU NH\ HYHQWV RI WKH VNLQ VHQVLWLVDWLRQ $23 DV ZHOO DV QRQWHVWLQJPHWKRGVLQFOXGLQJUHDGDFURVVIURPFKHPLFDODQDORJXHV
7KH WHVW PHWKRG GHVFULEHG LQ WKLV 7HVW *XLGHOLQH FDQ EH XVHG LQ FRPELQDWLRQ ZLWK RWKHUFRPSOHPHQWDU\LQIRUPDWLRQWRVXSSRUWWKHGLVFULPLQDWLRQEHWZHHQVNLQVHQVLWLVHUV LH81*+6&DWHJRU\ DQGQRQVHQVLWLVHUVLQWKHFRQWH[WRI,$7$7KLV7HVW*XLGHOLQHFDQQRWEHXVHGRQLWVRZQQHLWKHUWR
VXEFDWHJRULVH VNLQ VHQVLWLVHUV LQWR VXEFDWHJRULHV $ DQG % DV GHILQHG E\ 81 *+6   IRU DXWKRULWLHVLPSOHPHQWLQJ WKHVH WZR RSWLRQDO VXEFDWHJRULHV QRU WR SUHGLFW SRWHQF\ IRU VDIHW\ DVVHVVPHQW GHFLVLRQV+RZHYHUGHSHQGLQJRQWKHUHJXODWRU\IUDPHZRUNDSRVLWLYHUHVXOWZLWKWKH'35$PD\EHXVHGRQLWVRZQWRFODVVLI\DFKHPLFDOLQWR81*+6FDWHJRU\
7KH'35$WHVWPHWKRGSURYHGWREHWUDQVIHUDEOHWRODERUDWRULHVH[SHULHQFHGLQKLJKSHUIRUPDQFH
OLTXLGFKURPDWRJUDSK\ +3/& DQDO\VLV7KHOHYHORIUHSURGXFLELOLW\LQSUHGLFWLRQVWKDWFDQEHH[SHFWHG
IURPWKHWHVWPHWKRGLVLQWKHRUGHURIZLWKLQODERUDWRULHVDQGEHWZHHQODERUDWRULHV  5HVXOWVJHQHUDWHGLQWKHYDOLGDWLRQVWXG\  DQGSXEOLVKHGVWXGLHV  RYHUDOOLQGLFDWHWKDWWKHDFFXUDF\RIWKH
'35$ LQ GLVFULPLQDWLQJ VHQVLWLVHUV LH 81 *+6 &DW   IURP QRQVHQVLWLVHUV LV  1   ZLWK D
VHQVLWLYLW\RI  DQGVSHFLILFLW\RI  ZKHQFRPSDUHGWR//1$UHVXOWV7KH'35$LVPRUHOLNHO\WRXQGHUSUHGLFWFKHPLFDOVVKRZLQJDORZWRPRGHUDWHVNLQVHQVLWLVDWLRQSRWHQF\ LH81*+6
VXEFDWHJRU\% WKDQFKHPLFDOVVKRZLQJDKLJKVNLQVHQVLWLVDWLRQSRWHQF\ LH81*+6VXEFDWHJRU\$    +RZHYHUWKHDFFXUDF\YDOXHVJLYHQKHUHIRUWKH'35$DVDVWDQGDORQHWHVWPHWKRGDUHRQO\LQGLFDWLYHVLQFHWKHWHVWPHWKRGVKRXOGEHFRQVLGHUHGLQFRPELQDWLRQZLWKRWKHUVRXUFHVRILQIRUPDWLRQLQ
WKHFRQWH[W RI DQ ,$7$ DQG LQ DFFRUGDQFH ZLWKWKH SURYLVLRQV RI SDUDJUDSK  DERYH )XUWKHUPRUH ZKHQHYDOXDWLQJQRQDQLPDOPHWKRGVIRUVNLQVHQVLWLVDWLRQLWVKRXOGEHNHSWLQPLQGWKDWWKH//1$WHVWDVZHOODVRWKHUDQLPDOWHVWVPD\QRWIXOO\UHIOHFWWKHVLWXDWLRQLQWKHVSHFLHVRILQWHUHVWLHKXPDQV2QWKHEDVLVRIWKHRYHUDOOGDWDDYDLODEOHWKH'35$ZDVVKRZQWREHDSSOLFDEOHWRWHVWFKHPLFDOVFRYHULQJDYDULHW\RIRUJDQLF IXQFWLRQDO JURXSV UHDFWLRQ PHFKDQLVPV VNLQ VHQVLWLVDWLRQ SRWHQF\ DV GHWHUPLQHG LQ in vivoVWXGLHV  DQG SK\VLFRFKHPLFDO SURSHUWLHV        7DNHQ WRJHWKHUWKLVLQIRUPDWLRQLQGLFDWHV WKHXVHIXOQHVVRIWKH'35$WRFRQWULEXWHWRWKHLGHQWLILFDWLRQRIVNLQVHQVLWLVDWLRQKD]DUG
7KHWHUPWHVWFKHPLFDOLVXVHGLQWKLV7HVW*XLGHOLQHWRUHIHUWRZKDWLVEHLQJWHVWHG DQGLVQRWUHODWHGWRWKHDSSOLFDELOLW\RIWKH'35$WRWKHWHVWLQJRIVXEVWDQFHVDQGRUPL[WXUHV7KLV7HVW*XLGHOLQHLV
 ,Q-XQHWKH-RLQW0HHWLQJDJUHHGWKDWZKHUHSRVVLEOHDPRUHFRQVLVWHQWXVHRIWKHWHUP³WHVWFKHPLFDO´GHVFULELQJZKDWLV
EHLQJWHVWHGVKRXOGQRZEHDSSOLHGLQQHZDQGXSGDWHG7HVW*XLGHOLQHV © OECD, (2015)
24



OECD/OCDETG 442CQRW DSSOLFDEOH IRU WKH WHVWLQJ RI PHWDO FRPSRXQGV VLQFH WKH\ DUH NQRZQ WR UHDFW ZLWK SURWHLQV ZLWKPHFKDQLVPVRWKHUWKDQFRYDOHQWELQGLQJ$WHVWFKHPLFDOVKRXOGEHVROXEOHLQDQDSSURSULDWHVROYHQWDWDILQDO FRQFHQWUDWLRQ RI  P0 VHH SDUDJUDSK   +RZHYHU WHVW FKHPLFDOV WKDW DUH QRW VROXEOH DW WKLVFRQFHQWUDWLRQPD\VWLOOEHWHVWHGDWORZHUVROXEOHFRQFHQWUDWLRQV,QVXFKDFDVHDSRVLWLYHUHVXOWFRXOGVWLOO
EHXVHGWRVXSSRUWWKHLGHQWLILFDWLRQRIWKHWHVWFKHPLFDODVDVNLQVHQVLWLVHUEXWQRILUPFRQFOXVLRQRQWKH
ODFNRIUHDFWLYLW\VKRXOGEHGUDZQIURPDQHJDWLYHUHVXOW/LPLWHGLQIRUPDWLRQLVFXUUHQWO\DYDLODEOHRQWKHDSSOLFDELOLW\ RI WKH '35$ WR PL[WXUHV RI NQRZQ FRPSRVLWLRQ     7KH '35$ LV QHYHUWKHOHVVFRQVLGHUHG WR EH WHFKQLFDOO\ DSSOLFDEOH WR WKH WHVWLQJ RI PXOWLFRQVWLWXHQW VXEVWDQFHV DQG PL[WXUHV RI
NQRZQFRPSRVLWLRQ VHHSDUDJUDSK %HIRUHXVHRIWKLV7HVW*XLGHOLQHRQDPL[WXUHIRUJHQHUDWLQJGDWD
IRU DQ LQWHQGHG UHJXODWRU\ SXUSRVH LW VKRXOG EH FRQVLGHUHG ZKHWKHU DQG LI VR ZK\ LW PD\ SURYLGH
DGHTXDWH UHVXOWV IRU WKDW SXUSRVH 6XFK FRQVLGHUDWLRQV DUH QRW QHHGHG ZKHQ WKHUH LV D UHJXODWRU\UHTXLUHPHQWIRUWHVWLQJRIWKHPL[WXUH7KHFXUUHQWSUHGLFWLRQPRGHOFDQQRWEHXVHGIRUFRPSOH[PL[WXUHVRIXQNQRZQFRPSRVLWLRQRUIRUVXEVWDQFHVRIXQNQRZQRUYDULDEOHFRPSRVLWLRQFRPSOH[UHDFWLRQSURGXFWVRUELRORJLFDOPDWHULDOV LH89&%VXEVWDQFHV GXHWRWKHGHILQHGPRODUUDWLRRIWHVWFKHPLFDODQGSHSWLGH
)RUWKLVSXUSRVHDQHZSUHGLFWLRQPRGHOEDVHGRQDJUDYLPHWULFDSSURDFKZLOOQHHGWREHGHYHORSHG,Q
FDVHVZKHUHHYLGHQFHFDQEHGHPRQVWUDWHGRQWKHQRQDSSOLFDELOLW\RIWKH7HVW*XLGHOLQHWRRWKHUVSHFLILF
FDWHJRULHVRIFKHPLFDOVWKHWHVWPHWKRGVKRXOGQRWEHXVHGIRUWKRVHVSHFLILFFDWHJRULHVRIFKHPLFDOV
7KH WHVW PHWKRG GHVFULEHG LQ WKLV 7HVW *XLGHOLQH LV DQ in chemico PHWKRG WKDW GRHV QRWHQFRPSDVV D PHWDEROLF V\VWHP &KHPLFDOV WKDW UHTXLUH HQ]\PDWLF ELRDFWLYDWLRQ WR H[HUW WKHLU VNLQVHQVLWLVDWLRQ SRWHQWLDO LH SURKDSWHQV  FDQQRW EH GHWHFWHG E\ WKH WHVW PHWKRG &KHPLFDOV WKDW EHFRPH
VHQVLWLVHUVDIWHUDELRWLFWUDQVIRUPDWLRQ LHSUHKDSWHQV DUHUHSRUWHGWREHLQVRPHFDVHVFRUUHFWO\GHWHFWHGE\WKHWHVWPHWKRG  ,QWKHOLJKWRIWKHDERYHQHJDWLYHUHVXOWVREWDLQHGZLWKWKHWHVWPHWKRGVKRXOGEHLQWHUSUHWHG LQ WKH FRQWH[W RI WKH VWDWHG OLPLWDWLRQV DQG LQ WKH FRQQHFWLRQ ZLWK RWKHU LQIRUPDWLRQ VRXUFHVZLWKLQWKHIUDPHZRUNRIDQ,$7$7HVWFKHPLFDOVWKDWGRQRWFRYDOHQWO\ELQGWRWKHSHSWLGHEXWSURPRWHLWV
R[LGDWLRQ LH F\VWHLQH GLPHULVDWLRQ  FRXOG OHDG WR D SRWHQWLDO RYHU HVWLPDWLRQ RI SHSWLGH GHSOHWLRQUHVXOWLQJ LQ SRVVLEOH IDOVH SRVLWLYH SUHGLFWLRQV DQGRU DVVLJQHPHQW WR D KLJKHU UHDFWLYLW\ FODVV VHHSDUDJUDSKVDQG 
$V GHVFULEHG WKH '35$ DVVD\ VXSSRUWV WKH GLVFULPLQDWLRQ EHWZHHQ VNLQ VHQVLWLVHUV DQG QRQVHQVLWLVHUV+RZHYHULWPD\DOVRSRWHQWLDOO\FRQWULEXWHWRWKHDVVHVVPHQWRIVHQVLWLVLQJSRWHQF\  ZKHQ
XVHGLQLQWHJUDWHG DSSURDFKHV VXFKDV ,$7$ +RZHYHUIXUWKHU ZRUN SUHIHUDEO\ EDVHGRQKXPDQGDWDLVUHTXLUHGWRGHWHUPLQHKRZ'35$UHVXOWVPD\SRVVLEO\LQIRUPSRWHQF\DVVHVVPHQW
PRINCIPLE OF THE TEST
7KH'35$LVDQin chemicoPHWKRGZKLFKTXDQWLILHVWKHUHPDLQLQJFRQFHQWUDWLRQRIF\VWHLQHRU
O\VLQHFRQWDLQLQJSHSWLGHIROORZLQJKRXUVLQFXEDWLRQZLWKWKHWHVWFKHPLFDODWr&7KHV\QWKHWLF
SHSWLGHVFRQWDLQSKHQ\ODODQLQHWRDLGLQWKHGHWHFWLRQ5HODWLYHSHSWLGHFRQFHQWUDWLRQLVPHDVXUHGE\KLJKSHUIRUPDQFHOLTXLGFKURPDWRJUDSK\ +3/& ZLWKJUDGLHQWHOXWLRQDQG89GHWHFWLRQDWQP&\VWHLQH
DQG O\VLQH SHSWLGH SHUFHQW GHSOHWLRQ YDOXHV DUH WKHQ FDOFXODWHG DQG XVHG LQ D SUHGLFWLRQ PRGHO VHHSDUDJUDSK ZKLFKDOORZVDVVLJQLQJWKHWHVWFKHPLFDOWRRQHRIIRXUUHDFWLYLW\FODVVHVXVHGWRVXSSRUWWKH
GLVFULPLQDWLRQEHWZHHQVHQVLWLVHUVDQGQRQVHQVLWLVHUV
3ULRU WR URXWLQH XVH RI WKH PHWKRG GHVFULEHG LQ WKLV 7HVW *XLGHOLQH ODERUDWRULHV VKRXOG
GHPRQVWUDWHWHFKQLFDOSURILFLHQF\XVLQJWKHWHQSURILFLHQF\VXEVWDQFHVOLVWHGLQ$QQH[PROCEDURE

7KLV7HVW*XLGHOLQHLVEDVHGRQWKH'35$'%$/0SURWRFROQR  ZKLFKUHSUHVHQWVWKH
SURWRFROXVHGIRUWKH(85/(&9$0FRRUGLQDWHGYDOLGDWLRQVWXG\,WLVUHFRPPHQGHGWKDWWKLVSURWRFROLV
© OECD, (2015)




25

TG 442C

OECD/OCDE
XVHG ZKHQ LPSOHPHQWLQJ DQG XVLQJ WKH PHWKRG LQ WKH ODERUDWRU\ 7KH IROORZLQJ LV D GHVFULSWLRQ RI WKHPDLQFRPSRQHQWVDQGSURFHGXUHVIRUWKH'35$,IDQDOWHUQDWLYH+3/&VHWXSLVXVHGLWVHTXLYDOHQFHWR
WKH YDOLGDWHG VHWXS GHVFULEHG LQ WKH '%$/0 SURWRFRO VKRXOG EH GHPRQVWUDWHG HJ E\ WHVWLQJ WKHSURILFLHQF\VXEVWDQFHVLQ$QQH[ Preparation of the cysteine or lysine-containing peptides
17.
Stock solutions of F\VWHLQH $F5)$$C$$&22+  DQG O\VLQH $F5)$$K$$&22+ 
FRQWDLQLQJV\QWKHWLFSHSWLGHVRISXULW\KLJKHUWKDQDQGSUHIHUDEO\LQWKHUDQJHRIVKRXOGEHIUHVKO\SUHSDUHGMXVWEHIRUHWKHLULQFXEDWLRQZLWKWKHWHVWFKHPLFDO7KHILQDOFRQFHQWUDWLRQRIWKHF\VWHLQHSHSWLGH VKRXOG EH  P0 LQ S+  SKRVSKDWH EXIIHU ZKHUHDV WKH ILQDO FRQFHQWUDWLRQ RI WKH O\VLQHSHSWLGHVKRXOGEHP0LQS+DPPRQLXPDFHWDWHEXIIHU7KH+3/&UXQVHTXHQFHVKRXOGEHVHW
XSLQRUGHUWRNHHSWKH+3/&DQDO\VLVWLPHOHVVWKDQKRXUV)RUWKH+3/&VHWXSXVHGLQWKHYDOLGDWLRQVWXG\DQGGHVFULEHGLQWKLV7HVW*XLGHOLQHXSWRDQDO\VLVVDPSOHV ZKLFKLQFOXGHWKHWHVWFKHPLFDOWKH
SRVLWLYHFRQWURODQGWKHDSSURSULDWHQXPEHURIVROYHQWFRQWUROVEDVHGRQWKHQXPEHURILQGLYLGXDOVROYHQWV
XVHGLQWKHWHVWHDFKWHVWHGLQWULSOLFDWH FDQEHDFFRPPRGDWHGLQDVLQJOH+3/&UXQ$OORIWKHUHSOLFDWHVDQDO\VHG LQ WKH VDPH UXQ VKRXOG XVH WKH LGHQWLFDO F\VWHLQH DQG O\VLQH SHSWLGH VWRFN VROXWLRQV ,W LV
UHFRPPHQGHGWRSURYHLQGLYLGXDOSHSWLGHEDWFKHVIRUSURSHUVROXELOLW\SULRUWRWKHLUXVH
Preparation of the test chemical

6ROXELOLW\RIWKHWHVWFKHPLFDOLQDQDSSURSULDWHVROYHQWVKRXOGEHDVVHVVHGEHIRUHSHUIRUPLQJWKH
DVVD\ IROORZLQJ WKH VROXELOLVDWLRQ SURFHGXUH GHVFULEHG LQ WKH '35$ '%$/0 SURWRFRO   $Q
DSSURSULDWH VROYHQW ZLOO GLVVROYH WKH WHVW FKHPLFDO FRPSOHWHO\ 6LQFH LQ WKH '35$ WKH WHVW FKHPLFDO LV
LQFXEDWHGLQODUJHH[FHVVZLWKHLWKHUWKHF\VWHLQHRUWKHO\VLQHSHSWLGHVYLVXDOLQVSHFWLRQRIWKHIRUPLQJRI
DFOHDUVROXWLRQLVFRQVLGHUHGVXIILFLHQWWRDVFHUWDLQWKDWWKHWHVWFKHPLFDO DQGDOORILWVFRPSRQHQWVLQWKH
FDVHRIWHVWLQJDPXOWLFRQVWLWXHQWVXEVWDQFHRUDPL[WXUH LVGLVVROYHG6XLWDEOHVROYHQWVDUHDFHWRQLWULOHZDWHU  PL[WXUH ZDWHUDFHWRQLWULOH LVRSURSDQRO DFHWRQH RU  PL[WXUH DFHWRQHDFHWRQLWULOH 2WKHUVROYHQWV FDQ EH XVHG DV ORQJ DV WKH\ GR QRW LPSDFW RQ WKH VWDELOLW\ RI WKH SHSWLGH DV PRQLWRUHG ZLWKUHIHUHQFHFRQWUROV& LHVDPSOHVFRQVWLWXWHGE\WKHSHSWLGHDORQHGLVVROYHGLQWKHDSSURSULDWHVROYHQWVHH
$QQH[ $VDODVWRSWLRQLIWKHWHVWFKHPLFDOLVQRWVROXEOHLQDQ\RIWKHVHVROYHQWVDWWHPSWVVKRXOGEH
PDGHWRVROXELOLVHLWLQȝ/RI'062DQGGLOXWHWKHUHVXOWLQJVROXWLRQZLWKȝ/RIDFHWRQLWULOHDQG
LIWKHWHVWFKHPLFDOLVQRWVROXEOHLQWKLVPL[WXUHDWWHPSWVVKRXOGEHPDGHWRVROXELOLVHWKHVDPHDPRXQWRI
WHVWFKHPLFDOVLQȝ/RI'062DQGGLOXWHWKHUHVXOWLQJVROXWLRQZLWKȝ/RIDFHWRQLWULOH7KHWHVWFKHPLFDOVKRXOGEHSUHZHLJKHGLQWRJODVVYLDOVDQGGLVVROYHGLPPHGLDWHO\EHIRUHWHVWLQJLQDQDSSURSULDWH
VROYHQW WR SUHSDUH D  P0 VROXWLRQ )RU PL[WXUHV DQG PXOWLFRQVWLWXHQW VXEVWDQFHV RI NQRZQFRPSRVLWLRQ D VLQJOH SXULW\ VKRXOG EH GHWHUPLQHG E\ WKH VXP RI WKH SURSRUWLRQ RI LWV FRQVWLWXHQWV
H[FOXGLQJ ZDWHU  DQG D VLQJOH DSSDUHQW PROHFXODU ZHLJKW VKRXOG EH GHWHUPLQHG E\ FRQVLGHULQJ WKHLQGLYLGXDO PROHFXODU ZHLJKWV RI HDFK FRPSRQHQW LQ WKH PL[WXUH H[FOXGLQJ ZDWHU  DQG WKHLU LQGLYLGXDOSURSRUWLRQV 7KH UHVXOWLQJ SXULW\ DQG DSSDUHQW PROHFXODU ZHLJKW VKRXOG WKHQ EH XVHG WR FDOFXODWH WKHZHLJKWRIWHVWFKHPLFDOQHFHVVDU\WRSUHSDUHDP0VROXWLRQ)RUSRO\PHUVIRUZKLFKDSUHGRPLQDQWPROHFXODUZHLJKWFDQQRWEHGHWHUPLQHGWKHPROHFXODUZHLJKWRIWKHPRQRPHU RUWKHDSSDUHQWPROHFXODUZHLJKW RI WKH YDULRXV PRQRPHUV FRQVWLWXWLQJ WKH SRO\PHU  PD\ EH FRQVLGHUHG WR SUHSDUH D  P0
VROXWLRQ +RZHYHU ZKHQ WHVWLQJ PL[WXUHV PXOWLFRQVWLWXHQW VXEVWDQFHV RU SRO\PHUV RI NQRZQFRPSRVLWLRQLWVKRXOGEHFRQVLGHUHGWRDOVRWHVWWKHQHDWFKHPLFDO)RUOLTXLGVWKHQHDWFKHPLFDOVKRXOGEH
WHVWHGDVVXFKZLWKRXWDQ\SULRUGLOXWLRQE\LQFXEDWLQJLWDWDQGUDWLRZLWKWKHF\VWHLQHDQGO\VLQHSHSWLGHV UHVSHFWLYHO\ )RU VROLGV WKH WHVW FKHPLFDO VKRXOG EH GLVVROYHG WR LWV PD[LPXP VROXEOH
FRQFHQWUDWLRQLQWKHVDPHVROYHQWXVHGWRSUHSDUHWKHDSSDUHQWP0VROXWLRQ,WVKRXOGWKHQEHWHVWHGDVVXFK ZLWKRXW DQ\ IXUWKHU GLOXWLRQ E\ LQFXEDWLQJ LW DW  DQG  UDWLR ZLWK WKH F\VWHLQH DQG O\VLQHSHSWLGHVUHVSHFWLYHO\&RQFRUGDQWUHVXOWV UHDFWLYHRUQRQUHDFWLYH EHWZHHQWKHDSSDUHQWP0VROXWLRQ
DQGWKHQHDWFKHPLFDOVKRXOGDOORZIRUDILUPFRQFOXVLRQRQWKHUHVXOW© OECD, (2015)
26



OECD/OCDETG 442C

Preparation of the positive control, reference controls and coelution controls
&LQQDPLFDOGHK\GH &$6tIRRGJUDGHSXULW\ VKRXOGEHXVHGDVSRVLWLYHFRQWURO
3& DWDFRQFHQWUDWLRQRIP0LQDFHWRQLWULOH2WKHUVXLWDEOHSRVLWLYHFRQWUROVSUHIHUHQWLDOO\SURYLGLQJPLGUDQJH GHSOHWLRQ YDOXHV PD\ EH XVHG LI KLVWRULFDO GDWD DUH DYDLODEOH WR GHULYH FRPSDUDEOH UXQDFFHSWDQFHFULWHULD,QDGGLWLRQUHIHUHQFHFRQWUROV LHVDPSOHVFRQWDLQLQJRQO\WKHSHSWLGHGLVVROYHGLQWKH
DSSURSULDWH VROYHQW VKRXOG DOVREHLQFOXGHGLQWKH +3/& UXQ VHTXHQFH DQG WKHVH DUH XVHG WR YHULI\ WKH
+3/&V\VWHPVXLWDELOLW\SULRUWRWKHDQDO\VLV UHIHUHQFHFRQWUROV$ WKHVWDELOLW\RIWKHUHIHUHQFHFRQWUROVRYHUWLPH UHIHUHQFHFRQWURO% DQGWRYHULI\WKDWWKHVROYHQWXVHGWRGLVVROYHWKHWHVWFKHPLFDOGRHVQRWLPSDFWWKHSHUFHQWSHSWLGHGHSOHWLRQ UHIHUHQFHFRQWURO&  VHH$QQH[ 7KHDSSURSULDWHUHIHUHQFHFRQWURO
IRUHDFKVXEVWDQFHLVXVHGWRFDOFXODWHWKHSHUFHQWSHSWLGHGHSOHWLRQIRUWKDWVXEVWDQFH VHHSDUDJUDSK ,Q DGGLWLRQ D FRHOXWLRQ FRQWURO FRQVWLWXWHG E\ WKH WHVW FKHPLFDO DORQH IRU HDFK RI WKH WHVW FKHPLFDOVDQDO\VHG VKRXOG EH LQFOXGHG LQ WKH UXQ VHTXHQFH WR GHWHFW SRVVLEOH FRHOXWLRQ RI WKH WHVW FKHPLFDO ZLWKHLWKHUWKHO\VLQHRUWKHF\VWHLQHSHSWLGH
Incubation of the test chemical with the cysteine and lysine peptide solutions
&\VWHLQHDQGO\VLQHSHSWLGHVROXWLRQVVKRXOGEHLQFXEDWHGLQJODVVDXWRVDPSOHUYLDOVZLWKWKHWHVWFKHPLFDODWDQGUDWLRUHVSHFWLYHO\,IDSUHFLSLWDWHLVREVHUYHGLPPHGLDWHO\XSRQDGGLWLRQRIWKH
WHVW FKHPLFDO VROXWLRQ WR WKH SHSWLGH VROXWLRQ GXHWR ORZ DTXHRXVVROXELOLW\ RI WKHWHVW FKHPLFDOLQWKLV
FDVH RQH FDQQRW EH VXUH KRZ PXFK WHVW FKHPLFDO UHPDLQHG LQ WKH VROXWLRQ WR UHDFW ZLWK WKH SHSWLGH
7KHUHIRUHLQVXFKDFDVHDSRVLWLYHUHVXOWFRXOGVWLOOEHXVHGEXWDQHJDWLYHUHVXOWLVXQFHUWDLQDQGVKRXOG
EHLQWHUSUHWHGZLWKGXHFDUH VHHDOVRSURYLVLRQVLQSDUDJUDSKIRUWKHWHVWLQJRIFKHPLFDOVQRWVROXEOHXSWRDFRQFHQWUDWLRQRIP0 7KHUHDFWLRQVROXWLRQVKRXOGEHOHIWLQWKHGDUNDWr&IRUrKRXUVEHIRUHUXQQLQJWKH+3/&DQDO\VLV(DFKWHVW FKHPLFDOVKRXOGEHDQDO\VHGLQWULSOLFDWHIRUERWKSHSWLGHV
6DPSOHV KDYH WR EH YLVXDOO\ LQVSHFWHG SULRU WR +3/& DQDO\VLV ,I D SUHFLSLWDWH RU SKDVH VHSDUDWLRQ LV
REVHUYHGVDPSOHVPD\EHFHQWULIXJHGDWORZVSHHG [J WRIRUFHSUHFLSLWDWHWRWKHERWWRPRIWKH
YLDO DV D SUHFDXWLRQ VLQFH ODUJH DPRXQWV RI SUHFLSLWDWH PD\ FORJ WKH +3/& WXELQJ RU FROXPQV ,I D
SUHFLSLWDWLRQ RU SKDVH VHSDUDWLRQ LV REVHUYHG DIWHU WKH LQFXEDWLRQ SHULRG SHSWLGH GHSOHWLRQ PD\ EH
XQGHUHVWLPDWHG DQG DFRQFOXVLRQ RQWKHODFN RI UHDFWLYLW\ FDQQRW EH GUDZQ ZLWK VXIILFLHQW FRQILGHQFHLQ
FDVHRIDQHJDWLYHUHVXOW
Preparation of the HPLC standard calibration curve$ VWDQGDUG FDOLEUDWLRQFXUYH VKRXOG EH JHQHUDWHG IRU ERWK WKH F\VWHLQH DQGWKH O\VLQHSHSWLGHV
3HSWLGH VWDQGDUGV VKRXOG EH SUHSDUHG LQ D VROXWLRQ RI  RU  DFHWRQLWULOHEXIIHU XVLQJ SKRVSKDWH
EXIIHU S+   IRU WKH F\VWHLQH SHSWLGH DQG DPPRQLXP DFHWDWH EXIIHU S+   IRU WKH O\VLQH SHSWLGH
8VLQJVHULDOGLOXWLRQVWDQGDUGVRIWKHSHSWLGHVWRFNVROXWLRQ P0 FDOLEUDWLRQVROXWLRQVVKRXOGEHSUHSDUHG WR FRYHU WKH UDQJH IURP  WR  P0 $ EODQN RI WKH GLOXWLRQ EXIIHU VKRXOG DOVR EH
LQFOXGHGLQWKHVWDQGDUGFDOLEUDWLRQFXUYH6XLWDEOHFDOLEUDWLRQFXUYHVVKRXOGKDYHDQU!
HPLC preparation and analysis

7KH VXLWDELOLW\ RI WKH +3/& V\VWHP VKRXOG EH YHULILHG EHIRUH FRQGXFWLQJ WKH DQDO\VLV 3HSWLGH
GHSOHWLRQ LV PRQLWRUHG E\ +3/& FRXSOHG ZLWK DQ 89 GHWHFWRU SKRWRGLRGH DUUD\ GHWHFWRU RU IL[HGZDYHOHQJWK DEVRUEDQFH GHWHFWRU ZLWK  QP VLJQDO  7KH DSSURSULDWH FROXPQ LV LQVWDOOHG LQ WKH +3/&
V\VWHP7KH+3/&VHWXSGHVFULEHGLQWKHYDOLGDWHGSURWRFROXVHVD=RUED[6%&PP[PP[ PLFURQ DV SUHIHUUHG FROXPQ :LWK WKLV UHYHUVHGSKDVH +3/& FROXPQ WKH HQWLUH V\VWHP VKRXOG EH
HTXLOLEUDWHG DW & ZLWK  SKDVH $  YY  WULIOXRURDFHWLF DFLG LQ ZDWHU  DQG  SKDVH %
 YY WULIOXRURDFHWLFDFLGLQDFHWRQLWULOH IRUDWOHDVWKRXUVEHIRUH UXQQLQJ7KH+3/&DQDO\VLVVKRXOGEHSHUIRUPHGXVLQJDIORZUDWHRIP/PLQDQGDOLQHDUJUDGLHQWIURPWRDFHWRQLWULOH
© OECD, (2015)




27

TG 442C

OECD/OCDERYHU  PLQXWHV IROORZHG E\ D UDSLG LQFUHDVH WR  DFHWRQLWULOH WR UHPRYH RWKHU PDWHULDOV (TXDOYROXPHV RI HDFK VWDQGDUG VDPSOH DQG FRQWURO VKRXOG EH LQMHFWHG 7KH FROXPQ VKRXOG EH UHHTXLOLEUDWHG
XQGHU LQLWLDO FRQGLWLRQV IRU  PLQXWHV EHWZHHQ LQMHFWLRQV ,I D GLIIHUHQW UHYHUVHGSKDVH +3/& FROXPQ LV
XVHGWKHVHWXSSDUDPHWHUVGHVFULEHGDERYHPD\QHHGWREHDGMXVWHGWRJXDUDQWHHDQDSSURSULDWHHOXWLRQ
DQG LQWHJUDWLRQ RI WKH F\VWHLQH DQG O\VLQH SHSWLGHV LQFOXGLQJ WKH LQMHFWLRQ YROXPH ZKLFK PD\ YDU\DFFRUGLQJWRWKHV\VWHPXVHG W\SLFDOO\LQWKHUDQJHIURPȝ/ ,PSRUWDQWO\LIDQDOWHUQDWLYH+3/&
VHWXS LV XVHG LWV HTXLYDOHQFH WR WKH YDOLGDWHG VHWXS GHVFULEHG DERYH VKRXOG EH GHPRQVWUDWHG HJ E\
WHVWLQJWKHSURILFLHQF\VXEVWDQFHVLQ$QQH[ $EVRUEDQFHLVPRQLWRUHGDWQP,IDSKRWRGLRGHDUUD\GHWHFWRULVXVHGDEVRUEDQFHDWQPVKRXOGDOVREHUHFRUGHG,W VKRXOGEHQRWHGWKDWVRPHVXSSOLHVRIDFHWRQLWULOHFRXOGKDYHDQHJDWLYHLPSDFWRQSHSWLGHVWDELOLW\DQGWKLVKDVWREHDVVHVVHGZKHQDQHZEDWFKRIDFHWRQLWULOHLVXVHG7KHUDWLRRIWKHSHDNDUHDDQGWKHSHDNDUHDFDQEHXVHGDVDQLQGLFDWRURIFRHOXWLRQ)RUHDFKVDPSOHDUDWLRLQWKHUDQJHRIPHDQDUHDUDWLRRIFRQWUROVDPSOHVZRXOG
JLYHDJRRGLQGLFDWLRQWKDWFRHOXWLRQKDVQRWRFFXUUHG
7KHUHPD\EHWHVWFKHPLFDOVZKLFKFRXOGSURPRWHWKHR[LGDWLRQRIWKHF\VWHLQHSHSWLGH7KHSHDNRIWKHGLPHULVHGF\VWHLQHSHSWLGHPD\EHYLVXDOO\PRQLWRUHG,IGLPHULVDWLRQDSSHDUVWRKDYHRFFXUUHGWKLVVKRXOGEHQRWHGDVSHUFHQWSHSWLGHGHSOHWLRQPD\EH RYHUHVWLPDWHGOHDGLQJWRIDOVHSRVLWLYHSUHGLFWLRQV
DQGRUDVVLJQPHQWWRDKLJKHUUHDFWLYLW\FODVV VHHSDUDJUDSKVDQG 
+3/&DQDO\VLVIRUWKHF\VWHLQHDQGO\VLQHSHSWLGHVFDQEHSHUIRUPHGFRQFXUUHQWO\ LIWZR+3/&
V\VWHPVDUHDYDLODEOH RURQVHSDUDWHGD\V,IDQDO\VLVLVFRQGXFWHGRQVHSDUDWHGD\VWKHQDOOWHVWFKHPLFDOVROXWLRQVVKRXOGEHIUHVKO\SUHSDUHGIRUERWKDVVD\VRQHDFKGD\ 7KHDQDO\VLVVKRXOGEHWLPHGWRDVVXUHWKDWWKHLQMHFWLRQRIWKHILUVWVDPSOHVWDUWVWRKRXUVDIWHUWKHWHVWFKHPLFDOZDVPL[HGZLWKWKHSHSWLGHVROXWLRQ7KH+3/&UXQVHTXHQFHVKRXOGEHVHWXSLQRUGHUWRNHHSWKH+3/&DQDO\VLVWLPHOHVVWKDQKRXUV )RU WKH +3/& VHW XS XVHG LQ WKH YDOLGDWLRQ VWXG\ DQG GHVFULEHG LQ WKLV 7HVW *XLGHOLQH XS WR 
DQDO\VLV VDPSOHV FDQ EH DFFRPPRGDWHG LQ D VLQJOH +3/& UXQ VHH DOVR SDUDJUDSK   $Q H[DPSOH RI
+3/&DQDO\VLVVHTXHQFHLVSURYLGHGLQ$QQH[DATA AND REPORTING
Data evaluation

7KHFRQFHQWUDWLRQRIF\VWHLQHRUO\VLQHSHSWLGHLVSKRWRPHWULFDOO\GHWHUPLQHGDWQPLQHDFKVDPSOH E\ PHDVXULQJ WKH SHDN DUHD DUHD XQGHU WKH FXUYH $8&  RI WKH DSSURSULDWH SHDNV DQG E\
FDOFXODWLQJWKHFRQFHQWUDWLRQRISHSWLGHXVLQJWKHOLQHDUFDOLEUDWLRQFXUYHGHULYHGIURPWKHVWDQGDUGV
7KH SHUFHQW SHSWLGH GHSOHWLRQ LV GHWHUPLQHG LQ HDFK VDPSOH E\ PHDVXULQJ WKH SHDN DUHD DQGGLYLGLQJ LW E\ WKH PHDQ SHDN DUHD RI WKH UHOHYDQW UHIHUHQFH FRQWUROV & VHH $QQH[   DFFRUGLQJ WR WKHIRUPXODGHVFULEHGEHORZ

3HUFHQWSHSWLGHGHSOHWLRQª §·º
3HSWLGHSHDNDUHDLQUHSOLFDWHLQMHFWLRQ¸¸» u  «  ¨¨C
0HDQSHSWLGH

SHDN
DUHD

LQ
UHIHUHQFH

FRQWUROV©
¹¼¬

)RUPHDQLWLVPHDQWDULWKPHWLFPHDQWKURXJKRXWWKHGRFXPHQW

© OECD, (2015)
28



OECD/OCDETG 442C

Acceptance criteria

7KHIROORZLQJFULWHULDVKRXOGEHPHWIRUDUXQWREHFRQVLGHUHGYDOLGD WKHVWDQGDUGFDOLEUDWLRQFXUYHVKRXOGKDYHDQU!E WKHPHDQSHUFHQWSHSWLGHGHSOHWLRQYDOXHRIWKHWKUHHUHSOLFDWHVIRUWKH
SRVLWLYH FRQWURO FLQQDPLF DOGHK\GH VKRXOG EH EHWZHHQ  DQG  IRU WKH F\VWHLQH SHSWLGH DQGEHWZHHQDQGIRUWKHO\VLQHSHSWLGHDQGWKHPD[LPXPVWDQGDUGGHYLDWLRQ 6' IRUWKHSRVLWLYHFRQWUROUHSOLFDWHVVKRXOGEHIRUWKHSHUFHQWF\VWHLQHGHSOHWLRQDQGIRUWKHSHUFHQWO\VLQH
GHSOHWLRQDQGF WKHPHDQSHSWLGHFRQFHQWUDWLRQRIUHIHUHQFHFRQWUROV$VKRXOGEHrP0DQGWKH
FRHIILFLHQWRIYDULDWLRQ &9 RISHSWLGHSHDNDUHDVIRUWKHQLQHUHIHUHQFHFRQWUROV%DQG&LQDFHWRQLWULOHVKRXOGEH,IRQHRUPRUHRIWKHVHFULWHULDLVQRWPHWWKHUXQVKRXOGEHUHSHDWHG

7KHIROORZLQJFULWHULDVKRXOGEHPHWIRUDWHVWFKHPLFDO¶VUHVXOWVWREHFRQVLGHUHGYDOLGD WKH
PD[LPXP VWDQGDUG GHYLDWLRQ IRU WKH WHVW FKHPLFDO UHSOLFDWHV VKRXOG EH  IRU WKH SHUFHQW F\VWHLQH
GHSOHWLRQ DQG  IRU WKH SHUFHQW O\VLQH GHSOHWLRQ E  WKH PHDQ SHSWLGH FRQFHQWUDWLRQ RI WKH WKUHH
UHIHUHQFHFRQWUROV&LQWKHDSSURSULDWHVROYHQWVKRXOGEHrP0,IWKHVHFULWHULDDUHQRWPHWWKH
GDWDVKRXOGEHUHMHFWHGDQGWKHUXQVKRXOGEHUHSHDWHGIRUWKDWVSHFLILFWHVWFKHPLFDO
Prediction model
7KHPHDQSHUFHQWF\VWHLQHDQGSHUFHQWO\VLQHGHSOHWLRQYDOXHLVFDOFXODWHGIRUHDFKWHVWFKHPLFDO
1HJDWLYHGHSOHWLRQLVFRQVLGHUHGDV³´ZKHQFDOFXODWLQJWKHPHDQ%\XVLQJWKHF\VWHLQHO\VLQH
SUHGLFWLRQ PRGHO VKRZQ LQ 7DEOH WKH WKUHVKROG RI  DYHUDJH SHSWLGH GHSOHWLRQ VKRXOG EH XVHG WR
VXSSRUW WKH GLVFULPLQDWLRQ EHWZHHQ VNLQ VHQVLWLVHUV DQG QRQVHQVLWLVHUV LQ WKH IUDPHZRUN RI DQ ,$7$
$SSOLFDWLRQRIWKHSUHGLFWLRQPRGHOIRUDVVLJQLQJDWHVWFKHPLFDOWRDUHDFWLYLW\FODVV LHORZPRGHUDWH
DQGKLJKUHDFWLYLW\ PD\SHUKDSVSURYHXVHIXOWRLQIRUPSRWHQF\DVVHVVPHQWZLWKLQWKHIUDPHZRUNRIDQ,$7$


Table1: Cysteine 1:10/lysine 1:50 prediction model1
Mean of cysteine and lysine % depletion

Reactivity ClassDPRA Prediction2

dPHDQGHSOHWLRQd

1RRUPLQLPDOUHDFWLYLW\1HJDWLYHPHDQGHSOHWLRQd

/RZUHDFWLYLW\PHDQGHSOHWLRQd

0RGHUDWHUHDFWLYLW\PHDQGHSOHWLRQd

+LJKUHDFWLYLW\

3RVLWLYH

7KHQXPEHUVUHIHUWRVWDWLVWLFDOO\JHQHUDWHGWKUHVKROGYDOXHVDQGDUHQRWUHODWHGWRWKHSUHFLVLRQRIWKHPHDVXUHPHQW$'35$SUHGLFWLRQVKRXOGEHFRQVLGHUHGLQWKH IUDPHZRUNRIDQ,$7$DQGLQDFFRUGDQFHZLWKWKHSURYLVLRQVRISDUDJUDSKVDQG


7KHUHPLJKWEHFDVHVZKHUHWKHWHVWFKHPLFDO WKHVXEVWDQFHRURQHRUVHYHUDORIWKHFRPSRQHQWV
RIDPXOWLFRQVWLWXHQWVXEVWDQFHRUDPL[WXUH DEVRUEVVLJQLILFDQWO\DWQPDQGKDVWKHVDPHUHWHQWLRQ
WLPHRIWKHSHSWLGH FRHOXWLRQ &RHOXWLRQPD\EHUHVROYHGE\VOLJKWO\DGMXVWLQJWKH+3/&VHWXSLQRUGHUWRIXUWKHUVHSDUDWHWKHHOXWLRQWLPHRIWKHWHVWFKHPLFDODQGWKHSHSWLGH,IDQDOWHUQDWLYH+3/&VHWXSLV
XVHGWRWU\WRUHVROYHFRHOXWLRQLWVHTXLYDOHQFHWRWKHYDOLGDWHGVHWXSVKRXOGEHGHPRQVWUDWHG HJE\WHVWLQJWKHSURILFLHQF\VXEVWDQFHVLQ$QQH[ :KHQFRHOXWLRQRFFXUVWKHSHDNRIWKHSHSWLGHFDQQRWEH
LQWHJUDWHG DQG WKH FDOFXODWLRQ RI WKH SHUFHQW SHSWLGH GHSOHWLRQ LV QRW SRVVLEOH ,I FRHOXWLRQ RI VXFK WHVWFKHPLFDOV RFFXUV ZLWK ERWK WKH F\VWHLQH DQG WKH O\VLQH SHSWLGHV WKHQ WKH DQDO\VLV VKRXOG EH UHSRUWHG DV
© OECD, (2015)




29

TG 442C

OECD/OCDE³LQFRQFOXVLYH´ ,Q FDVHV ZKHUH FRHOXWLRQ RFFXUV RQO\ ZLWK WKH O\VLQH SHSWLGH WKHQ WKH F\VWHLQH 
SUHGLFWLRQPRGHOUHSRUWHGLQ7DEOHFDQEHXVHG

© OECD, (2015)
30



OECD/OCDETG 442CTable2: Cysteine 1:10 prediction model1
Cysteine (Cys) % depletion

Reactivity class

DPRA prediction2

d&\VGHSOHWLRQd

1RRUPLQLPDOUHDFWLYLW\1HJDWLYH&\VGHSOHWLRQd

/RZUHDFWLYLW\&\VGHSOHWLRQd

0RGHUDWHUHDFWLYLW\&\VGHSOHWLRQd

+LJKUHDFWLYLW\

3RVLWLYH

7KHQXPEHUVUHIHUWRVWDWLVWLFDOO\JHQHUDWHGWKUHVKROGYDOXHVDQGDUHQRWUHODWHGWRWKHSUHFLVLRQRIWKHPHDVXUHPHQW$'35$SUHGLFWLRQVKRXOGEHFRQVLGHUHGLQWKH IUDPHZRUNRIDQ,$7$DQGLQDFFRUGDQFHZLWKWKHSURYLVLRQVRISDUDJUDSKVDQG



31.
There might be other cases where WKH RYHUODS LQ UHWHQWLRQ WLPH EHWZHHQ WKH WHVW FKHPLFDO DQGHLWKHURIWKHSHSWLGHVLVLQFRPSOHWH,QVXFKFDVHV SHUFHQWSHSWLGHGHSOHWLRQYDOXHVFDQEHHVWLPDWHGDQG
XVHG LQ WKH F\VWHLQH O\VLQH  SUHGLFWLRQ PRGHO KRZHYHU DVVLJQPHQW RI WKH WHVW FKHPLFDO WR D
UHDFWLYLW\FODVVFDQQRWEHPDGHZLWKDFFXUDF\$VLQJOH+3/&DQDO\VLVIRUERWKWKHF\VWHLQHDQGWKHO\VLQHSHSWLGHVKRXOGEHVXIILFLHQWIRUDWHVWFKHPLFDO ZKHQ WKH UHVXOW LV XQHTXLYRFDO +RZHYHU LQ FDVHV RI UHVXOWV FORVH WR WKH WKUHVKROG XVHG WR
GLVFULPLQDWH EHWZHHQ SRVLWLYH DQG QHJDWLYH UHVXOWV LH ERUGHUOLQH UHVXOWV  DGGLWLRQDO WHVWLQJ PD\ EH
QHFHVVDU\,IVLWXDWLRQVZKHUHWKHPHDQSHUFHQWGHSOHWLRQIDOOVLQWKHUDQJHRIWRIRUWKHF\VWHLQHO\VLQHSUHGLFWLRQPRGHORUWKHF\VWHLQHSHUFHQWGHSOHWLRQIDOOVLQWKHUDQJHRIWRIRUWKH
F\VWHLQH  SUHGLFWLRQ PRGHO D VHFRQG UXQ VKRXOG EH FRQVLGHUHG DV ZHOO DV D WKLUG RQH LQ FDVH RI
GLVFRUGDQWUHVXOWVEHWZHHQWKHILUVWWZRUXQVTest report

7KHWHVWUHSRUWVKRXOGLQFOXGHWKHIROORZLQJLQIRUPDWLRQTest chemicalxx

0RQRFRQVWLWXHQWVXEVWDQFHo&KHPLFDO LGHQWLILFDWLRQ VXFK DV ,83$& RU &$6 QDPH V  &$6 QXPEHU V  60,/(6 RU
,Q&K,FRGHVWUXFWXUDOIRUPXODDQGRURWKHULGHQWLILHUVo

3K\VLFDO DSSHDUDQFH ZDWHU VROXELOLW\ PROHFXODU ZHLJKW DQG DGGLWLRQDO UHOHYDQWSK\VLFRFKHPLFDOSURSHUWLHVWRWKHH[WHQWDYDLODEOHo

3XULW\FKHPLFDOLGHQWLW\RILPSXULWLHVDVDSSURSULDWHDQGSUDFWLFDOO\IHDVLEOHHWFo

7UHDWPHQWSULRUWRWHVWLQJLIDSSOLFDEOH HJZDUPLQJJULQGLQJ o&RQFHQWUDWLRQ V WHVWHG

o

6WRUDJHFRQGLWLRQVDQGVWDELOLW\WRWKHH[WHQWDYDLODEOH

0XOWLFRQVWLWXHQWVXEVWDQFH89&%DQGPL[WXUHo&KDUDFWHULVDWLRQ DV IDU DV SRVVLEOH E\ HJ FKHPLFDO LGHQWLW\ VHH DERYH  SXULW\TXDQWLWDWLYH RFFXUUHQFH DQG UHOHYDQW SK\VLFRFKHPLFDO SURSHUWLHV VHH DERYH  RI WKHFRQVWLWXHQWVWRWKHH[WHQWDYDLODEOH

© OECD, (2015)




31

TG 442C

OECD/OCDEo

3K\VLFDODSSHDUDQFHZDWHUVROXELOLW\DQGDGGLWLRQDOUHOHYDQWSK\VLFRFKHPLFDOSURSHUWLHVWRWKHH[WHQWDYDLODEOH

o

0ROHFXODU ZHLJKW RU DSSDUHQW PROHFXODU ZHLJKW LQ FDVH RI PL[WXUHVSRO\PHUV RI NQRZQFRPSRVLWLRQVRURWKHULQIRUPDWLRQUHOHYDQWIRUWKHFRQGXFWRIWKHVWXG\o

7UHDWPHQWSULRUWRWHVWLQJLIDSSOLFDEOH HJZDUPLQJJULQGLQJ o&RQFHQWUDWLRQ V WHVWHG

o

6WRUDJHFRQGLWLRQVDQGVWDELOLW\WRWKHH[WHQWDYDLODEOH
Controlsxx

3RVLWLYHFRQWUROo&KHPLFDO LGHQWLILFDWLRQ VXFK DV ,83$& RU &$6 QDPH V  &$6 QXPEHU V  60,/(6 RU
,Q&K,FRGHVWUXFWXUDOIRUPXODDQGRURWKHULGHQWLILHUVo

3K\VLFDO DSSHDUDQFH ZDWHU VROXELOLW\ PROHFXODU ZHLJKW DQG DGGLWLRQDO UHOHYDQWSK\VLFRFKHPLFDOSURSHUWLHVWRWKHH[WHQWDYDLODEOHo

3XULW\FKHPLFDOLGHQWLW\RILPSXULWLHVDVDSSURSULDWHDQGSUDFWLFDOO\IHDVLEOHHWFo

7UHDWPHQWSULRUWRWHVWLQJLIDSSOLFDEOH HJZDUPLQJJULQGLQJ o&RQFHQWUDWLRQ V WHVWHG

o

6WRUDJHFRQGLWLRQVDQGVWDELOLW\WRWKHH[WHQWDYDLODEOHo

5HIHUHQFH WR KLVWRULFDO SRVLWLYH FRQWURO UHVXOWV GHPRQVWUDWLQJ VXLWDEOH UXQ DFFHSWDQFH
FULWHULDLIDSSOLFDEOH

6ROYHQWYHKLFOH
o

6ROYHQWYHKLFOHXVHGDQGUDWLRRILWVFRQVWLWXHQWVLIDSSOLFDEOHo&KHPLFDOLGHQWLILFDWLRQ V VXFKDV,83$&RU&$6QDPH V &$6QXPEHU V DQGRURWKHU
LGHQWLILHUVo

3XULW\FKHPLFDOLGHQWLW\RILPSXULWLHVDVDSSURSULDWHDQGSUDFWLFDOO\IHDVLEOHHWFo

3K\VLFDODSSHDUDQFHPROHFXODUZHLJKWDQGDGGLWLRQDOUHOHYDQWSK\VLFRFKHPLFDOSURSHUWLHVLQWKHFDVHRWKHUVROYHQWVYHKLFOHVWKDQWKRVHPHQWLRQHGLQWKH7HVW*XLGHOLQHDUHXVHG
DQGWRWKHH[WHQWDYDLODEOHo

6WRUDJHFRQGLWLRQVDQGVWDELOLW\WRWKHH[WHQWDYDLODEOHo-XVWLILFDWLRQIRUFKRLFHRIVROYHQWIRUHDFKWHVWFKHPLFDOo)RUDFHWRQLWULOHUHVXOWVRIWHVWRILPSDFWRQSHSWLGHVWDELOLW\
Preparation of peptides, positive control and test chemicalx&KDUDFWHULVDWLRQRISHSWLGHVROXWLRQV VXSSOLHUORWH[DFWZHLJKWRISHSWLGHYROXPHDGGHGIRUWKHVWRFNVROXWLRQ x&KDUDFWHULVDWLRQ RI SRVLWLYH FRQWURO VROXWLRQ H[DFW ZHLJKW RI SRVLWLYH FRQWURO VXEVWDQFH YROXPHDGGHGIRUWKHWHVWVROXWLRQ © OECD, (2015)
32



OECD/OCDEx

TG 442C

&KDUDFWHULVDWLRQ RI WHVW FKHPLFDO VROXWLRQV H[DFW ZHLJKW RI WHVW FKHPLFDO YROXPH DGGHG IRU WKH
WHVWVROXWLRQ 
HPLC instrument setting and analysisx

7\SHRI+3/&LQVWUXPHQW+3/&DQGJXDUGFROXPQVGHWHFWRUDXWRVDPSOHUx

3DUDPHWHUVUHOHYDQWIRU WKH +3/& DQDO\VLVVXFK DV FROXPQ WHPSHUDWXUH LQMHFWLRQ YROXPHV IORZUDWHDQGJUDGLHQW
System suitabilityx

3HSWLGHSHDNDUHDDWQPRIHDFKVWDQGDUGDQGUHIHUHQFHFRQWURO$UHSOLFDWH

x/LQHDUFDOLEUDWLRQFXUYHJUDSKLFDOO\UHSUHVHQWHGDQGWKHUUHSRUWHG

x

3HSWLGHFRQFHQWUDWLRQRIHDFKUHIHUHQFHFRQWURO$UHSOLFDWH

x

0HDQSHSWLGHFRQFHQWUDWLRQ P0 RIWKHWKUHHUHIHUHQFHFRQWUROV$6'DQG&9

x

3HSWLGHFRQFHQWUDWLRQRIUHIHUHQFHFRQWUROV$DQG&
Analysis sequencexxx)RUUHIHUHQFHFRQWUROVo

3HSWLGHSHDNDUHDDWQPRIHDFK%DQG&UHSOLFDWHo0HDQSHSWLGHSHDNDUHDDWQPRIWKHQLQHUHIHUHQFHFRQWUROV%DQG&LQDFHWRQLWULOH
6'DQ&9 IRUVWDELOLW\RIUHIHUHQFHFRQWUROVRYHUDQDO\VLVWLPH o)RU HDFK VROYHQW XVHG WKH PHDQ SHSWLGH SHDN DUHD DW  QP RI WKH WKUHH DSSURSULDWHUHIHUHQFHFRQWUROV& IRUWKHFDOFXODWLRQRISHUFHQWSHSWLGHGHSOHWLRQ o)RUHDFKVROYHQWXVHGWKHSHSWLGHFRQFHQWUDWLRQ P0 RIWKHWKUHHDSSURSULDWHUHIHUHQFH
FRQWUROV&

o)RU HDFK VROYHQW XVHG WKH PHDQ SHSWLGH FRQFHQWUDWLRQ P0  RI WKH WKUHH DSSURSULDWHUHIHUHQFHFRQWUROV&6'DQG&9

)RUSRVLWLYHFRQWUROo

3HSWLGHSHDNDUHDDWQPRIHDFKUHSOLFDWHo

3HUFHQWSHSWLGHGHSOHWLRQRIHDFKUHSOLFDWHo0HDQSHUFHQWSHSWLGHGHSOHWLRQRIWKHWKUHHUHSOLFDWHV6'DQG&9

)RUHDFKWHVWFKHPLFDO
o$SSHDUDQFH RI SUHFLSLWDWH LQ WKH UHDFWLRQ PL[WXUH DW WKH HQG RI WKH LQFXEDWLRQ WLPH LI
REVHUYHG,ISUHFLSLWDWHZDVUHVROXELOLVHGRUFHQWULIXJHGo

3UHVHQFHRIFRHOXWLRQo'HVFULSWLRQRIDQ\RWKHUUHOHYDQWREVHUYDWLRQVLIDSSOLFDEOHo

3HSWLGHSHDNDUHDDWQPRIHDFKUHSOLFDWHo

3HUFHQWSHSWLGHGHSOHWLRQRIHDFKUHSOLFDWH

© OECD, (2015)




33

TG 442C

OECD/OCDEo

0HDQRISHUFHQWSHSWLGHGHSOHWLRQRIWKHWKUHHUHSOLFDWH6'DQG&9o

0HDQRISHUFHQWF\VWHLQHDQGSHUFHQWO\VLQHGHSOHWLRQYDOXHVo

3UHGLFWLRQPRGHOXVHGDQG'35$SUHGLFWLRQ
Proficiency testingx,I DSSOLFDEOH WKH SURFHGXUH XVHG WR GHPRQVWUDWH SURILFLHQF\ RI WKH ODERUDWRU\ LQ SHUIRUPLQJ WKH
WHVWPHWKRG HJE\WHVWLQJRISURILFLHQF\VXEVWDQFHV RUWRGHPRQVWUDWHUHSURGXFLEOHSHUIRUPDQFH
RIWKHWHVWPHWKRGRYHUWLPH


Discussion of the resultsx'LVFXVVLRQRIWKHUHVXOWVREWDLQHGZLWKWKH'35$WHVWPHWKRG

x'LVFXVVLRQ RI WKH WHVW PHWKRG UHVXOWV LQ WKH FRQWH[W RI DQ ,$7$ LI RWKHU UHOHYDQW LQIRUPDWLRQ LV
DYDLODEOH

Conclusion© OECD, (2015)
34



OECD/OCDETG 442C

LITERATURE(1)8QLWHG 1DWLRQV 81    *OREDOO\ +DUPRQL]HG 6\VWHP RI &ODVVLILFDWLRQ DQG /DEHOOLQJ RI
&KHPLFDOV *+6  )LIWK UHYLVHG HGLWLRQ 81 1HZ <RUN DQG *HQHYD  $YDLODEOH DW
KWWSZZZXQHFHRUJWUDQVGDQJHUSXEOLJKVJKVBUHYILOHVBHKWPO(2)2(&'   7KH $GYHUVH 2XWFRPH 3DWKZD\ IRU 6NLQ 6HQVLWLVDWLRQ ,QLWLDWHG E\ &RYDOHQW%LQGLQJ WR 3URWHLQV 3DUW  6FLHQWLILF (YLGHQFH 6HULHV RQ 7HVWLQJ DQG $VVHVVPHQW 1R 
2(&'3DULV(3)2(&'   6NLQ 6HQVLWLVDWLRQ 2(&' *XLGHOLQH IRU WKH 7HVWLQJ RI &KHPLFDOV 1R 2UJDQLVDWLRQ IRU (FRQRPLF &RRSHUDWLRQ DQG 'HYHORSPHQW 3DULV $YDLODEOH DW
KWWSZZZRHFGRUJHQYWHVWJXLGHOLQHV(4)2(&'  7KH/RFDO/\PSK1RGH$VVD\2(&'*XLGHOLQHIRUWKH7HVWLQJRI&KHPLFDOV
1R  2UJDQLVDWLRQ IRU (FRQRPLF &RRSHUDWLRQ DQG 'HYHORSPHQW 3DULV $YDLODEOH DW
KWWSZZZRHFGRUJHQYWHVWJXLGHOLQHV(5)2(&'   6NLQ 6HQVLWLVDWLRQ /RFDO /\PSK 1RGH $VVD\ '$ 2(&' *XLGHOLQH IRU WKH7HVWLQJ RI &KHPLFDOV 1R $ 2UJDQLVDWLRQ IRU (FRQRPLF &RRSHUDWLRQ DQG 'HYHORSPHQW
3DULV$YDLODEOHDWKWWSZZZRHFGRUJHQYWHVWJXLGHOLQHV(6)2(&'   6NLQ 6HQVLWLVDWLRQ %UG8(/,6$ '$ 2(&' *XLGHOLQH IRU WKH 7HVWLQJ RI
&KHPLFDOV 1R % 2UJDQLVDWLRQ IRU (FRQRPLF &RRSHUDWLRQ DQG 'HYHORSPHQW 3DULV$YDLODEOHDWKWWSZZZRHFGRUJHQYWHVWJXLGHOLQHV

(7)$GOHUet al.  $OWHUQDWLYH QRQDQLPDO PHWKRGVIRUFRVPHWLFVWHVWLQJFXUUHQWVWDWXVDQG
IXWXUHSURVSHFWV$UFKLYHVRI7R[LFRORJ\

(8)*HUEHULFN et al.   'HYHORSPHQW RI D SHSWLGH UHDFWLYLW\ DVVD\ IRU VFUHHQLQJ FRQWDFWDOOHUJHQV7R[LFRORJLFDO6FLHQFHV

(9)*HUEHULFN et al.   4XDQWLILFDWLRQ RI FKHPLFDO SHSWLGH UHDFWLYLW\ IRU VFUHHQLQJ FRQWDFWDOOHUJHQV$FODVVLILFDWLRQWUHHPRGHODSSURDFK7R[LFRORJLFDO6FLHQFHV

(10)(&(85/(&9$0  5HFRPPHQGDWLRQRQWKH'LUHFW3HSWLGH5HDFWLYLW\$VVD\ '35$ 
IRUVNLQVHQVLWLVDWLRQWHVWLQJ$YDLODEOHDWKWWSLKFSMUFHFHXURSDHXRXUBODEVHXUOHFYDPHXUOHFYDPUHFRPPHQGDWLRQVHXUOHFYDPUHFRPPHQGDWLRQRQWKHGLUHFWSHSWLGHUHDFWLYLW\DVVD\GSUD-DZRUVND et al.  %D\HVLDQLQWHJUDWHGWHVWLQJVWUDWHJ\WRDVVHVVVNLQVHQVLWL]DWLRQSRWHQF\
IURPWKHRU\WRSUDFWLFH-RXUQDORI$SSOLHG7R[LFRORJ\SXEOLVKHGRQOLQH 0D\'2,MDW


















(11)


(12)

%DXFK et al   3XWWLQJ WKH SDUWV WRJHWKHU FRPELQLQJ LQ YLWUR PHWKRGV WR WHVW IRU VNLQVHQVLWL]LQJSRWHQWLDO5HJXODWRU\7R[LFRORJ\DQG3KDUPDFRORJ\

(13)

1XNDGD et al.  'DWDLQWHJUDWLRQRIQRQDQLPDOWHVWVIRUWKHGHYHORSPHQWRIDWHVWEDWWHU\© OECD, (2015)




35

TG 442C

OECD/OCDEWRSUHGLFWWKHVNLQVHQVLWL]LQJSRWHQWLDODQGSRWHQF\RIFKHPLFDOV7R[LFRORJ\,Q9LWUR


(14)

%DOOet al  (YDOXDWLQJWKHVHQVLWL]DWLRQSRWHQWLDORIVXUIDFWDQWVLQWHJUDWLQJGDWDIURPWKH
ORFDO O\PSK QRGH DVVD\ JXLQHD SLJ PD[LPL]DWLRQ WHVW DQG LQ YLWUR PHWKRGV LQ D ZHLJKWRIHYLGHQFHDSSURDFK5HJXODWRU\7R[LFRORJ\DQG3KDUPDFRORJ\

(15)/DQGVWHLQHU DQG -DFREV   6WXGLHV RQ WKH VHQVLWL]DWLRQ RI DQLPDOV ZLWK VLPSOH FKHPLFDOFRPSRXQGV-RXUQDORI([SHULPHQWDO0HGLFLQH(16)'XSXLV DQG %HQH]UD   $OOHUJLF FRQWDFW GHUPDWLWLV WR VLPSOH FKHPLFDOV D PROHFXODUDSSURDFK1HZ<RUN %DVHO0DUFHO'HNNHU,QF

(17)/HSRLWWHYLQ et al.  $OOHUJLFFRQWDFWGHUPDWLWLVWKHPROHFXODUEDVLV6SULQJHU%HUOLQ(18)(&(85/(&9$0  'LUHFW3HSWLGH5HDFWLYLW\$VVD\ '35$ 9DOLGDWLRQ6WXG\5HSRUWSS
$FFHVVLEOH
DW
KWWSLKFSMUFHFHXURSDHXRXUBODEVHXUOHFYDPHXUOHFYDP
UHFRPPHQGDWLRQVHXUOHFYDPUHFRPPHQGDWLRQRQWKHGLUHFWSHSWLGHUHDFWLYLW\DVVD\GSUD(19)

1DWVFK et al.   $ GDWDVHW RQ  FKHPLFDOV WHVWHG LQ DOWHUQDWLYH DVVD\V IRU VNLQVHQVLWL]DWLRQ XQGHUJRLQJ SUHYDOLGDWLRQ -RXUQDO RI $SSOLHG 7R[LFRORJ\ SXEOLVKHG RQOLQH 
$SULO'2,MDW

(20)'%$/0 ,19,772;  3URWRFRO  'LUHFW 3HSWLGH 5HDFWLYLW\ DVVD\ '35$  IRU VNLQVHQVLWLVDWLRQWHVWLQJSS$FFHVVLEOHDWKWWSHFYDPGEDOPMUFHFHXURSDHX

(21)

2(&'  *XLGDQFH'RFXPHQWRQWKH9DOLGDWLRQDQG,QWHUQDWLRQDO$FFHSWDQFHRI1HZRU
8SGDWHG 7HVW 0HWKRGV IRU +D]DUG $VVHVVPHQW 2(&' 6HULHV RQ 7HVWLQJ DQG $VVHVVPHQW
1R2UJDQLVDWLRQIRU(FRQRPLF&RRSHUDWLRQDQG'HYHORSPHQW3DULV)UDQFH(22))'$ )RRG DQG 'UXJ $GPLQLVWUDWLRQ   *XLGDQFH IRU ,QGXVWU\ %LRDQDO\WLFDO 0HWKRG
9DOLGDWLRQSS
$FFHVVLEOH
DWZZZIGDJRYGRZQORDGVGUXJVJXLGDQFHFRPSOLDQFHUHJXODWRU\LQIRUPDWLRQJXLGDQFHXFPSGI

(23)(&(72&   &RQWDFW VHQVLWL]DWLRQ &ODVVLILFDWLRQ DFFRUGLQJ WR SRWHQF\ (XURSHDQ &HQWUH
IRU(FRWR[LFRORJ\ 7R[LFRORJ\RI&KHPLFDOV 7HFKQLFDO5HSRUW1R 












© OECD, (2015)
36



OECD/OCDETG 442C

ANNEX 1DEFINITIONS
Accuracy:7KHFORVHQHVVRIDJUHHPHQWEHWZHHQWHVWPHWKRGUHVXOWVDQGDFFHSWHGUHIHUHQFHYDOXHV,WLVD
PHDVXUHRIWHVWPHWKRGSHUIRUPDQFHDQGRQHDVSHFWRI³UHOHYDQFH´7KHWHUPLVRIWHQXVHGLQWHUFKDQJHDEO\ZLWK³FRQFRUGDQFH´WRPHDQWKHSURSRUWLRQRIFRUUHFWRXWFRPHVRIDWHVWPHWKRG  AOP (Adverse Outcome Pathway): VHTXHQFHRIHYHQWVIURPWKHFKHPLFDOVWUXFWXUHRIDWDUJHWFKHPLFDO
RUJURXSRIVLPLODUFKHPLFDOVWKURXJKWKHPROHFXODULQLWLDWLQJHYHQWWRDQin vivoRXWFRPHRILQWHUHVW  
Calibration curve: 7KH UHODWLRQVKLS EHWZHHQ WKH H[SHULPHQWDO UHVSRQVH YDOXH DQG WKH DQDO\WLFDO
FRQFHQWUDWLRQ DOVRFDOOHGstandard curve RIDNQRZQVXEVWDQFH

Coefficient of variation: D PHDVXUH RI YDULDELOLW\ WKDW LV FDOFXODWHG IRU D JURXS RI UHSOLFDWH GDWD E\GLYLGLQJWKHVWDQGDUGGHYLDWLRQE\WKHPHDQ,WFDQEHPXOWLSOLHGE\IRUH[SUHVVLRQDVDSHUFHQWDJH
Hazard: ,QKHUHQWSURSHUW\RIDQDJHQWRUVLWXDWLRQKDYLQJWKHSRWHQWLDOWRFDXVHDGYHUVHHIIHFWVZKHQDQ
RUJDQLVPV\VWHPRU VXE SRSXODWLRQLVH[SRVHGWRWKDWDJHQW
IATA (Integrated Approach to Testing and Assessment): $ VWUXFWXUHG DSSURDFK XVHG IRU KD]DUG
LGHQWLILFDWLRQ SRWHQWLDO KD]DUGFKDUDFWHULVDWLRQ SRWHQF\ DQGRUVDIHW\DVVHVVPHQW SRWHQWLDOSRWHQF\DQG
H[SRVXUH RIDFKHPLFDORUJURXSRIFKHPLFDOVZKLFKVWUDWHJLFDOO\LQWHJUDWHVDQGZHLJKWVDOOUHOHYDQWGDWD
WRLQIRUPUHJXODWRU\GHFLVLRQUHJDUGLQJSRWHQWLDOKD]DUGDQGRUULVNDQGRUWKHQHHGIRUIXUWKHUWDUJHWHGDQG
WKHUHIRUHPLQLPDOWHVWLQJ
Molecular Initiating Event: &KHPLFDOLQGXFHGSHUWXUEDWLRQRIDELRORJLFDOV\VWHPDWWKHPROHFXODUOHYHOLGHQWLILHGWREHWKHVWDUWLQJHYHQWLQWKHDGYHUVHRXWFRPHSDWKZD\Mixture: $PL[WXUHRUDVROXWLRQFRPSRVHGRIWZRRUPRUHVXEVWDQFHVLQZKLFKWKH\GRQRWUHDFW  
Mono-constituent substance: $ VXEVWDQFH GHILQHG E\ LWV TXDQWLWDWLYH FRPSRVLWLRQ LQ ZKLFK RQH PDLQFRQVWLWXHQWLVSUHVHQWWRDWOHDVW ZZ 
Multi-constituent substance: $ VXEVWDQFH GHILQHG E\ LWV TXDQWLWDWLYH FRPSRVLWLRQ LQ ZKLFK PRUH WKDQ
RQH PDLQ FRQVWLWXHQW LV SUHVHQW LQ D FRQFHQWUDWLRQ   ZZ  DQG   ZZ  $ PXOWLFRQVWLWXHQWVXEVWDQFHLVWKHUHVXOWRIDPDQXIDFWXULQJSURFHVV7KHGLIIHUHQFHEHWZHHQPL[WXUHDQGPXOWLFRQVWLWXHQWVXEVWDQFHLVWKDWDPL[WXUHLVREWDLQHGE\EOHQGLQJRIWZRRUPRUHVXEVWDQFHVZLWKRXWFKHPLFDOUHDFWLRQ$PXOWLFRQVWLWXHQWVXEVWDQFHLVWKHUHVXOWRIDFKHPLFDOUHDFWLRQ
Positive control: $ UHSOLFDWH FRQWDLQLQJ DOO FRPSRQHQWV RI D WHVW V\VWHP DQG WUHDWHG ZLWK D VXEVWDQFH
NQRZQWRLQGXFHDSRVLWLYHUHVSRQVH7RHQVXUHWKDWYDULDELOLW\LQWKHSRVLWLYHFRQWUROUHVSRQVHDFURVVWLPH
FDQEHDVVHVVHGWKHPDJQLWXGHRIWKHSRVLWLYHUHVSRQVHVKRXOGQRWEHH[FHVVLYH
© OECD, (2015)




37

TG 442C

OECD/OCDE
Reference control:$QXQWUHDWHGVDPSOHFRQWDLQLQJDOOFRPSRQHQWVRIDWHVWV\VWHPLQFOXGLQJWKHVROYHQW
RU YHKLFOH WKDW LV SURFHVVHG ZLWK WKH WHVW FKHPLFDO WUHDWHG DQG RWKHU FRQWURO VDPSOHV WR HVWDEOLVK WKHEDVHOLQHUHVSRQVHIRUWKHVDPSOHVWUHDWHGZLWKWKHWHVWFKHPLFDOGLVVROYHGLQWKHVDPHVROYHQWRUYHKLFOH:KHQ WHVWHG ZLWK D FRQFXUUHQW QHJDWLYH FRQWURO WKLV VDPSOH DOVR GHPRQVWUDWHV ZKHWKHU WKH VROYHQW RU
YHKLFOHLQWHUDFWVZLWKWKHWHVWV\VWHP
Relevance: 'HVFULSWLRQRIUHODWLRQVKLSRIWKHWHVWWRWKHHIIHFWRILQWHUHVWDQGZKHWKHULWLVPHDQLQJIXODQG
XVHIXO IRU D SDUWLFXODU SXUSRVH ,W LV WKH H[WHQW WR ZKLFK WKH WHVW FRUUHFWO\ PHDVXUHV RU SUHGLFWV WKHELRORJLFDOHIIHFWRILQWHUHVW5HOHYDQFHLQFRUSRUDWHVFRQVLGHUDWLRQRIWKHDFFXUDF\ FRQFRUGDQFH RIDWHVWPHWKRG  
Reliability: 0HDVXUHVRIWKHH[WHQWWKDWDWHVWPHWKRGFDQEHSHUIRUPHGUHSURGXFLEO\ZLWKLQDQGEHWZHHQODERUDWRULHV RYHU WLPH ZKHQ SHUIRUPHG XVLQJ WKH VDPH SURWRFRO ,W LV DVVHVVHG E\ FDOFXODWLQJ LQWUD DQGLQWHUODERUDWRU\UHSURGXFLELOLW\DQGLQWUDODERUDWRU\UHSHDWDELOLW\  
Reproducibility: 7KHDJUHHPHQWDPRQJUHVXOWVREWDLQHGIURPWHVWLQJWKHVDPHVXEVWDQFHXVLQJWKHVDPH
WHVWSURWRFRO VHHUHOLDELOLW\   
Sensitivity:7KHSURSRUWLRQRIDOOSRVLWLYHDFWLYHFKHPLFDOVWKDWDUHFRUUHFWO\FODVVLILHGE\WKHWHVWPHWKRG
,W LV D PHDVXUH RI DFFXUDF\ IRU D WHVW PHWKRG WKDW SURGXFHV FDWHJRULFDO UHVXOWV DQG LV DQ LPSRUWDQWFRQVLGHUDWLRQLQDVVHVVLQJWKHUHOHYDQFHRIDWHVWPHWKRG  Specificity: 7KH SURSRUWLRQ RI DOO QHJDWLYHLQDFWLYH FKHPLFDOV WKDW DUH FRUUHFWO\ FODVVLILHG E\ WKH WHVWPHWKRG,WLVDPHDVXUHRIDFFXUDF\IRUDWHVWPHWKRGWKDWSURGXFHVFDWHJRULFDOUHVXOWVDQGLVDQLPSRUWDQWFRQVLGHUDWLRQLQDVVHVVLQJWKHUHOHYDQFHRIDWHVWPHWKRG  
Substance: &KHPLFDO HOHPHQWV DQG WKHLU FRPSRXQGV LQ WKH QDWXUDO VWDWH RU REWDLQHG E\ DQ\ SURGXFWLRQSURFHVV LQFOXGLQJ DQ\ DGGLWLYH QHFHVVDU\ WR SUHVHUYH WKH VWDELOLW\ RI WKH SURGXFW DQG DQ\ LPSXULWLHVGHULYLQJIURPWKHSURFHVVXVHGEXW H[FOXGLQJDQ\VROYHQWZKLFKPD\EHVHSDUDWHGZLWKRXWDIIHFWLQJWKH
VWDELOLW\RIWKHVXEVWDQFHRUFKDQJLQJLWVFRPSRVLWLRQ  System suitability'HWHUPLQDWLRQRILQVWUXPHQWSHUIRUPDQFH HJVHQVLWLYLW\ E\DQDO\VLVRIDUHIHUHQFH
VWDQGDUGSULRUWRUXQQLQJWKHDQDO\WLFDOEDWFK  
Test chemical: 7KHWHUPWHVWFKHPLFDOLVXVHGWRUHIHUWRZKDWLVEHLQJWHVWHG
United Nations Globally Harmonized System of Classification and Labelling of Chemicals (UNGHS): $ V\VWHP SURSRVLQJ WKH FODVVLILFDWLRQ RI FKHPLFDOV VXEVWDQFHV DQG PL[WXUHV  DFFRUGLQJ WR
VWDQGDUGLVHGW\SHVDQGOHYHOVRISK\VLFDOKHDOWKDQGHQYLURQPHQWDOKD]DUGVDQGDGGUHVVLQJFRUUHVSRQGLQJFRPPXQLFDWLRQ HOHPHQWV VXFK DV SLFWRJUDPV VLJQDO ZRUGV KD]DUG VWDWHPHQWV SUHFDXWLRQDU\ VWDWHPHQWV
DQGVDIHW\GDWDVKHHWVVRWKDWWRFRQYH\LQIRUPDWLRQRQWKHLUDGYHUVHHIIHFWVZLWKDYLHZWRSURWHFWSHRSOH
LQFOXGLQJ HPSOR\HUV ZRUNHUV WUDQVSRUWHUV FRQVXPHUV DQG HPHUJHQF\ UHVSRQGHUV  DQG WKH HQYLURQPHQW © OECD, (2015)
38



OECD/OCDETG 442CUVCB: VXEVWDQFHV RI XQNQRZQ RU YDULDEOH FRPSRVLWLRQ FRPSOH[ UHDFWLRQ SURGXFWV RU ELRORJLFDOPDWHULDOVValid test method: $ WHVW PHWKRG FRQVLGHUHG WR KDYH VXIILFLHQW UHOHYDQFH DQG UHOLDELOLW\ IRU D VSHFLILF
SXUSRVHDQGZKLFKLVEDVHGRQVFLHQWLILFDOO\VRXQGSULQFLSOHV$WHVWPHWKRGLVQHYHUYDOLGLQDQDEVROXWH
VHQVHEXWRQO\LQUHODWLRQWRDGHILQHGSXUSRVH  © OECD, (2015)




39

TG 442C

OECD/OCDEANNEX 2PROFICIENCY SUBSTANCESIn Chemico Skin Sensitisation: Direct Peptide Reactivity Assay
3ULRU WRURXWLQH XVH RI WKHWHVW PHWKRG GHVFULEHGLQWKLV7HVW *XLGHOLQH ODERUDWRULHV VKRXOG GHPRQVWUDWH
WHFKQLFDO SURILFLHQF\ E\ FRUUHFWO\ REWDLQLQJ WKH H[SHFWHG '35$ SUHGLFWLRQ IRU WKH  SURILFLHQF\VXEVWDQFHVUHFRPPHQGHGLQ7DEOHDQGE\REWDLQLQJF\VWHLQHDQGO\VLQHGHSOHWLRQYDOXHVWKDWIDOOZLWKLQ
WKH UHVSHFWLYH UHIHUHQFH UDQJH IRU  RXW RI WKH  SURILFLHQF\ VXEVWDQFHV IRU HDFK SHSWLGH 7KHVH
SURILFLHQF\ VXEVWDQFHV ZHUH VHOHFWHG WR UHSUHVHQW WKH UDQJH RI UHVSRQVHV IRU VNLQ VHQVLWLVDWLRQ KD]DUGV2WKHUVHOHFWLRQFULWHULDZHUHWKDWWKH\DUHFRPPHUFLDOO\DYDLODEOHWKDWKLJKTXDOLW\in vivoUHIHUHQFHGDWD
DQGKLJKTXDOLW\in vitroGDWDJHQHUDWHGZLWKWKH'35$DUHDYDLODEOHDQGWKDWWKH\ZHUHXVHGLQWKH(85/(&9$0FRRUGLQDWHGYDOLGDWLRQVWXG\WRGHPRQVWUDWHVXFFHVVIXOLPSOHPHQWDWLRQRIWKHWHVWPHWKRGLQWKH
ODERUDWRULHVSDUWLFLSDWLQJLQWKHVWXG\
7DEOH  5HFRPPHQGHG SURILFLHQF\ VXEVWDQFHV IRU GHPRQVWUDWLQJ WHFKQLFDO SURILFLHQF\ ZLWK WKH 'LUHFW
3HSWLGH5HDFWLYLW\$VVD\Proficiency substances

CASRN

Physicalstate

In vivoprediction1

DPRA
prediction2

Range3 of %cysteine peptide
depletion

Range3 of %lysine peptide
depletion

'LQLWURFKORUREHQ]HQH



6ROLG

3RVLWLYH





6ROLG

3RVLWLYH



)RUPDOGHK\GH

/LTXLG

3RVLWLYH



%HQ]\OLGHQHDFHWRQH



6ROLG

3RVLWLYH)DUQHVDO /LTXLG

3RVLWLYH



%XWDQHGLRQH

/LTXLG

3RVLWLYH



%XWDQRO

/LTXLG

6HQVLWLVHU
H[WUHPH 
6HQVLWLVHU
H[WUHPH 
6HQVLWLVHUVWURQJ 
6HQVLWLVHUPRGHUDWH 
6HQVLWLVHUZHDN 
6HQVLWLVHUZHDN 
1RQVHQVLWLVHU

1HJDWLYH

0HWK\OFRXPDULQ

6ROLG

1RQVHQVLWLVHU

1HJDWLYH/DFWLF$FLG



/LTXLG

1RQVHQVLWLVHU

1HJDWLYH

0HWKR[\DFHWRSKHQRQH



6ROLG

1RQVHQVLWLVHU

1HJDWLYH

2[D]RORQH



7KHin vivoKD]DUGDQG SRWHQF\ SUHGLFWLRQVDUHEDVHGRQ//1$GDWD  7KHin vivoSRWHQF\LVGHULYHGXVLQJWKH
FULWHULDSURSRVHGE\(&(72&  $'35$SUHGLFWLRQVKRXOGEHFRQVLGHUHGLQWKH IUDPHZRUNRIDQ,$7$DQGLQDFFRUGDQFHZLWKWKHSURYLVLRQVRISDUDJUDSKVDQG
5DQJHVGHWHUPLQHGRQWKHEDVLVRIDWOHDVWGHSOHWLRQYDOXHVJHQHUDWHGE\LQGHSHQGHQWODERUDWRULHV

© OECD, (2015)
40



OECD/OCDETG 442C

ANNEX 3EXAMPLES OF ANALYSIS SEQUENCE
Calibration standards and reference controls

Co-elution controls

Reference controls

First set of replicates

Second set of replicates

Third set of replicates

Reference controls

67'
67'
67'
67'
67'
67'
'LOXWLRQEXIIHU
5HIHUHQFHFRQWURO$UHS
5HIHUHQFHFRQWURO$UHS
5HIHUHQFHFRQWURO$UHS
&RHOXWLRQ FRQWURO  IRU WHVWFKHPLFDO&RHOXWLRQ FRQWURO  IRU WHVWFKHPLFDO
5HIHUHQFHFRQWURO%UHS
5HIHUHQFHFRQWURO%UHS
5HIHUHQFHFRQWURO%UHS
5HIHUHQFHFRQWURO&UHS&LQQDPLFDOGHK\GHUHS
6DPSOHUHS
6DPSOHUHS
5HIHUHQFHFRQWURO&UHS&LQQDPLFDOGHK\GHUHS
6DPSOHUHS
6DPSOHUHS
5HIHUHQFHFRQWURO&UHS&LQQDPLFDOGHK\GHUHS
6DPSOHUHS
6DPSOHUHS
5HIHUHQFHFRQWURO%UHS
5HIHUHQFHFRQWURO%UHS
5HIHUHQFHFRQWURO%UHS7KUHHVHWVRIUHIHUHQFHFRQWUROV LHVDPSOHVFRQVWLWXWHGRQO\E\WKHSHSWLGHGLVVROYHGLQWKHDSSURSULDWH
VROYHQW VKRXOGEHLQFOXGHGLQWKHDQDO\VLVVHTXHQFH
5HIHUHQFHFRQWURO$XVHGWRYHULI\WKHVXLWDELOLW\RIWKH+3/&V\VWHP
5HIHUHQFHFRQWURO%LQFOXGHGDWWKHEHJLQQLQJDQGDWWKHHQGRIWKHDQDO\VLVVHTXHQFHWRYHULI\VWDELOLW\RIUHIHUHQFHFRQWUROVRYHUWKHDQDO\VLVWLPH
5HIHUHQFHFRQWURO&LQFOXGHGLQWKHDQDO\VLVVHTXHQFHWRYHULI\WKDWWKHVROYHQWXVHGWRGLVVROYHWKHWHVWFKHPLFDOGRHVQRWLPSDFWWKHSHUFHQWSHSWLGHGHSOHWLRQ© OECD, (2015)




41

42

EURL ECVAM Recommendation on the
Direct Peptide Reactivity Assay (DPRA)
for Skin Sensitisation Testing

October 2013

Report EUR 25946 EN

43European Commission
Joint Research Centre
Institute for Health and Consumer Protection (IHCP)
Contact information
European Reference Laboratory for Alternatives to Animal Testing
Address: Joint Research Centre, Via Enrico Fermi 2749, 21027 Ispra (VA), Italy
E-mail: JRC-ECVAM-CONTACT@ec.europa.eu
http://ihcp.jrc.ec.europa.eu/
http://www.jrc.ec.europa.eu/
This publication is a Reference Report by the Joint Research Centre of the European Commission.
Legal Notice
Neither the European Commission nor any person acting on behalf of the Commission
is responsible for the use which might be made of this publication.
Europe Direct is a service to help you find answers to your questions about the European Union
Freephone number (*): 00 800 6 7 8 9 10 11(*) Certain mobile telephone operators do not allow access to 00 800 numbers or these calls may be billed.

A great deal of additional information on the European Union is available on the Internet.
It can be accessed through the Europa server http://europa.eu/.
JRC85936
EUR 26383 EN
ISBN 978-92-79-34886-0 (pdf)
ISSN 1831-9424 (online)
doi: 10.2788/48229
Luxembourg: Publications Office of the European Union, 2013
© European Union, 2013
Reproduction is authorized provided the source is acknowledged.
Printed in Ispra

44

EUROPEAN COMMISSIONJOINT RESEARCH CENTRE
Institute for Health and Consumer Protection
EU Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM)EURL ECVAM RECOMMENDATION
on the Direct Peptide Reactivity Assay (DPRA) for
Skin Sensitisation Testing

November 201345

ACKNOWLEDGEMENTS
This Recommendation was prepared by the EU Reference Laboratory for Alternatives to Animal
Testing (EURL ECVAM), part of the Institute for Health and Consumer Protection (IHCP),
Directorate-General Joint Research Centre (DG JRC) of the European Commission.
The Recommendation was drafted on the basis of the ESAC Opinion and ESAC Working Group
Report summarising the detailed scientific peer review of the EURL ECVAM-coordinated study
on the Direct Peptide Reactivity Assay (DPRA). The Recommendation further benefitted fromcomments and suggestions received from members of PARERE (EURL ECVAM's advisory bodyfor Preliminary Assessment of Regulatory Relevance that brings together representatives ofMember State regulatory bodies as well as EU agencies including ECHA, EFSA and EMA), andESTAF (EURL ECVAM's Stakeholder Forum). Input was also provided by partner organisations of
EURL ECVAM in the framework of the International Collaboration on Alternative Test Methods(ICATM), and by the general public.
Coordinator/Project leader of the validation study was Silvia Casati. Coordinator of the ESAC
Peer Review and EURL ECVAM Recommendation was Claudius Griesinger.

Comments or enquiries related to this EURL ECVAM Recommendation should be sent to:
EU Reference Laboratory for Alternatives to Animal Testing
European Commission DG Joint Research Centre,
Institute for Health and Consumer Protection,
Via E. Fermi 2749,
I-21027 Ispra (VA), Italy.
e-mail: JRC-ECVAM-CONTACT@ec.europa.eu

346

TABLE OF CONTENTSEXECUTIVE SUMMARY ....................................................................................................... 5
1. Introduction ................................................................................................................... 7
2. Test Method definition .................................................................................................. 8
3. Overall performance of the Direct Peptide Reactivity Assay ....................................... 9
4. Limitations.................................................................................................................... 10
5. Suggested regulatory use ............................................................................................ 11
6. Follow-up activities recommended by EURL ECVAM ................................................. 13
References ........................................................................................................................ 14
Annex 1ESAC Opinion .................................................................................... 17
Annex 2EURL ECVAM request for ESAC advice ............................................ 25

BACKGROUND TO EURL ECVAM RECOMMENDATIONS
The aim of a EURL ECVAM Recommendation is to provide EURL ECVAM views on the validity ofthe test method in question, to advise on possible regulatory applicability, limitations andproper scientific use of the test method, and to suggest possible follow-up activities in view ofaddressing knowledge gaps.
During the development of its Recommendation, EURL ECVAM consults with its advisory bodyfor Preliminary Assessment of Regulatory Relevance (PARERE) and its EURL ECVAM Stakeholder
Forum (ESTAF). Moreover, EURL ECVAM consults with other Commission services and its
international validation partner organisations of the International Cooperation on Alternative
Test Methods (ICATM). Before finalising its recommendations, EURL ECVAM also invites
comments from the general public and, if applicable, from the test method submitter.

4

47

EXECUTIVE SUMMARYEURL ECVAM fully endorses the ESAC opinion (Annex I) on the ECVAM-coordinated validation
study of the Direct Peptide Reactivity Assay (DPRA) that assessed mainly protocol transferability
and within- and between-laboratory reproducibility. The study was conducted in view of the
DPRA's possible use as a component of an integrated approach for testing the potential ofchemicals to cause skin sensitisation resulting in Allergic Contact Dermatitis (ACD). On the basisof the ESAC Opinion on the DPRA study, EURL ECVAM makes the following Recommendations:(1) Haptenation, i.e. the covalent binding of low-molecular weight substances ("haptens") toproteins present in skin is considered a prominent mechanism through which chemicals or
their metabolites become antigenic. Haptenation has been described as a "molecular
initiating event" in the OECD Adverse Outcome Pathway (AOP) for skin sensitisation whichsummarises the key events known to be involved in chemically-induced ACD (OECD, 2012).
Therefore, information from peptide reactivity assays such as the DPRA is relevant for theassessment of the skin sensitisation potential of chemicals.
(2) The EURL ECVAM study showed that the DPRA is transferable to suitably equippedlaboratories that are proficient in high performance liquid chromatography (HPLC) analysis
and the results obtained demonstrated within- and between-laboratory reproducibility of
87% and 75%, respectively.
(3) Full evaluation of the predictive capacity and applicability domain of the DPRA were outside
the scope of the EURL ECVAM study. However, based on the study results and excluding
metal compounds for which the test is not applicable, the accuracy of the DPRA for
distinguishing sensitisers from non-sensitisers was 82% (sensitivity of 76%, specificity of92%) which is in agreement with published information from previous studies (Gerberick etal., 2007; Bauch et al., 2012; Natsch et al., 2013).
(4) In addition to supporting identification of sensitisers/non-sensitisers, the DPRA may also beable to contribute to the assessment of sensitising potency, e.g. by supporting, within an
integrated approach, the subcategorisation of sensitisers according to the United Nations
Globally Harmonised System of Classification and Labelling of Chemicals (UN GHS; UN,2011). More work however is required to determine to which extent DPRA results relate topotency categories.
(5) As the DPRA is an in chemico test method lacking metabolic capacity, substances that
require metabolic (pro-haptens) or abiotic activation (pre-haptens) may not be detected by
the DPRA. In addition, the DPRA specifically detects peptide reactivity associated with lysine
and cysteine amino acids. These factors should be taken into account when considering
negative results.
(6) In view of the mechanistic complexity of skin sensitisation, DPRA data should always be
considered in combination with other information in the context of integrated approaches
such as Weight of Evidence (WoE) or Integrated Testing Strategies (ITS). Complementary
information may be derived from test methods addressing other key events involved in skinsensitisation (OECD 2012) as well as non-testing methods including read-across information.
Thus, EURL ECVAM recommends the development of integrated approaches for identifying
and characterising skin sensitisation hazard (EURL ECVAM 2013) and potency. These
approaches should be tailored to specific needs (e.g. depending on various sectorial andregulatory requirements).
548

(7) To support development of integrated approaches employing peptide reactivity assays(such as DPRA) and other sources of information, the applicability of the DPRA should befurther characterised, e.g. through a retrospective analysis of existing data and, in case ofidentified data gaps, by generating additional information through targeted prospective
testing. In particular, as pre-haptens are not consistently misclassified by the DPRA, theassay's applicability to these substances should be further investigated. Additionally,
attention should be given to substances with electrophilic residues that react preferentiallywith amino acids other than cysteine or lysine.
(8) Respecting the provision of Directive 2010/63/EU (EU, 2010) on the protection of animals
used for scientific purposes, before embarking on animal experiments to identify substanceswith skin sensitisation potential, data from the DPRA test method should be considered in
combination with complementary information in order to reduce and possibly avoid animal
testing. In agreement with the provision of Annex XI point 1.2 of the REACH Regulation (EU,2006) data from non-standard testing methods, such as the DPRA, may be used to adapt thestandard information requirements in the context of Weight of Evidence judgments.

649

1. Introduction
1) The assessment of skin sensitisation potential is an important component in the safety
evaluation of substances and represents a standard requirement of legislation on
chemicals in the EU. These include: the Classification Labelling and Packaging of substancesand mixtures (CLP) Regulation (EU, 2008a), the REACH Regulation (EU, 2006), the Plant
Protection Products (PPP) Regulation (EU, 2009a), the Biocides Regulation (EU, 2012) andthe Cosmetics Directive (EU, 2009b). As outlined in the EURL ECVAM Strategy for
Replacement of Animal Testing for Skin Sensitisation Hazard Identification andClassification (EURL ECVAM, 2013), determining the skin sensitisation hazard properties ofsubstances is a key requirement satisfying already the majority of regulatory needs, e.g.
under the CLP and REACH Regulations in the EU. Other regulatory contexts can require anunderstanding of the relative potency of skin sensitisers with regard to both induction as
well as elicitation of contact dermatitis in order to support a full risk assessment andappropriate risk management measures (e.g. setting of appropriate thresholds).
2) Currently there are only in vivo regulatory accepted test methods to generate datasatisfying regulatory requirements on skin sensitisation. For instance, in the frameworks of
the Organisation for Economic Cooperation and Development (OECD) and the EU Test
Methods Regulation (EU, 2008b), there are four accepted guidelines, describing: theBuehler Test and Guinea-pig Maximisation Test (GPMT), TG406 (OECD, 1992; EU test
method B.6), the Local Lymph Node Assay (LLNA), TG429 (OECD, 2010a; EU test method
B.42) and its non-radio-isotopic variants, the Local Lymph Node Assay: DA and the Local
Lymph Node Assay: BrdU Elisa , TG 422A and TG 422B respectively (OECD, 2010b; OECD
2010c).
3) The key mechanistic events underpinning the skin sensitisation process that leads toAllergic Contact Dermatitis (ACD) in humans are well understood and have been recently
summarised in the OECD report on “The Adverse Outcome Pathway (AOP) for Skin
Sensitisation Initiated by Covalent Binding to Proteins“(OECD 2012). These include 1) thecovalent binding of the chemical to the skin protein (haptenation), 2) events inkeratinocytes including the production of danger signals and release of pro-inflammatory
mediators 3) the maturation and mobilisation of dendritic cells (DC), the immunocompetent cells in the skin, and 5) the antigen presentation to naïve T-cells and theproliferation of memory T-cells. Considerable progress has been made in recent years
towards the development of alternative non-animal methods that address these key
events. It is plausible that the initial event of haptenation is the major determinant of theskin sensitisation process and thus the protein-binding properties of a chemical should be
intrinsically linked to its sensitisation potential and potency (Roberts & Aptula, 2008).
4) There is general agreement within the scientific community that, in the near future, it isunlikely that one single alternative method will be able to provide sufficient information to
replace the use of animals for this endpoint (Adler et al., 2011). Instead it is held that
information from different alternative testing and non-testing methods used in
combination will need to be integrated to address this health endpoint (Jowsey et al.,2006; Adler et al., 2011). These methods should address different key events leading toskin sensitisation thus covering the mechanistic complexity of this endpoint. Nevertheless,it should not be ruled out a priori that skin sensitisation testing may, in the future, be
addressed by one single test method.
7505) EURL ECVAM coordinated a validation study of DPRA following a modular approach(Hartung et al., 2004) which had the following objectives:xxx

To fully assess the reliability of the DPRA protocol, i.e. its transferability and withinand between-laboratory reproducibility.
To conduct a preliminary evaluation of the ability of the DPRA to discriminate skinsensitising from non-sensitising chemicals as defined by the Globally Harmonised
System (GHS) for the classification and labelling of substances for skin sensitisation
and as implemented in the European Union CLP Regulation concerning bothsubstances and mixtures. Characterisation of preliminary predictive capacity was
performed in view of determining the potential contribution of the method tocontribute to decisions on hazard within integrated approaches.
To consider the ability of the DPRA to contribute to sub-categorisation of skinsensitising chemicals, e.g. into Sub-category 1A and Sub-category 1B as adopted inthe 3rd revised version of the GHS.

6) After completion of the study and finalisation of the Validation Study Report (EC-ECVAM2012), EURL ECVAM requested the ECVAM Scientific Advisory Committee (ESAC) to provide
an ESAC Opinion on the study. An ESAC Working group (WG) was subsequently establishedwhich drafted an ESAC WG report, which then formed the basis of the ESAC Opinion (seeannex) adopted by the ESAC on 17. 12. 2012.

2. Test Method definition
7) The correlation of protein reactivity with skin sensitisation potential is well recognised(Landsteiner and Jacobs, 1936; Dupuis & Benezra, 1982; Lepottevin et al., 1998). Chemical
covalent binding to nucleophilic centres in skin proteins is regarded to be the molecular
initiating event in the skin sensitisation AOP (OECD, 2012) without which skin sensitisation
would not occur. Thus, chemicals capable of reacting with proteins either directly or after
biotic or abiotic transformation may have the potential to act as a contact allergen. Itshould be noted that, in its current design, the DPRA does not provide a measure ofreaction rate constant.
8) The DPRA is an in chemico method which addresses peptide reactivity by measuring
depletion of synthetic heptapeptides containing either cysteine or lysine following 24
hours incubation with the test substance. Depletion of the peptide in the reaction mixture
is measured by HPLC using UV detection. Average peptide depletion data for cysteine andlysine are then interpreted by using a classification model developed on the basis of adataset of chemicals with known reactivity properties, in which chemicals are classified ashaving minimal, low, moderate or high reactivity. Substances with low to high reactivity areassociated with substances that have skin sensitisation potential while those categorised ashaving minimal reactivity are considered to lack skin sensitisation potential. Due to theabsence of a metabolic competent system in the assay, the DPRA is not suitable for theevaluation of pro-haptens, which require metabolic activation to act as sensitisers. The
ability of the DPRA to detect pre-haptens, which require abiotic activation (e.g. through851

oxidation by air), is not clear, although some pre-haptens are reported to be correctly
identified by the DPRA.
9) As a result of the ECVAM-coordinated study (EC EURL ECVAM, 2012), the standardised
protocol was found to be transferable and reproducible within and between laboratories
experienced in HPLC analysis. Some minor aspects of the protocol have been refined as aresult of the experienced gained in the validation study.
10) EURL ECVAM will publish in its DataBase service for ALternative Methods (DB-ALM, see
http://ecvam-dbalm.jrc.ec.europa.eu), a comprehensive protocol including a detailed
description of the test method and all necessary technical details needed by an end-userlaboratory to implement it in a self-sufficient manner.

3. Overall performance of the Direct Peptide Reactivity Assay
Reference data
A key criterion employed for selecting the validation test chemicals was availability of highquality in vivo testing data from the murine LLNA and the GPMT with concordant classificationfrom these two assays. The set of chemicals used in the study consisted of one third of nonsensitisers and two thirds of sensitisers with a balanced representation of potency classes(weak, moderate strong and extreme). Reference chemicals from the LLNA performancestandards (OECD 2010a) were included in the chemical set. Additional details can be found in
the Validation Study Report (EC EURL ECVAM, 2012).
When interpreting the data of alternative methods, such as the DPRA, that have been largely
developed and validated using animal reference data such as LLNA or GPMT the limitations of
the reference data should be kept in mind. For instance, the predictive relevance of reference
animal tests may not fully reflect the situation in the species of interest, i.e. humans. Notably,an evaluation of the LLNA in comparison to human data has shown an accuracy of about 72%(Anderson et al., 2011), i.e. there is a risk of false negative and false positive results. Moreover
there is indication that the LLNA is deficient in detecting low to moderate sensitisers as well as
metals and organometal compounds (EC, 2000).
Transferability and Reproducibility11) On the basis of the results obtained during the study, it is evident that the DPRA can bereadily transferred to new laboratories that are properly equipped and experienced with
HPLC instruments and techniques.
12) The assessment of the reproducibility was performed on the basis of concordance inclassification (sensitiser/non-sensitiser). The experimental data generated in the study
indicate that the within-laboratory reproducibility (ranging from 73% in the lead laboratory
to 100% in one of the two naïve laboratory) and the between-laboratory reproducibility(75%) are acceptable for the proposed future use of the DPRA (i.e. in combination withother complementary methods).

952

Preliminary evaluation of predictive capacity based on the ring trial data
13) Full evaluation of the predictive capacity of the DPRA was not within the scope of the EURLECVAM study. However, the accuracy of the DPRA for dichotomous classification(sensitiser/non-sensitiser) on the basis of all 24 chemicals tested (including two metals,
one pro-hapten, dihydroeugenol, and two pre-haptens, 4-phenylendiamine and R(+)Limonene), was 79% (sensitivity=71%, specificity=92%). When excluding the two metalcompounds (which are considered outside the applicability domain and can be readily
excluded from testing during practical application of the assay), the accuracy was 82%(76% sensitivity and 92% specificity). Thus, the predictive capacity determined in the study
is consistent with published information from a larger set of data (Gerberick et al., 2007).
Importantly, substances reported as false negatives in the EURL ECVAM study weregenerally substances with a low sensitisation potency in vivo.
14) In relation to the ability of the DPRA to categorise substances in reactivity classes, datafrom the validation study does not support the use of the DPRA as a standalone method
for potency categorisation. This is consistent with published information. However the
study results indicate that the assignment of a chemical to a DPRA reactivity category may
have the potential to contribute to the determination of its potency.

4. Limitations
4.1 Technical limitations
15) Solubility of test substances: Peptide depletion values for substances with limited
solubility in the solvents prescribed by the DPRA SOP cannot be derived with sufficientaccuracy. Despite the fact that all the chemicals selected for the EURL ECVAM study were
found to be compatible with the test system, limitations with the testing of insoluble
chemicals have been reported in the submission to ECVAM.
16) Co-elution: In those instances, mainly attributable to specific instrument settings, where
the test substance or the reaction products elute at the same time as the peptide (coelution), an accurate measurement of peptide depletion cannot be made. The DPRA SOP
provides instructions on how to approach different instances of co-elution, allowing incertain cases an estimation of the peptide depletion and reactivity class assignment.
However there might be circumstances were this type of approximation is not appropriate.
17) Cysteine dimerisation: Accurate determination of peptide depletion can also be hamperedby substances promoting the oxidation of the thiol group in the cysteine peptide that leads
to the formation of the cystine dimer. In such cases depletion of the peptide would beoverestimated.
4.2 Limitations with regard to applicability
The following limitations of DPRA should be taken into consideration:

105318) Restriction to lysine and cysteine: The DPRA is designed to measure reactivity of theelectrophile towards two amino acids: the thiol group of cysteine and the primary aminogroups of lysine. As other amino acids are not present in the assay, chemicals withpreferential reactivity towards amino acids other than cysteine or lysine (e.g. nucleophilic
sites in histidine), may lead to false negative results when tested in the DPRA. However,when considering this limitation, it should be also kept in mind that the relative
percentages of substances reacting preferably with amino acids other than cysteine andlysine is at present unclear and that the cysteine and lysine peptides represent softer toharder model nucleophiles (OECD, 2012; Schwöbel et al., 2011) which would coverdifferent reaction mechanisms19) Metal compounds: DPRA is not designed to accommodate the spectrum of reaction
mechanisms considered to be associated with sensitising metals. For example Nickel, themost important metal allergen, is postulated to form coordination bonds with nucleophilic
residues in histidine. However, metal compounds can be readily excluded from testing
based on chemical structure and, therefore, this limitation can be easily addressed bysimply avoiding the DPRA for the testing of metal compounds.
20) Pro-haptens and pre-haptens: The DPRA is not designed to detect the sensitisingproperties of pro-haptens which require bioactivation, or pre-haptens which require
abiotic transformation. Nevertheless, pre-haptens are in some cases reported to becorrectly detected as sensitisers by the DPRA, as was the case in the EURL ECVAM study(n=2). However, the reasons why specific pre-haptens are detected while others are notremain unclear. To address the issue of pre- and pro-haptens, in silico expert systems suchas TIMES-SS (Patlewicz et al., 2007; Roberts et al., 2007) and the OECD QSAR toolbox(www.qsartoolbox.org) could prove useful. Notably, a variation of the DPRA including an
additional protocol step which mimics oxidative activation (co-incubation with horseradish
peroxidase and hydrogen peroxide) to detect pre- and pro- haptens is under development.
(Gerberick et al., 2009).
21) Oxidation: Some substances that have oxidative properties (e.g. oxidative colourants)
without necessarily causing haptenation may lead to possible false positive results whentested in the DPRA.

5. Suggested regulatory use22) Due to the complexity of the mechanisms underlying skin sensitisation, it is likely that
information from different methods (in silico, in chemico, in vitro) is needed to reduce orreplace the need for animal testing, both for hazard identification and potency
characterisation purposes. The DPRA is a reliable test method that provides information on
peptide reactivity, which is considered to be the molecular initiating event of skinsensitisation (OECD 2012). Therefore, peptide depletion values generated with the DPRA
could be used to support read-across from chemical analogues or combined withinformation from other non-animal methods in the context of a Weight of Evidence (WoE)
approach or Integrated Testing Strategy (ITS). The extent of information needed tocomplement a DPRA result will depend on the intended application (e.g. hazard
1154

identification, classification or potency assessment) and context (availability and quality ofother information).
23) For the purpose of hazard identification (i.e. identifying substances with sensitisingpotential), it is plausible that an unequivocal depletion value in the DPRA combined withthe presence of a structural alert or positive QSAR prediction for skin sensitisation may
prove sufficient for decision making, thus justifying the waiving of an animal test. To
conclude on the absence of sensitising potential, additional information would be needed
to increase confidence, such as in vitro data on downstream events. In any case a negative
DPRA result should be interpreted with care, taking into consideration the possibility offalse negatives due to (1) possible reactivity with amino acid residues other than cysteine
and lysine, (2) the lack of metabolic capacity of the assay leading to possible
misclassification of pro-haptens as well as (3) the uncertain capacity of the DPRA tocorrectly pick up pre-haptens. For hazard assessment purposes, possible uses of DPRA datain the context of a WoE or ITS have been reported in several scientific publications (Ball etal., 2011; Bauch et al., 2012).
24) Use of results generated with the DPRA for potency prediction has also been proposed(Jaworska et al., 2011; Nukada et al., 2012). Results from the EURL ECVAM study showedthat the limited number of substances with high DPRA reactivity fell into Category 1A of
the UN GHS (UN, 2011), suggesting the potential application of DPRA results for potency
sub-categorisation. However, further efforts are required to explore how DPRA data may
support potency assessment, possibly in combination with data from other methods.
25) When employed within an integrated approach, the DPRA may be useful to satisfy
information requirements for Cosmetics (Regulation EC/1223/2009), Chemicals (Regulation
EC/1907/2006), Biocides (EC/528/2012) and Plant Protection Products (Regulation
EC/1107/2009).

1255

6. Follow-up activities recommended by EURL ECVAM(1)

In view of further testing with the DPRA, EURL ECVAM recommends that the revised
protocolavailableat
EURL
ECVAM's
DB-ALM
service(http://ecvamdbalm.jrc.ec.europa.eu) be used.

(2)

The predictive capacity of the DPRA for assessing the sensitisation potential of substances
should be further evaluated in the context of its use as part of integrated approaches totesting and assessment.

(3)

DPRA data should be analysed to understand the potential of the method to contribute to
the potency assessment of substances, including sub-categorisation according to GHS (i.e.
categories 1A and 1B). Use of existing human data and data from the LLNA are likely to be
useful for this purpose. A study correlating DPRA data with potency categories derived
from LLNA has recently been published (Natsch et al., 2013).

(4)

To support ITS development and to increase confidence in the DPRA method, additional
prospective testing with the DPRA should be tailored towards better understanding of its
applicability domain to better define how the method performs with (a) weak sensitisers,(b) pre-haptens and (c) chemicals that have selective reactivity towards amino acids otherthan cysteine and lysine. The reason for false positive predictions also deserves further
investigation.

(5)

EURL ECVAM supports the development of an OECD Test Guideline for the DPRA. A
project proposal has already been submitted to the OECD and included in the OECD 2012
work program. As this test is best employed in combination with complementary
methods, it should be considered in the current initiative being undertaken at OECD todevelop a guidance document on Integrated Approaches for Testing and Assessment(IATA) for skin sensitisation.

(6)

EURL ECVAM recommends continued investment in the development of the next
generation of peptide reactivity assays which can potentially address some of thelimitations of the DPRA method.

13

56

References
Adler S, Basketter D, Creton S, Pelkonen O, van Benthem J, Zuang V, Andersen KE, Angers-Loustau
A, Aptula A, Bal-Price A, Benfenati E, Bernauer U, Bessems J, Bois FY, Boobis A, Brandon E, Bremer
S, Broschard T, Casati S, Coecke S, Corvi R, Cronin M, Daston G, Dekant W, Felter S, Grignard E,
Gundert-Remy U, Heinonen T, Kimber I, Kleinjans J, Komulainen H, Kreiling R, Kreysa J, Leite SB,
Loizou G, Maxwell G, Mazzatorta P, Munn S, Pfuhler S, Phrakonkham P, Piersma A, Poth A, Prieto
P, Repetto G, Rogiers V, Schoeters G, Schwarz M, Serafimova R, Tähti H, Testai E, van Delft J, vanLoveren H, Vinken M, Worth A, Zaldivar JM. (2011). Alternative (non-animal) methods forcosmetics testing: current status and future prospects-2010. Archives of Toxicology 85, 367-485.
Anderson SE, Siegel PD, Meade BJ. (2011). The LLNA: A Brief Review of Recent Advances andLimitations. J Allergy (Cairo). Epub 2011 Jun 16. Ball N, Cagen S, Carrillo JC, Certa H, Eigler D,
Emter R, Faulhammer F, Garcia C, Graham C, Haux C, Kolle SN, Kreiling R, Natsch A, Mehling A,(2011). Evaluating the sensitization potential of surfactants: integrating data from the local
lymph node assay, guinea pig maximization test, and in vitro methods in a weight-of-evidence
approach. Regulatory Toxicology and Pharmacology 60, 389-400.
Ball N, Cagen S, Carrillo JC, Certa H, Eigler D, Emter R, Faulhammer F, Garcia C, Graham C, Haux
C, Kolle SN, Kreiling R, Natsch A, Mehling A. (2011) Evaluating the sensitization potential of
surfactants: integrating data from the local lymph node assay, guinea pig maximization test, andin vitro methods in a weight-of-evidence approach. Regul Toxicol Pharmacol. Aug;60(3):389400.
Bauch C, Kolle SN, Ramirez T, Eltze T, Fabian E, Mehling A, Teubner W, van Ravenzwaay B,
Landsiedel R (2012). Putting the parts together: combining in vitro methods to test for skinsensitizing potential. Regulatory Toxicology and Pharmacology 63: 489-504.
EURL ECVAM (2013). EURL ECVAM Strategy for Replacement of Animal Testing for Skin
Sensitisation Hazard Identification and Classification. JRC Scientific and Policy Reports. Publication
Office of the European Union
http://publications.jrc.ec.europa.eu/repository/handle/111111111/27708
Dupuis, G. & Benezra, C.,1982. Allergic contact dermatitis to simple chemicals: a molecularapproach. New York & Basel: Marcel Dekker Inc.
EURL ECVAM (2012). Direct Peptide Reactivity Assay (DPRA) ECVAM validation study report.
EC (2000): Opinion on the Murine Local Lymph Node Assay (LLNA) adopted by the SCCNFP during
the 12th plenary meeting of 3 May 2000.
http://ec.europa.eu/health/scientific_committees/consumer_safety/opinions/sccnfp_opinions_9
7_04/sccp_out114_en.htm. Last accessed July 2013.
EU (2006) Regulation (EC) No 1907/2006 of the European Parliament and of the Council of 18
December 2006 concerning the Registration, Evaluation, Authorisation and Restriction ofChemicals (REACH), establishing a European Chemicals Agency, amending Directive 1999/45/EC
and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94 as
well as Council Directive 76/769/EEC and Commission Directives 91/155/EEC, 93/67/EEC,
93/105/EC and 2000/21/EC. Official Journal No L 396, p. 0001-1355.
EU (2008a). Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16
December 2008 on classification, labelling and packaging of substances and mixtures, amending
1457

and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No
1907/2006. Official Journal No L 353, p. 0001-1355.
EU (2008b). Regulation (EC) No 440/2008 of 30 May 2008 laying down test methods pursuant toRegulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration,
Evaluation, Authorisation and Restriction of Chemicals (REACH). Official Journal L 142 ,31/05/2008 P. 0001 – 0739.
EU (2009a). Regulation (EC) No 1107/2009 of the European Parliament and of the Council of 21
October 2009 concerning the placing of plant protection products on the market and repealing
Council Directives 79/117/EEC and 91/414/EEC Official Journal No L 309, p. 01-50.
EU (2009b). Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30
November 2009 on cosmetic products. Official Journal No L 342, p. 01-59.
EU (2010). Directive 2010/63/EU of the European Parliament and of the Council of 22 September
2010 on the protection of animals used for scientific purposes. Official Journal L 276, 20/10/2010
P. 0033 – 0079.
EU (2012). Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May
2012 concerning the making available on the market and use of biocidal products. Official Journal
L 167, 27.6.2012, p. 1–123
Gerberick GF, Vassallo JD, Foertsch LM, Price BB, Chaney JG, Lepoittevin JP., (2007). Quantificationof chemical peptide reactivity for screening contact allergens: a classification tree model
approach. Toxicological Sciences 97, 417-427.
Gerberick GF, Troutman JA, Foertsch LM, Vassallo JD, Quijano M, Dobson RL, Goebel C,
Lepoittevin JP (2009) Investigation of peptide reactivity of pro-hapten skin sensitizers using aperoxidase-peroxide oxidation system. Toxicol Sci. Nov;112(1):164-74.
Hartung T, Bremer S, Casati S, Coecke S, corvi R, Fortaner S, Gribaldo L, Halder M, Hoffman S, Roi
AJ, Prieto P, Sabbioni E, Scott L, Worth A, Zuang V. (2004). A modular approach to the ECVAM
principles on test validity. Alternatives to Laboratory Animals 32, 467-472.
Jaworska J, Harol A, Kern PS, Gerberick GF, (2011). Integrating non-animal test information into an
adaptive testing strategy - skin sensitization proof of concept case. ALTEX 28, 211-225.
Jowsey IR, Basketter DA, Westmoreland C, Kimber I (2006). A future approach to measuring
relative skin sensitising potency: a proposal. Journal of Applied Toxicology 26: 341-350.
Landsteiner, K. & Jacobs, J., (1936). Studies on the sensitization of animals with simple chemicalcompounds. Journal of Experimental Medicine 64, 625-639.
Lepoittevin J-P, Basketter DA, Goossens A, Karlberg A-T, (1998). Allergic contact dermatitis: themolecular basis. Springer, Berlin.
Natsch, A, Ryan C.A., Foertsch L., Emter R, Jaworska J, Gerberick F, Kern P (2013) A dataset on 145
chemicals tested in alternative assays for skin sensitisation undergoing prevalidation. Journal ofApplied Toxicology. Epub, ahead of print.
Nukada Y, Miyazawa M, Kazutoshi S, Sakaguchi H, Nishiyama N., 2012. Data integration of nonanimal tests for the development of a test battery to predict the skin sensitizing potential andpotency of chemicals. Toxicology In Vitro 27, 609-618.
1558

OECD (1992). OECD Guideline for the Testing of Chemicals No. 406: Skin Sensitisation. Paris,
France: Organisation for Economic Cooperation and Development. Online at:
http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-of-chemicals-section4-health-effects_20745788
OECD (2010a). OECD Guideline for the Testing of Chemicals No. 429: Skin Sensitisation: Local
Lymph Node Assay. Paris, France: Organisation for Economic Cooperation and Development.
Online at: http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-ofchemicals-section-4 health-effects_20745788
OECD (2010b). OECD Guideline for the Testing of Chemicals No. 442a Skin Sensitisation: Local
Lymph Node Assay DA. Paris, France: Organisation for Economic Cooperation and Development.
Online at: http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-the-testing-ofchemicals-section-4-health-effects_20745788
OECD (2010c). OECD Guideline for the Testing of Chemicals No. 442b: Skin Sensitisation: Local
Lymph Node Assay BrdU-ELISA. Paris, France: Organisation for Economic Cooperation andDevelopment. Online at: http://www.oecd-ilibrary.org/environment/oecd-guidelines-for-thetesting-of-chemicals-section-4-health-effects_20745788
OECD (2012). The Adverse Outcome Pathway for Skin Sensitisation Initiated by Covalent Binding
to Proteins. Part 1: Scientific Evidence. Series on Testing and Assessment No. 168. Online at:
http://www.oecd.org/officialdocuments/publicdisplaydocumentpdf/?cote=ENV/JM/MONO(2012)
10/PART1&docLanguage=En
Patlewicz G, Dimitrov SD, Low LK, Kern PS, Dimitrova GD, Comber MIH, Aptula AO, Phillips RD,
Niemela J, Madsen C, Wedebye EB, Roberts DW, Bailey PT, Mekenyan OG (2007) TIMES-SS – A
promising tool for the assessment of skin sensitization hazard. A characterisation with respect
to the OECD Validation Principles for (Q)SARs. Reg Toxicol Pharmacol 48: 225–239
Roberts DW, Patlewicz G, Dimitrov SD, Low LK, Aptula AO, Kern PS, Dimitrova GD, Comber MI,
Phillips RD, Niemelä J, Madsen C, Wedebye EB, Bailey PT, Mekenyan OG. (2007) TIMES-SS--amechanistic evaluation of an external validation study using reaction chemistry principles. Chem
Res Toxicol. 2007 Sep;20(9):1321-30. Epub 2007 Aug 23.
Roberts DW, Aptula AO. Determinants of skin sensitisation potential. J Appl Toxicol. 2008
Apr;28(3):377-87.
Schwöbel JA, Koleva YK, Enoch SJ, Bajot F, Hewitt M, Madden JC, Roberts DW, Schultz TW,
Cronin MT (2011) Measurement and estimation of electrophilic reactivity for predictive
toxicology. Chem Rev. Apr 13;111(4):2562-96.
UN (2011). Globally Harmonised System of Classification and Labelling of Chemicals (GHS). Part 3:
Health and Environmental Hazards. New York, NY, USA, and Geneva, Switzerland. United Nations
Economic Commission for Europe. Online at:
http://www.unece.org/trans/danger/publi/ghs/ghs_rev04/04files_e.html

1659

ANNEX 1

ESAC OPINION

Annex 1ESAC Opinion

Opinion of the EURL ECVAM Scientific Advisory Committee (EASC) on the
ECVAM-led study of the Direct Peptide Reactivity Assay (DPRA)
Ispra, 17 December 2012

Summary of the ESAC Opinion
The ESAC was asked to provide an opinion on an EURL-ECVAM led prevalidation study assessing
the transferability and reproducibility (within- and between-laboratories) of the DPRA test
method (primary objective of the study) in view of its possible future use as part of a nonanimal testing strategy for skin sensitization. The study had also been designed to provide
preliminary information on a) the predictive capacity of the test method and b) its potential use
for contributing to sub categorisation of sensitizing chemicals.
The ESAC considered the scientific work presented of good quality. Overall, the conclusions
made by the working group (WG) correspond well with the conclusions formulated in the reportby the Validation Management Group (VMG).
x
x
x
x
x

The within laboratory reproducibility (WLR) of the test method with respect toconcordance of classification (S/NS) was considered acceptable.
The data were considered strong enough to support transferability of the test to
properly equipped, trained and staffed laboratories with the appropriate analyticalcapabilities.
The between laboratory reproducibility (BLR) of the test method with respect toconcordance of classification was considered sufficient when compounds outside
the applicability domain were excluded.
The preliminary predictive capacity as evaluated in this study is consistent with the
published data (references 6, 7).
The potential for use of DPRA reactivity information in potency sub-categorisation
requires further examination with a larger dataset.

The ESAC had some questions about the statistical calculations underlying the determination ofan adequate sample size to analyse reproducibility as a primary study goal. The ESAC wasconcerned that possible limitations of the assay were not described in sufficient detail in thevalidation study report.
The predictive capacity, applicability domain and limitations of the test are not defined yet, but
the available data suggest that the test is a useful tool for early decision making during productdevelopment (screening) and a component in a weight-of-evidence (WoE) approach or
integrated testing strategy (ITS).
The ESAC recommends that the possible limitations of the DPRA should be further investigatedspecifically in relation to pre-/pro-haptens, either by additional prospective testing or throughanalysis of existing information as there may be a risk of false negative results associated withthese chemicals.

1760

ANNEX 1

1.

ESAC OPINION

Mandate of the ESAC

The opinion of ESAC should support ECVAM with respect to the development ofrecommendations regarding the reliability (transferability, within and between laboratory
reproducibility) of the DPRA and the potential regulatory use of the test method.
(1) Study design – transferability, reliability and relevancex

x

The ESAC was requested to review whether the prevalidation study was conducted
appropriately in view of the objective of the study:

Reproducibility of the DPRA method within one laboratory (WLR);

Transferability to other laboratories;

Reproducibility in other laboratories (BLR);

Predictive capacity of the test method.

With respect to the design and conduct of the study, the following issues were to beaddressed:
 Clarity of the test definition (module 1)
 Clarity of the definition of the study objective
 Appropriateness of the study design in view of study objective
 Appropriateness of the study execution:
 Appropriateness of the statistical analysis used for analysing WLR, transferability,
BLR and (preliminary) predictive capacity.

(2) Conclusions of the study
The ESAC was requested to assess the justification and plausibility ofReproducibility (WLR and BLR) and transferability;
Preliminary predictive capacity;
Possible gaps between study design and study conclusions which remain to beaddressed in view of the suggested conclusions/use;
Applicability and possible limitations of the test method, in particular in view of its
potential use within an ITS for sensitisation.

(3) Possible contribution of test method to integrated approach
The ESAC is requested (a) to evaluate, on the basis of the data submitted in the validation study,
the possible use of the test method (also within a strategy) to identify skin sensitisers, (b) tomake additional recommendations (as required) on the proper scientific use of the test method
within such a strategy taking specific aspects of this method into account (e.g. applicability,
limitations etc.) and (c) to identify possible further information required (i.e. are there gaps) tobe able to conclude on the plausibility of the suggested use (including within an ITS).

18

61

ANNEX 1

2.

ESAC OPINION

Detailed opinion of the ESAC

The ESAC was asked to provide an opinion on an EURL-ECVAM led study assessing thetransferability and reproducibility (within- and between-laboratories) of the DPRA (primaryobjective of the study) in view of its possible future use as part of a non-animal testing strategy
for skin sensitization. The study had also been designed to provide preliminary information on a)the predictive capacity of the test method and b) its potential use for contributing to subcategorisation of sensitizing chemicals.
(1) Study design – transferability, reliability and relevance.
The WLR was assessed at the level of concordance in prediction (S/NS). WLR for the threelaboratories was in the range from 73% to 100% . The lowest value derived from the leadlaboratory. The ESAC concluded that, in the context of the study, and in view of the fact thatboth naive laboratories exceeded the target of 85% as chosen by the VMG, the WLR was
sufficient.
x

x

x

x

x

The definition of the reproducibility target (85%) was based upon i) the backgroundand specific objectives of the validation study; ii) the standards of performance thatcan realistically be expected from an in vitro test and standards of performance
which have been considered acceptable in previous validation studies; iii) the
proposed used of the in vitro tests (i.e. as a partial replacement method to become
part of a toolbox of tests to be used in combination); and iv) the power of thedesign of the validation study.
Transferability activities were divided into Training, Transferability and Qualification
Runs The WLR was formulated for each partner to include 1) concordance inprediction, 2) depletion values for cysteine and lysine, as well as 3) control values.
The data were considered strong enough to support transferability of the test to
properly equipped, trained and staffed laboratories with the appropriate analyticalcapabilities.
During the transfer and blind testing phase one laboratory had difficulties inmeeting the acceptance criteria defined in the SOP, due to the Reference Control C
being marginally outside the acceptance criteria. The cause of the problem could
not be identified. The ESAC recommends that these acceptance criteria should be
re-examined.
The BLR was assessed in terms of 1) concordance in prediction and 2) depletion
values for cysteine and lysine. Eighteen of the 24 chemicals were consistently
classified (S/NS) by the three laboratories resulting in a BLR reproducibility of 75%,
which is below the target (80%). The reproducibility assessment included 3
chemicals (beryllium sulphate, nickel chloride and dihydroeugenol) that wereconsidered by the VMG as outside the applicability domain of the test. The
exclusion of these three substances considered to fall outside the applicability
domain would lead to a BLR of 87.5%. For 15 out of the 24 chemicals thelaboratories assigned the same reactivity class resulting in a BLR of 62.5%. Data
variability was observed for results from chemicals with low or no reactivity.
The secondary goals included a preliminary evaluation of the ability of the test to
discriminate skin sensitizers from non-sensitizers, and a preliminary considerationof the ability to contribute to sub-categorization of skin sensitising chemicals (GHS
sub-category 1A and 1B). The validation study report (VSR) did not present asummary of the predictive capacity based on all 24 chemicals tested, since the VMG
1962

ANNEX 1x

x

ESAC OPINION
judged three of them (beryllium sulphate, nickel chloride, dihydroeugenol) to falloutside the applicability domain. The two pre-haptens (4-phenylendeiamine andR(+)-Limonene) were included in the analysis as the VMG felt that there wasinsufficient evidence to exclude them from the evaluation of the predictive
performance. The predictive capacity for all 24 substances was 77.8% (sensitivity:
70.8%; specificity: 91,7%) while 82.4% (sensitivity: 73.5%; specificity: 91,7%) for the
19 substances (since the WG felt that other two substances would fall outside theapplicability domain, PPD and limonene).
The project was described and designed in clearly recognizable and well describedphases including Test Definition (Module 1), Transferability (Module 3), Within
Laboratory Reproducibility (WLR) (Module 2), Between Laboratory Reproducibility(BLR) (Module 4) and Predictive Capacity (Module 5).
Overall, the chosen statistical approach was considered appropriate. In thecalculations of suitable sample size it was not clear for the ESAC why a power of
75% was chosen for the BLR, especially as a more conventional 80% power wasused for the WLR. However, since more chemicals than the minimum number were
tested in both cases the actual power of the study was considered sufficient.

(2) Conclusions of the studyxxOverall, the study design and the quality of the selected chemicals (N=24) wereconsidered appropriate for the purpose of addressing the first objective of thestudy: Assessing the WLR and BLR of the DPRA.
x Overall, the conclusions made by the WG correspond well with the conclusions
drawn by the VMG as described in the VSR, indicating that these conclusions aresupported by the results shown in the report.
 The WLR of the test method with respect to concordance of classification (S/NS)
met the target of 85% and was considered sufficient for the purpose of thisstudy.
 The data were considered strong enough to support transferability of the test to
properly equipped, trained and staffed laboratories with the appropriate
analytical capabilities.
In spite of a BLR (75%) below the target of 80%, the BLR of the test method with respect
to concordance of classification was considered sufficient after the removal of thecompounds outside the applicability domain. The potential for use of DPRA reactivity
information in potency sub-categorisation requires further examination with a larger
dataset.
 The number of chemicals (N=24) did not provide support for a firm conclusion
about the predictive capacity of the test method. The preliminary data were,
however, considered promising.
 The number of chemicals did not allow drawing a conclusion about theapplicability domain of the test. Empirically the applicability domain seems to
exclude pre-/pro-haptens and metal salts.
x

Chemicals that preferably react with amino acids other then cysteine and lysine
may fall outside the applicability domain. In addition, some pre-/pro-haptens werereported as correctly identified. Finally, the data seem to indicate that the test
method has problems identifying weak sensitizers. The uncertainty about theapplicability domain may result in an unacceptable level of false negative results.

20

63

ANNEX 1

ESAC OPINION(3) Possible use of the test method within an integrated approach
As outlined in the VSR and the ECVAM request for ESAC advice, the DPRA cannot be used as astand-alone test method in a regulatory context but should be considered for use in an
Integrated Testing Strategy (ITS). On the basis of the present report, especially negative
outcomes have to be considered with care.
xxx

As pre-haptens are not consistently correctly predicted by the DPRA, there remains
uncertainty about whether to consider pre-haptens as part of the applicability
domain of the method or not.
Unless there are sufficiently accurate assays available identifying chemicals as pre/pro-haptens in view of excluding them from routine testing using the DPRA, suchcompounds will be tested in the DPRA and may cause false negative results.
The selection of cysteine and lysine-containing peptides selects for the majority, but
not all, reactive chemicals.

Regarding reactivity class, the data obtained did not support the possibility to use DPRA as astand-alone test method for potency classification. This is in agreement with the statement of
the VMG that the assay should be further evaluated for its capacity to "contribute" to a potencyclassification (VSR page 8).
Information generated by the DPRA can be used to support regulatory decision making whenused in the context of a weight-of-evidence approach or ITS. It is important to use the test in acontext that allows confident conclusions about the protein-reactivity of the chemical,
especially when the chemical in question is negative in the DPRA. As such the method may be
helpful to address testing requirements of e.g. the REACH legislation and the 7th Amendment of
the Cosmetic Directive.
Its inclusion into future ITSs can be considered for the purpose of an eventual full replacementof current in vivo hazard identification assays.
Recommendations:
The DPRA addresses a key mechanism (haptenation) in the development of skinsensitization/allergic contact dermatitis. Overall the provided data support transferability andreproducibility of the test to qualified laboratories. The predictive capacity of the test is notdefined yet, but the preliminary data profiles the test as a useful tool for early decision making
during product development (screening) and a component in a weight-of-evidence approach or
ITS for safety/hazard assessment.
The ESAC recommends that the limitations of the DPRA (risk of false negative results) arefurther investigated specifically in relation to pre-/pro-haptens either by additional prospective
testing or through analysis of existing information.

21

64

ANNEX 1
3.

ESAC OPINION

Informative background to the Mandate and Opinion

Skin sensitizsation is the toxicological endpoint associated with substances that have theintrinsic ability to cause Allergic Contact Dermatitis, ACD in humans. ACD represents the mostcommon manifestation of immunotoxicity in humans, i.e. adverse effects of xenobiotics
involving the immune system. The identification of the skin sensitization potential represents
an important component of the safety assessment of any new substance and especially for
those intended for topical application (e.g. cosmetics). Current regulatory predictive tests forskin sensitization rely on the use of animals, these include:a) the traditional guinea pig tests: Buehler Test and Guinea-pig Maximisation Test (OECDTG 406, Ref.1),b) the Local Lymph Node Assay (LLNA, OECD TG 429, Ref.2) and its recently OECD adopted
non-radioactive variants (OECD TG 422A, Ref.3 and OECD TG 422B, Ref.4).
Despite the progress that has been made in the development of alternative methods for skinsensitisation hazard identification, there are currently no validated methods available. In
addition none of the tests currently under development/evaluation is able to fully characterise
the relative potency of sensitising substances and therefore, none of these assays is considereda stand-alone method, capable of fully replacing current animal procedures, in particular as
regards to cosmetics.
The current view therefore is to combine different test methods in order to address different
key mechanisms of skin sensitisation: skin bioavailability, haptenation (the protein binding ofchemicals which triggers immunological responses), epidermal inflammation, dendritic cell
activation and migration, T cell proliferation. Test methods are currently under development
which have been specifically designed to address these key mechanistic steps involved in skinsensitisation. Before these test methods can be routinely used, e.g. in ITSs, their capacity to
produce reproducible results needs to be demonstrated as a first step.
The Direct Peptide Reactivity Assay DPRA is addressing one of the key upstream events in the
cascade of mechanisms leading to the induction of skin sensitisation. It measures the ability ofchemicals to react with proteins (haptenation). There is good evidence that haptenation is adeterminant step in the induction of skin sensitisation. Chemical allergens are usually low
molecular weight chemicals which are not immunogenic per se. However, chemical allergens (ortheir metabolites, oxidation products) have electrophilic properties that allow them to bindcovalently with the nucleophilic side chains of amino acids of skin proteins to form an
immunogenic conjugate. Already in 1936 this correlation between the reactivity of chemicals
with proteins and their skin sensitisation potential was described (Landsteiner and Jacobs,
Ref.5) and has in the meantime been extensively described in the literature. This knowledge isbeing exploited for the development of several in chemico reactivity assays with relevance forthe testing of sensitisation potential, amongst these the DPRA assay.
The DPRA is designed to screen the sensitisation potential of chemicals by measuring peptide
depletion with UV-HPLC, following incubation of the test chemicals with synthetic
heptapeptides containing either cysteine (peptide/chemical ratio in the reaction mixture 1:10)
or lysine residues (peptide/chemical ratio in the reaction mixture 1:50) (Gerberick 2004, Ref.6).
The average of peptide depletion values for cysteine and lysine are used to classify chemicals
into four reactivity categories: minimal, low, moderate and high reactivity (Gerberick 2007,
Ref.7). Based on the known correlation between haptenation/chemical reactivity andsensitisation potential, it is assumed that these reactivity classes as predicted by the DPRA may
contribute to the characterisation of sensitiser potency.
The possible predictive capacity of the DPRA is supported by the data of the original DPRA
submission. On the basis of 133 chemicals, the DPRA classified chemicals as sensitisers or nonsensitisers (in relation to LLNA data) with an accuracy of 86% (87% sensitivity, 83% specificity).
22

65

ANNEX 1

4.

ESAC OPINION

References1.

OECD, Organisation for Economic Cooperation and Development (1992) Skin Sensitisation
Guidelines for Testing of Chemicals No. 406, Paris

2.

OECD, Organisation for Economic Cooperation and Development (2002) The Local Lymph
Node Assay. Guidelines for Testing of Chemicals No. 429, Paris

3.

OECD, Organisation for Economic Cooperation and Development (2010a) Skin Sensitization:
Local Lymph Node Assay: DA, Guidelines for Testing of Chemicals No. 442A, Paris

4.

OECD, Organisation for Economic Cooperation and Development(2010b) Skin
Sensitization: Local Lymph Node Assay: BrdU-ELISA, Guidelines for Testing of Chemicals No.
442B, Paris

5.

Landsteiner K & Jacobs J (1936) Studies on the sensitisation of animals with simple
chemical compounds. Journal of Experimental Medicine 64, 625-639

6.

Gerberick GF, Vassallo JD, Bailey RE, Chaney JG, Morrall SW, Lepoittevin JP, (2004)
Development of a peptide reactivity assay for screening contact allergens. Toxicol Sci. 81;
332-43.

7.

Gerberick GF, Vassallo JD, Foertsch LM, Price BB, Chaney JG, Lepoittevin JP, (2007).
Quantification of chemical peptide reactivity for screening contact allergens: a classification
tree model approach. Toxicol Sci. 97, 417-27.

23

66

ANNEX 1

ESAC OPINIONEURL ECVAM Scientific Advisory Committee
x
x
x
x
x
x
x
x
x
x
x
x
x
x
x

Dr. Nathalie ALÉPÉE
Dr. David BASKETTER
Dr. Neil CARMICHAEL
Prof. Jacques R. CHRETIEN
Prof. Lucio G. COSTA
Dr. Rodger CURREN
Prof. A. Wallace HAYES
Prof. Coenraad HENDRIKSEN
Dr. Dagmar JÍROVÁ
Prof. Walter PFALLER
Dr. Erwin ROGGEN
Prof. Vera ROGIERS
Dr. Andrea SEILER
Prof. Kristin SCHIRMER
Prof. Ruud A. WOUTERSEN

ESAC Working Group Skin Sensitisation
x
x
x
x
x
x
x
x

Dr. Erwin ROGGEN (ESAC member, Chair of ESAC WG and rapporteur)
Prof. Walter PFALLER (ESAC member, ESAC Vice Chair)Prof. A. Wallace HAYES (ESAC member)Dr. Maja ALECSIC (external expert)
Dr. Emanuela CORSINI (external expert)
Dr. David LOVELL (external expert)
Dr. Michael WOOLHISER (external expert)
Prof. Yong HEO (external expert, ICATM nomination)

Coordination
x Dr. Claudius GRIESINGER (EURL ECVAM Coordinator for ESAC peer reviews and EURL ECVAM
recommendations)x Dr. Alexandre ANGERS (specific support)

2467

ANNEX 2

ECVAM REQUEST FOR ESAC ADVICE

Annex 2EURL ECVAM request for ESAC advice

EURL ECVAM request for ESAC advice on an ECVAM-coordinated study
concerning the transferability and reliability of the Direct Peptide
Reactivity Assay (DPRA) for skin sensitisation testing
1.
TYPE OF REQUEST
Request Type

Identify request ("YES")

1) ESAC Peer Review
of a Prevalidation Study or Validation StudyYES

If R1)applies please specify further:►Prevalidation StudyYES
At present (January 2012) ECVAM is conducting a
study of three test methods for skin sensitisation
testing: 1) the Direct Peptide Reactivity Assay(DPRA), 2) the human Cell Line Activation Test (hCLAT) and 3) the Myeloid U937 Skin Sensitisation
Test (MUSST).
The study assesses transferability andreproducibility of these test methods in view of
their possible future use (e.g. as partial replacement
methods) within an integrated approach for skinsensitisation hazard identification aiming at the full
replacement of the currently used regulatory in vivo
assays for this purpose. In addition the data
generated in this study will inform possible futureevaluations on the predictive capacity of theseassays.
While assessment of the h-CLAT and MUSST test
methods are foreseen to be completed in 2012, theevaluation of the DPRA test method was finalised in2011 and the adopted Validation Study Report isforeseen to be available by January 2012. ESAC
review will commence in February 2012 employing
the same ESAC WG which is currently (January2012) peer reviewing the KeratioSens submission.

68

Prospective Validation Study

No

Retrospective Validation StudyNo

Validation Study based on PerformanceStandards

No2) Scientific Advice on a test method submitted to ECVAM for
validation(e.g. the test method's biological relevance etc.)

No3) Other Scientific Advice

No25

ANNEX 2

ECVAM REQUEST FOR ESAC ADVICE(e.g. on test methods, their use; on technical issues such as cell
culturing, stem cells etc.)

2.
TITLE OF STUDY OR PROJECT FOR WHICH SCIENTIFIC ADVICE OF THE ESAC IS
REQUESTED
Prevalidation of the Direct Peptide Reactivity Assay (DPRA) for skin sensitisation testing3.
BRIEF DESCRIPTION OF THE STUDY OR PROJECT
1) Background to skin sensitization and current predictive tests
Skin sensitisation is the toxicological endpoint associated with substances that have the intrinsic
ability to cause Allergic Contact Dermatitis, ACD in humans. ACD represents the most common
manifestation of immunotoxicity in humans, i.e. adverse effects of xenobiotics involving theimmune system. The identification of the skin sensitization potential represents an importantcomponent of the safety assessment of any new substance and especially for those intended for
topical application (e.g. cosmetics). Current regulatory predictive tests for skin sensitization relyon the use of animals, these include:a) the traditional guinea pig tests: Buehler Test and Guinea-pig Maximisation Test (OECDTG 406, Ref.1),b) the Local Lymph Node Assay (LLNA, OECD TG 429, Ref.2) and its recently OECD adopted
non-radioactive variants (OECD TG 422A, Ref.3 and OECD TG 422B, Ref.4).
Despite the progress that has been made in the development of alternative methods for skinsensitisation hazard identification, there are currently no validated methods available. In
addition none of the tests currently under development/evaluation is able to fully characterise
the relative potency of sensitising substances and therefore, none of these assays is considereda stand-alone method, capable of fully replacing current animal procedures, in particular as
regards to cosmetics.
The current view therefore is to combine different test methods in order to address different
key mechanisms of skin sensitisation: skin bioavailability, haptenation (the protein binding ofchemicals which triggers immunological responses), epidermal inflammation, dendritic cell
activation and migration, T cell proliferation. Test methods are currently under development
which have been specifically designed to address these key mechanistic steps involved in skinsensitisation. Before these test methods can be routinely used, e.g. in integrated testing
strategies, their capacity to produce reproducible results needs to be demonstrated as a firststep.

2) Background to the DPRA, h-CLAT, MUSST
DPRA:
The Direct Peptide Reactivity Assay DPRA is addressing one of the key upstream events in the
cascade of mechanisms leading to the induction of skin sensitisation. It measures the ability ofchemicals to react with proteins (haptenation). There is good evidence that haptenation is adeterminant step in the induction of skin sensitisation. Chemical allergens are usually low
molecular weight chemicals which are not immunogenic per se. However, chemical allergens (ortheir metabolites, oxidation products) have electrophilic properties that allow them to bindcovalently with the nucleophilic side chains of amino acids of skin proteins to form an
immunogenic conjugate. Already in 1936 this correlation between the reactivity of chemicals
with proteins and their skin sensitisation potential was described (Landsteiner and Jacobs,

26

69

ANNEX 2

ECVAM REQUEST FOR ESAC ADVICE

Ref.5) and has in the meantime been extensively described in the literature. This knowledge isbeing exploited for the development of several in chemico reactivity assays with relevance forthe testing of sensitisation potential, amongst these the DPRA assay.
The DPRA is designed to screen the sensitisation potential of chemicals by measuring peptide
depletion with UV-HPLC, following incubation of the test chemicals with synthetic
heptapeptides containing either cysteine (peptide/chemical ratio in the reaction mixture 1:10)
or lysine residues (peptide/chemical ratio in the reaction mixture 1:50) (Gerberick 2004, Ref.6).
The average of peptide depletion values for cysteine and lysine are used to classify chemicals
into four reactivity categories: minimal, low, moderate and high reactivity (Gerberick 2007,
Ref.7). Based on the known correlation between haptenation/chemical reactivity andsensitisation potential, it is assumed that these reactivity classes as predicted by the DPRA may
contribute to the characterisation of sensitiser potency.
The possible predictive capacity of the DPRA is supported by the data of the original DPRA
submission. On the basis of 133 chemicals, the DPRA classified chemicals as sensitisers or nonsensitisers (in relation to LLNA data) with an accuracy of 86% (87% sensitivity, 83% specificity).
h-CLAT & MUSST
The h-CLAT and MUSST are based on the use of Dendritic Cell (DC)-like cell lines. Using flow
cytometry, these test methods monitor the induction of cell surface markers associated with DC
activation, following exposure to the chemical. In the MUSST, changes in CD86 expression in the
U937 cell line are detected; in the h-CLAT modulation of both CD86 and CD54 expression arerecorded in THP-1 cells.

3) Study goals and design
In the first quarter of 2009 the DPRA was formally submitted to ECVAM together with other two
test methods namely the human Cell Line Activation Test (h-CLAT) and the Myeloid U937 Skin
Sensitisation Test (MUSST), developed by companies associated with the European Cosmetics
Association (Colipa) and optimized within Colipa ring trials. Following detailed scientificassessment of the information submitted, ECVAM judged the three methods to be mature
enough to enter the ECVAM validation process.
In September 2009 a formal study on the three above mentioned test methods was launched,with the main overall objective to evaluate their transferability and reliability (reproducibility
within and between laboratories) when challenged with 24 coded chemicals.
As a secondary goal of the study, the experimental data will be used to perform:a) A preliminary evaluation of the ability of each of the three tests to reliably discriminate skinsensitising (S) from non-sensitising (NS) chemicals as defined by the Globally Harmonised
System (GHS, Ref. 6) for the classification and labelling of substances for skin sensitisation(category 1; no category) and as implemented in the European Commission Regulation (EC) No
1272/2008 (Ref.8) on classification, labelling and packaging (CLP) of substances and mixtures.
b) Where possible, a preliminary consideration of the ability of each of the three tests tocontribute to sub-categorisation of skin sensitising chemicals, e.g. into Sub-category 1A (strong
sensitisers) and Sub-category 1B (other sensitisers) as adopted in the 3rd revised version of the
GHS.
The study experimental design foresees the testing of the 24 coded test items in each of thethree participating laboratories for the assessment of the between-laboratory reproducibility. A
subset of 15 of these chemicals are being tested two additional times in each laboratory for the70

27

ANNEX 2

ECVAM REQUEST FOR ESAC ADVICE

evaluation of within-laboratory reproducibility.
With respect to ECVAM's modular approach of validation (Hartung et al., 2004, Ref.10) the
study will provide information on module 1) test definition, module 2) within laboratory
reproducibility, module 3) transferability and module 4) between laboratory reproducibility. In
addition, the data generated will provide preliminary information on module 5) predictive
capacity; however, the number of chemicals tested is based on statistical considerations related
to the evaluation of the reproducibility, and a larger sample size would be required for module
5 to be considered fulfilled.
References
8. OECD, Organisation for Economic Cooperation and Development (1992) Skin
Sensitisation Guidelines for Testing of Chemicals No. 406, Paris
9. OECD, Organisation for Economic Cooperation and Development (2002) The Local
Lymph Node Assay. Guidelines for Testing of Chemicals No. 429, Paris
10. OECD, Organisation for Economic Cooperation and Development (2010a) Skin
Sensitization: Local Lymph Node Assay: DA, Guidelines for Testing of Chemicals No.
442A, Paris
11. OECD, Organisation for Economic Cooperation and Development (2010b) Skin
Sensitization: Local Lymph Node Assay: BrdU-ELISA, Guidelines for Testing of Chemicals
No. 442B, Paris
12. Landsteiner K & Jacobs J (1936) Studies on the sensitisation of animals with simple
chemical compounds. Journal of Experimental Medicine 64, 625-639
13. Gerberick GF, Vassallo JD, Bailey RE, Chaney JG, Morrall SW, Lepoittevin JP, (2004)
Development of a peptide reactivity assay for screening contact allergens. Toxicol Sci.
81; 332-43.
14. Gerberick GF, Vassallo JD, Foertsch LM, Price BB, Chaney JG, Lepoittevin JP, (2007).
Quantification of chemical peptide reactivity for screening contact allergens: aclassification tree model approach. Toxicol Sci. 97, 417-27.
15. Anon. (2003). Globally Harmonised System of Classification and Labelling of Chemicals(GHS). Part 3: Health and Environmental Hazards, pp. 151-158. New York, NY, USA, andGeneva, Switzerland: United Nations Organisation.
16. EU (2008b) Regulation (EC) No 1272/2008 (16 December 2008) of the European
Parliament and of the Council on classification, labelling and packaging of substancesand mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, andamending Regulation (EC) No 1907/2006. Official Journal of the European Union L 353,
(31/12/2008) p. 1-1355.
17. Hartung, T., Bremer, S., Casati, S., Coecke, S., Corvi, R., Fortaner, S., Gribaldo, L., Halder,
M., Hoffmann, S., Roi A.J., Prieto, P., Sabbioni, E., Scott, L., Worth, A. and Zuang. V.
(2004) A Modular Approach to the ECVAM Principles on Test Validity. ATLA 32, 467-72.
4.
4.1

OBJECTIVES, QUESTIONS, TIMELINESOBJECTIVE

Objective
Why does ECVAM
require advice on
the current issue?

The opinion of ESAC should support ECVAM with respect to the development ofrecommendations regarding the reliability (transferability, within and between
laboratory reproducibility) of the DPRA and the potential regulatory use of the test
method.

28

71

ANNEX 2

ECVAM REQUEST FOR ESAC ADVICEIn addition the ESAC should advice with regard to the possible necessary further
work required (in relation to predictive capacity, applicability, limitations of thetest method) to assess the potential contribution of the DPRA to a future (not yet
designed) testing strategy or test battery that would aim to achieve full
replacement of the currently used animal tests for skin sensitisation hazard
assessment.
Moreover, based on the evaluation of the data submitted, the ESAC should
provide advice on the potential usefulness of the DPRA test method within atesting strategy for skin sensitisation testing and the proper scientific use of thetest method within such a testing strategy (e.g. with respect to its specificapplicability and limitations). It is explicitly noted that the ESAC is not requested tosuggest the precise placing of the submitted method in a hypothetical ITS, butrather to provide advice on the characteristics of the method relevant for its
subsequent integration into an ITS at a later point in time (i.e. when otherbuildings blocks of such an ITS are known).
4.2
QUESTION(S) TO BE ADDRESSEDQuestions
1) DESIGN & CONDUCT OF STUDY: The ESAC is requested to review whether the
What are theprevalidation study was conducted appropriately in view of the objective of thequestions andstudy. The study objective was to assess
issues that should (1) the reproducibility of the DPRA method within one laboratory
be addressed in(2) its transferability to other laboratories
view of achieving(3) its reproducibility in other laboratories (BLR).
the objective of(4) Furthermore, the study aimed at assessing, in a preliminary manner, thethe advice?
predictive capacity of the test method
When reviewing the design and conduct of the study, the following issues should
be addressed in particular:
Clarity of the test definition (module 1)
Clarity of the definition of the study objective
Appropriateness of the study design in view of study objective, inter alia:
Is the number of tested chemicals (24) sufficient for the purposes of the study?
Are the reference data used for assessing in particular the predictive capacity
appropriate and of good quality?
Was the identification of chemicals conducted in an appropriate manner (i.e.
presence or absence of selection criteria, justification etc.)?
Is the adverse effect range of the selected chemicals appropriate for the purposeof the study
In case of gaps (chemical class etc.) – are these justified?
Is the number of laboratories sufficient?
Appropriateness of the study execution (e.g. were there pre-defined acceptancecriteria, were these respected? How were exceptions / deviations handled? Wereprovisions specified for retesting? Was the number of repetitions sufficient? etc.)
Appropriateness of the statistical analysis used for analysing WLR, transferability,
BLR and (preliminary) predictive capacity.
2) CONCLUSIONS OF STUDY: The ESAC is requested to assess whether theconclusions, as presented in the Validation Study Report, are substantiated by the
information generated in the study and are plausible with respect to existing
information and current views (e.g. literature).
In particular:

72

29

ANNEX 2

ECVAM REQUEST FOR ESAC ADVICE

Are the conclusions on reproducibility (WLR and BLR) as well as transferability
justified and plausible?
Are the conclusions on preliminary predictive capacity justified and plausible withrespect to existing information
Are there possible gaps between study design and study conclusions which
remain to be addressed in view of the suggested conclusions / use (see also point3)?
Do the data generated with this defined set of chemicals and available existing
evidence provide sufficient information on applicability and possible limitationsof the test method, in particular in view of its potential use within an ITS for
sensitisation?
3) SUGGESTED USE OF THE TEST METHOD: The ESAC is requested (a) to evaluate,on the basis of the data submitted in the validation study, the possible use of thetest method (also within a strategy) to identify skin sensitisers, (b) to makeadditional recommendations (as required) on the proper scientific use of the test
method within such a strategy taking specific aspects of this method into account(e.g. applicability, limitations etc.) and (c) to identify possible further information
required (i.e. are there gaps) to be able to conclude on the plausibility of thesuggested use (including within an ITS).

30

73

ANNEX 2

4.3
TIMELINES
Timelines
concerning thisrequestWhen does
ECVAM require
the advice?

ECVAM REQUEST FOR ESAC ADVICE

Timeline
Finalised ESAC Opinion required by:
Request to be presented to ESAC bywritten procedure (e.g. due tourgency) prior to the next ESAC
Request to be presented to ESAC at
ESAC plenary meeting

Indication
ESAC 37, 6/7 October 2012 or before
through written procedure
YES, before ESAC 36 (20/21 March
2012)
NO

5.
ECVAM PROPOSALS ON HOW TO ADDRESS THE REQUEST WITHIN ESAC
5.1
ECVAM PROPOSAL REGARDING REQUEST-RELATED STRUCTURES REQUIREDSpecific
Structure(s) required
Required according to ECVAM? (YES/NO)
structures
required within
1) ESAC Rapporteur
NO
ESAC to address2) ESAC Working GroupYES
the request
3) Invited Experts
YES
Does the advice
Ad 3): If yes – list names andrequire an ESAC
affiliations of suggested
working group, an
experts to be invited andESAC rapporteur
specify whether these areetc.?
member of the EEP
If other than above (1-3):

DELIVERABLES AS PROPOSED BY ECVAM
5.2
Deliverables
Title of deliverable other than
What deliverables ESAC opinion(other than the
D1 ESAC Rapporteur Report
ESAC opinion) are and draft opinion
required forD2 ESAC Peer Review Reportaddressing theand draft opinion
request?
If other than above (D1-D2):

74

31

Required? (YES/NO)
NO
YES
NO

ANNEX 2

ECVAM REQUEST FOR ESAC ADVICE

6.
LIST OF DOCUMENTS TO BE MADE AVAILABLE TO THE ESACCount Description of document
Available (YES/NO)
1
OECD, Organisation for Economic
YES
Cooperation and Development(1992) Skin Sensitisation Guidelines
for Testing of Chemicals No. 406,
Paris
2OECD, Organisation for Economic
YES
Cooperation and Development(2002) The Local Lymph Node Assay.
Guidelines for Testing of Chemicals
No. 429, Paris
3
OECD, Organisation for Economic
YES
Cooperation and Development(2010a) Skin Sensitization: Local
Lymph Node Assay: DA, Guidelines
for Testing of Chemicals No. 442A,
Paris
4
OECD, Organisation for Economic
YES
Cooperation and Development(2010b) Skin Sensitization: Local
Lymph Node Assay: BrdU-ELISA,
Guidelines for Testing of Chemicals
No. 442B, Paris
5
Gerberick GF, Vassallo JD, Bailey RE,
YES
Chaney JG, Morrall SW, LepoittevinJP, (2004) Development of a peptide
reactivity assay for screening contact
allergens. Toxicol Sci. 81; 332-43.
6
Gerberick GF, Vassallo JD, Foertsch
YESLM, Price BB, Chaney JG, LepoittevinJP, (2007). Quantification of chemical
peptide reactivity for screening
contact allergens: a classification
tree model approach. Toxicol Sci. 97,
417-27.

32

File name
ER2011-03_TG 406

ER2011-03_TG 429

ER2011-03_TG 442A

ER2011-03_TG 442B

ER2011-03_scientificpaper on DPRA

ER201-03_DPRAClassification Tree
Model

75

ANNEX 2

7.

ECVAM REQUEST FOR ESAC ADVICETERMS OF REFERENCE OF THE ESAC WORKING GROUP

7.1
ESTABLISHMENT OF THE ESAC WORKING GROUP
During its 34th meeting on March 22-23 the ESAC plenary unanimously decided to establish an
ESAC Working Group Sensitisation charged with the detailed scientific review of four test
methods for skin sensitisation.
7.2
TITLE OF THE ESAC WORKING GROUP
Full title:
ESAC Working Group on Skin Sensitisation Test Methods
Abbreviated title:
ESAC WG Sensitisation
7.3
MANDATE OF THE ESAC WG
The EWG is requested to conduct a scientific review of the relevant studies concerning four skinsensitisation test methods (DPRA, MUSST, h-CLAT, Keratinosens). The review needs to address
the questions put forward to ESAC by ECVAM.
The review should focus on the appropriateness of design and conduct of the study in view ofthe study objective and should provide an appraisal to which extent the conclusions of the
Validation Management Team (VMT) / test method submitter are substantiated by the
information generated during the study and how the information generated relates to thescientific background available.
7.4
DELIVERABLE OF THE ESAC WG
The ESAC WG is requested to deliver to the chair of the ESAC and the ESAC Secretariat a
detailed ESAC Working Group Report outlining its analyses and conclusions. A reporting
template has been appended (Appendix 1) intended to facilitate the drafting of the report.
The conclusions drawn in the report should be based preferably on consensus. If no consensus
can be achieved, the report should clearly outline the differences in the appraisals and provide
appropriate scientific justifications.
The WG is further asked to prepare a draft ESAC opinion as basis for the discussions by theentire ESAC, which shall adopt its opinion to the extent possible by consensus and on the basisof the ESAC WG report as well as all documents that were made available to the WG as well as
to all ESAC members.
7.5
PROPOSED TIMELINES OF THE ESAC WG
The following timelines have been proposed by ECVAM. These should be agreed upon during
the face-to-face meeting (Item 1 in the table):
Item Proposed date/time
ActionDeliverable
1
1-3 February
Face to face meeting
1)Input on draft
mandate2) Initial drafting ofreport2
20. / 21. March
Progress report of WG Chair at
Presentation / oral
ESAC36summary3
14 MayFinal report to be delivered to
Final draft report
ESAC Coordinator/Secretariat.
4
8 JuneFeedback from ESAC to WG on
Feedback on final draft
draft report (written procedure)
report529 JuneFinal draft report available
Final report

7633

ANNEX 2

ECVAM REQUEST FOR ESAC ADVICE

7.6
QUESTIONS WHICH SHOULD BE ADDRESSED BY THE ESAC WG
The ESAC WG is requested to address the three questions posed to the ESAC which have beenbroken down further in more specific questions by Secretariat (see section 4.2) and werediscussed with the ESAC WG and approved by the ESAC.
When preparing the final ESAC WG report to address these questions, the ESAC WG isrequested to use a pre-defined reporting template. This template (see appendix 1) follows
ECVAM's modular approach and addresses to which extent the standard information
requirements have been addressed by the study. In addition, the template allows for addressing
the specific questions outlined in section 4.2. The Secretariat will provide guidance if necessary.
APPENDIX 1REPORTING STRUCTURE FOR THE ESAC WG REPORTThe following suggested structure follows the ECVAM information requirements ("modules") for
scientific review following validation and allows at the same time for the description of theanalysis and conclusions concerning more specific questions. A template has been created on
the basis of the structure below and this template will be made available to the ESAC.
The template can be used for various types of validation studies (e.g. prospective full studies,retrospective studies, performance-based studies and prevalidation studies). Depending on the
study type and the objective of the study, not all sections may be applicable. However, forreasons of consistency and to clearly identify which information requirements have not been
sufficiently addressed by a specific study, this template is uniformly used for the evaluation ofvalidation studies. The current template is version 5.

END OF EURL ECVAM RECOMMENDATION

34

77

European Commission
EUR 26383– Joint Research Centre – Institute for Health and Consumer Protection
Title: EUR 26383 - EURL ECVAM Recommendation on the Direct Peptide Reactivity Assay (DPRA) for Skin Sensitisation
Testing
Luxembourg: Publications Office of the European Union2013 – 36 pp. – 21.0 x 29.7 cm
EUR – Scientific and Technical Research series –ISSN 1831-9424 (online)
ISBN 978-92-79-34886-0 (pdf)
doi:10.2788/48229

Abstract
Identification of the skin sensitisation hazard of chemicals has traditionally relied on the use of animals. Progress in thedevelopment of alternative methods has been prompted by the increasing knowledge of the key biological mechanisms
underlying this human health effect, as documented by the OECD's recent report summarising the key biological events
leading to skin sensitisation ("Adverse Outcome Pathway" (AOP) for skin sensitisation). The molecular initiating event
defined within this AOP is the covalent binding of chemicals with skin proteins. Thus peptide reactivity assays may
provide valuable information in the context of integrated approaches such as Weight of Evidence (WoE) or Integrated
Testing Strategies (ITS) for skin sensitisation hazard and safety assessment. Based on these considerations, EURL ECVAM
coordinated a validation study on the Direct Peptide Reactivity Assay (DPRA) addressing mainly the test method’stransferability and within- and between-laboratory reproducibility. Following independent scientific peer review by the
EURL ECVAM’s Scientific Advisory Committee (ESAC) and having considered the input from regulators, stakeholders,international partners and the general public, EURL ECVAM concluded that the DPRA may prove a valuable componentof a WoE or ITS for skin sensitisation hazard assessment. In addition to this, the DPRA may also be able to contribute to
the assessment of sensitising potency, e.g. by supporting sub-categorisation of sensitisers according to UN GHS.
However it is recognised that further efforts are required to explore how DPRA data may contribute to potency
assessment.

78

35

LB-NA-26383-EN-Nz

As the Commission’s in-house science service, the Joint Research Centre’s mission is to provide
EU policies with independent, evidence-based scientific and technical support throughout thewhole policy cycle.
Working in close cooperation with policy Directorates-General, the JRC addresses key societal
challenges while stimulating innovation through developing new standards, methods and tools,
and sharing and transferring its know-how to the Member States and international community.
Key policy areas include: environment and climate change; energy and transport; agriculture
and food security; health and consumer protection; information society and digital agenda;
safety and security including nuclear; all supported through a cross-cutting and multidisciplinary approach.

36

79

80